pk,ara,result_subjectNode_name,result_subjectNode_id,result_subjectNode_cat,result_objectNode_name,result_objectNode_id,result_objectNode_cat,rank,sugeno_score,comp_confidence_score,comp_novelty_score,comp_clinical_evidence_score,weighted_mean_score,normalized_score,ARAX,ARAX_score,unsecret,unsecret_score,improving_agent,improving_agent_score,biothings_explorer,biothings_explorer_score,aragorn,aragorn_score,ARA_list,ARA_count,result_counter,edge_id,edge_object,edge_objectNode_name,edge_objectNode_cats,edge_objectNode_cat,edgeg_subject,edge_subjectNode_name,edge_subjectNode_cats,edge_subjectNode_cat,predicate,qualifiers,edge_type,qualified_predicate,causal_mechanism_qualifier,subject_direction_qualifier,subject_aspect_qualifier,subject_form_or_variant_qualifier,object_direction_qualifier,object_aspect_qualifier,object_form_or_variant_qualifier,publications,phrase,primary_source,publications_count,agg1
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,imatinib methanesulfonate,CHEBI:31690,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,1,1.0,1.0,0.0,0.0,0.5,100.0,False,-0.0,False,1.0,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,1,medik:creative_edge#1,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,CHEBI:31690,imatinib methanesulfonate,['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:treats,[],creative,,,,,,,,,[],DEFAULT PHRASE,infores:unsecret-agent,0,
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,imatinib methanesulfonate,CHEBI:31690,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,1,1.0,1.0,0.0,0.0,0.5,100.0,False,-0.0,False,1.0,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,1,medik:edge#2,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,CHEBI:31690,imatinib methanesulfonate,['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:affects,[],one-hop,,,,,,,,,['PMID:27924459'],DEFAULT PHRASE,infores:dgidb,1,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,imatinib methanesulfonate,CHEBI:31690,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,1,1.0,1.0,0.0,0.0,0.5,100.0,False,-0.0,False,1.0,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,1,medik:edge#3,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,biolink:gene_associated_with_condition,[],one-hop,,,,,,,,,['PMID:16439621'],DEFAULT PHRASE,infores:disgenet,1,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,Temsirolimus,CHEBI:79699,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,2,0.992,0.992,0.0,0.0,0.496,99.2,False,-0.0,False,0.992,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,2,medik:creative_edge#0,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,CHEBI:79699,Temsirolimus,['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:treats,[],creative,,,,,,,,,[],DEFAULT PHRASE,infores:unsecret-agent,0,
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,Temsirolimus,CHEBI:79699,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,2,0.992,0.992,0.0,0.0,0.496,99.2,False,-0.0,False,0.992,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,2,medik:edge#0,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,CHEBI:79699,Temsirolimus,['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:affects,[],one-hop,,,,,,,,,['PMID:21216929'],DEFAULT PHRASE,infores:dgidb,1,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,Temsirolimus,CHEBI:79699,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,2,0.992,0.992,0.0,0.0,0.496,99.2,False,-0.0,False,0.992,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,2,medik:edge#1,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,biolink:gene_associated_with_condition,[],one-hop,,,,,,,,,['PMID:16439621'],DEFAULT PHRASE,infores:disgenet,1,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,Hormone Antagonists,UMLS:C0019927,biolink:Drug,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,3,0.984,0.984,0.0,0.0,0.492,98.4,False,-0.0,False,0.984,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,3,medik:creative_edge#2,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,UMLS:C0019927,Hormone Antagonists,['biolink:Drug'],biolink:Drug,biolink:treats,[],creative,,,,,,,,,[],DEFAULT PHRASE,infores:unsecret-agent,0,
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,Hormone Antagonists,UMLS:C0019927,biolink:Drug,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,3,0.984,0.984,0.0,0.0,0.492,98.4,False,-0.0,False,0.984,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,3,medik:edge#4,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,UMLS:C0019927,Hormone Antagonists,['biolink:Drug'],biolink:Drug,biolink:affects,"[{'qualifier_type_id': 'biolink:object_aspect_qualifier', 'qualifier_value': 'activity'}, {'qualifier_type_id': 'biolink:object_direction_qualifier', 'qualifier_value': 'decreased'}, {'qualifier_type_id': 'biolink:qualified_predicate', 'qualifier_value': 'biolink:causes'}]",one-hop,causes,,,,,decreased,activity,,['PMID:30640701'],Hormone Antagonists causes decreased activity of BRAF,infores:semmeddb,1,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,Hormone Antagonists,UMLS:C0019927,biolink:Drug,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,3,0.984,0.984,0.0,0.0,0.492,98.4,False,-0.0,False,0.984,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,3,medik:edge#5,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,biolink:gene_associated_with_condition,[],one-hop,,,,,,,,,['PMID:16439621'],DEFAULT PHRASE,infores:disgenet,1,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"4-((4-ethylpiperazin-1-yl)methyl)-N-((1S,1aS,6bS)-5-((2-oxo-1,2,3,4-tetrahydropyrido[2,3-d]pyrimidin-5-yl)oxy)-1a,6b-dihydro-1H-cyclopropa[b]benzofuran-1-yl)-3-(trifluoromethyl)benzamide",PUBCHEM.COMPOUND:117807447,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,4,0.976,0.976,0.0,0.0,0.488,97.6,False,-0.0,False,0.976,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,4,medik:creative_edge#88,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,PUBCHEM.COMPOUND:117807447,"4-((4-ethylpiperazin-1-yl)methyl)-N-((1S,1aS,6bS)-5-((2-oxo-1,2,3,4-tetrahydropyrido[2,3-d]pyrimidin-5-yl)oxy)-1a,6b-dihydro-1H-cyclopropa[b]benzofuran-1-yl)-3-(trifluoromethyl)benzamide",['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:treats,[],creative,,,,,,,,,[],DEFAULT PHRASE,infores:unsecret-agent,0,
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"4-((4-ethylpiperazin-1-yl)methyl)-N-((1S,1aS,6bS)-5-((2-oxo-1,2,3,4-tetrahydropyrido[2,3-d]pyrimidin-5-yl)oxy)-1a,6b-dihydro-1H-cyclopropa[b]benzofuran-1-yl)-3-(trifluoromethyl)benzamide",PUBCHEM.COMPOUND:117807447,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,4,0.976,0.976,0.0,0.0,0.488,97.6,False,-0.0,False,0.976,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,4,medik:edge#176,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,PUBCHEM.COMPOUND:117807447,"4-((4-ethylpiperazin-1-yl)methyl)-N-((1S,1aS,6bS)-5-((2-oxo-1,2,3,4-tetrahydropyrido[2,3-d]pyrimidin-5-yl)oxy)-1a,6b-dihydro-1H-cyclopropa[b]benzofuran-1-yl)-3-(trifluoromethyl)benzamide",['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:affects,"[{'qualifier_type_id': 'biolink:object_aspect_qualifier', 'qualifier_value': 'activity'}, {'qualifier_type_id': 'biolink:object_direction_qualifier', 'qualifier_value': 'decreased'}, {'qualifier_type_id': 'biolink:qualified_predicate', 'qualifier_value': 'biolink:causes'}]",one-hop,causes,,,,,decreased,activity,,[],"4-((4-ethylpiperazin-1-yl)methyl)-N-((1S,1aS,6bS)-5-((2-oxo-1,2,3,4-tetrahydropyrido[2,3-d]pyrimidin-5-yl)oxy)-1a,6b-dihydro-1H-cyclopropa[b]benzofuran-1-yl)-3-(trifluoromethyl)benzamide causes decreased activity of BRAF",infores:bindingdb,0,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"4-((4-ethylpiperazin-1-yl)methyl)-N-((1S,1aS,6bS)-5-((2-oxo-1,2,3,4-tetrahydropyrido[2,3-d]pyrimidin-5-yl)oxy)-1a,6b-dihydro-1H-cyclopropa[b]benzofuran-1-yl)-3-(trifluoromethyl)benzamide",PUBCHEM.COMPOUND:117807447,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,4,0.976,0.976,0.0,0.0,0.488,97.6,False,-0.0,False,0.976,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,4,medik:edge#177,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,biolink:gene_associated_with_condition,[],one-hop,,,,,,,,,['PMID:16439621'],DEFAULT PHRASE,infores:disgenet,1,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"1-[(1S,1aS,6bS)-5-[9-(2-trimethylsilylethoxymethyl)purin-6-yl]oxy-1a,6b-dihydro-1H-cyclopropa[b][1]benzofuran-1-yl]-3-[4-fluoro-3-(trifluoromethyl)phenyl]urea",PUBCHEM.COMPOUND:134686656,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,5,0.968,0.968,0.0,0.0,0.484,96.8,False,-0.0,False,0.968,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,5,medik:creative_edge#23,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,PUBCHEM.COMPOUND:134686656,"1-[(1S,1aS,6bS)-5-[9-(2-trimethylsilylethoxymethyl)purin-6-yl]oxy-1a,6b-dihydro-1H-cyclopropa[b][1]benzofuran-1-yl]-3-[4-fluoro-3-(trifluoromethyl)phenyl]urea",['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:treats,[],creative,,,,,,,,,[],DEFAULT PHRASE,infores:unsecret-agent,0,
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"1-[(1S,1aS,6bS)-5-[9-(2-trimethylsilylethoxymethyl)purin-6-yl]oxy-1a,6b-dihydro-1H-cyclopropa[b][1]benzofuran-1-yl]-3-[4-fluoro-3-(trifluoromethyl)phenyl]urea",PUBCHEM.COMPOUND:134686656,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,5,0.968,0.968,0.0,0.0,0.484,96.8,False,-0.0,False,0.968,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,5,medik:edge#46,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,PUBCHEM.COMPOUND:134686656,"1-[(1S,1aS,6bS)-5-[9-(2-trimethylsilylethoxymethyl)purin-6-yl]oxy-1a,6b-dihydro-1H-cyclopropa[b][1]benzofuran-1-yl]-3-[4-fluoro-3-(trifluoromethyl)phenyl]urea",['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:affects,"[{'qualifier_type_id': 'biolink:object_aspect_qualifier', 'qualifier_value': 'activity'}, {'qualifier_type_id': 'biolink:object_direction_qualifier', 'qualifier_value': 'decreased'}, {'qualifier_type_id': 'biolink:qualified_predicate', 'qualifier_value': 'biolink:causes'}]",one-hop,causes,,,,,decreased,activity,,[],"1-[(1S,1aS,6bS)-5-[9-(2-trimethylsilylethoxymethyl)purin-6-yl]oxy-1a,6b-dihydro-1H-cyclopropa[b][1]benzofuran-1-yl]-3-[4-fluoro-3-(trifluoromethyl)phenyl]urea causes decreased activity of BRAF",infores:bindingdb,0,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"1-[(1S,1aS,6bS)-5-[9-(2-trimethylsilylethoxymethyl)purin-6-yl]oxy-1a,6b-dihydro-1H-cyclopropa[b][1]benzofuran-1-yl]-3-[4-fluoro-3-(trifluoromethyl)phenyl]urea",PUBCHEM.COMPOUND:134686656,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,5,0.968,0.968,0.0,0.0,0.484,96.8,False,-0.0,False,0.968,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,5,medik:edge#47,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,biolink:gene_associated_with_condition,[],one-hop,,,,,,,,,['PMID:16439621'],DEFAULT PHRASE,infores:disgenet,1,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"1-[(1S,1aS,6bS)-5-(7H-purin-6-yloxy)-1a,6b-dihydro-1H-cyclopropa[b][1]benzofuran-1-yl]-3-(2,4-difluorophenyl)urea",PUBCHEM.COMPOUND:117807107,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,6,0.96,0.96,0.0,0.0,0.48,96.0,False,-0.0,False,0.96,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,6,medik:creative_edge#14,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,PUBCHEM.COMPOUND:117807107,"1-[(1S,1aS,6bS)-5-(7H-purin-6-yloxy)-1a,6b-dihydro-1H-cyclopropa[b][1]benzofuran-1-yl]-3-(2,4-difluorophenyl)urea",['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:treats,[],creative,,,,,,,,,[],DEFAULT PHRASE,infores:unsecret-agent,0,
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"1-[(1S,1aS,6bS)-5-(7H-purin-6-yloxy)-1a,6b-dihydro-1H-cyclopropa[b][1]benzofuran-1-yl]-3-(2,4-difluorophenyl)urea",PUBCHEM.COMPOUND:117807107,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,6,0.96,0.96,0.0,0.0,0.48,96.0,False,-0.0,False,0.96,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,6,medik:edge#28,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,PUBCHEM.COMPOUND:117807107,"1-[(1S,1aS,6bS)-5-(7H-purin-6-yloxy)-1a,6b-dihydro-1H-cyclopropa[b][1]benzofuran-1-yl]-3-(2,4-difluorophenyl)urea",['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:affects,"[{'qualifier_type_id': 'biolink:object_aspect_qualifier', 'qualifier_value': 'activity'}, {'qualifier_type_id': 'biolink:object_direction_qualifier', 'qualifier_value': 'decreased'}, {'qualifier_type_id': 'biolink:qualified_predicate', 'qualifier_value': 'biolink:causes'}]",one-hop,causes,,,,,decreased,activity,,[],"1-[(1S,1aS,6bS)-5-(7H-purin-6-yloxy)-1a,6b-dihydro-1H-cyclopropa[b][1]benzofuran-1-yl]-3-(2,4-difluorophenyl)urea causes decreased activity of BRAF",infores:bindingdb,0,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"1-[(1S,1aS,6bS)-5-(7H-purin-6-yloxy)-1a,6b-dihydro-1H-cyclopropa[b][1]benzofuran-1-yl]-3-(2,4-difluorophenyl)urea",PUBCHEM.COMPOUND:117807107,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,6,0.96,0.96,0.0,0.0,0.48,96.0,False,-0.0,False,0.96,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,6,medik:edge#29,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,biolink:gene_associated_with_condition,[],one-hop,,,,,,,,,['PMID:16439621'],DEFAULT PHRASE,infores:disgenet,1,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"N-(5-tert-butyl-1,2-oxazol-3-yl)-3-[4-[5-(2-fluoroethylamino)pyridin-3-yl]triazol-1-yl]-4-methylbenzamide",PUBCHEM.COMPOUND:53464656,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,7,0.952,0.952,0.0,0.0,0.476,95.2,False,-0.0,False,0.952,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,7,medik:creative_edge#37,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,PUBCHEM.COMPOUND:53464656,"N-(5-tert-butyl-1,2-oxazol-3-yl)-3-[4-[5-(2-fluoroethylamino)pyridin-3-yl]triazol-1-yl]-4-methylbenzamide",['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:treats,[],creative,,,,,,,,,[],DEFAULT PHRASE,infores:unsecret-agent,0,
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"N-(5-tert-butyl-1,2-oxazol-3-yl)-3-[4-[5-(2-fluoroethylamino)pyridin-3-yl]triazol-1-yl]-4-methylbenzamide",PUBCHEM.COMPOUND:53464656,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,7,0.952,0.952,0.0,0.0,0.476,95.2,False,-0.0,False,0.952,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,7,medik:edge#74,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,PUBCHEM.COMPOUND:53464656,"N-(5-tert-butyl-1,2-oxazol-3-yl)-3-[4-[5-(2-fluoroethylamino)pyridin-3-yl]triazol-1-yl]-4-methylbenzamide",['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:affects,"[{'qualifier_type_id': 'biolink:object_aspect_qualifier', 'qualifier_value': 'activity'}, {'qualifier_type_id': 'biolink:object_direction_qualifier', 'qualifier_value': 'decreased'}, {'qualifier_type_id': 'biolink:qualified_predicate', 'qualifier_value': 'biolink:causes'}]",one-hop,causes,,,,,decreased,activity,,[],"N-(5-tert-butyl-1,2-oxazol-3-yl)-3-[4-[5-(2-fluoroethylamino)pyridin-3-yl]triazol-1-yl]-4-methylbenzamide causes decreased activity of BRAF",infores:bindingdb,0,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"N-(5-tert-butyl-1,2-oxazol-3-yl)-3-[4-[5-(2-fluoroethylamino)pyridin-3-yl]triazol-1-yl]-4-methylbenzamide",PUBCHEM.COMPOUND:53464656,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,7,0.952,0.952,0.0,0.0,0.476,95.2,False,-0.0,False,0.952,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,7,medik:edge#75,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,biolink:gene_associated_with_condition,[],one-hop,,,,,,,,,['PMID:16439621'],DEFAULT PHRASE,infores:disgenet,1,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"3-[5-[3-[3-[[ethyl(methyl)sulfamoyl]amino]-2,6-difluorobenzoyl]-1H-pyrrolo[2,3-b]pyridin-5-yl]thiophen-2-yl]-5-methyl-1,2,4-oxadiazole",PUBCHEM.COMPOUND:60164446,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,8,0.944,0.944,0.0,0.0,0.472,94.4,False,-0.0,False,0.944,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,8,medik:creative_edge#124,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,PUBCHEM.COMPOUND:60164446,"3-[5-[3-[3-[[ethyl(methyl)sulfamoyl]amino]-2,6-difluorobenzoyl]-1H-pyrrolo[2,3-b]pyridin-5-yl]thiophen-2-yl]-5-methyl-1,2,4-oxadiazole",['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:treats,[],creative,,,,,,,,,[],DEFAULT PHRASE,infores:unsecret-agent,0,
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"3-[5-[3-[3-[[ethyl(methyl)sulfamoyl]amino]-2,6-difluorobenzoyl]-1H-pyrrolo[2,3-b]pyridin-5-yl]thiophen-2-yl]-5-methyl-1,2,4-oxadiazole",PUBCHEM.COMPOUND:60164446,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,8,0.944,0.944,0.0,0.0,0.472,94.4,False,-0.0,False,0.944,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,8,medik:edge#248,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,PUBCHEM.COMPOUND:60164446,"3-[5-[3-[3-[[ethyl(methyl)sulfamoyl]amino]-2,6-difluorobenzoyl]-1H-pyrrolo[2,3-b]pyridin-5-yl]thiophen-2-yl]-5-methyl-1,2,4-oxadiazole",['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:affects,"[{'qualifier_type_id': 'biolink:object_aspect_qualifier', 'qualifier_value': 'activity'}, {'qualifier_type_id': 'biolink:object_direction_qualifier', 'qualifier_value': 'decreased'}, {'qualifier_type_id': 'biolink:qualified_predicate', 'qualifier_value': 'biolink:causes'}]",one-hop,causes,,,,,decreased,activity,,[],"3-[5-[3-[3-[[ethyl(methyl)sulfamoyl]amino]-2,6-difluorobenzoyl]-1H-pyrrolo[2,3-b]pyridin-5-yl]thiophen-2-yl]-5-methyl-1,2,4-oxadiazole causes decreased activity of BRAF",infores:bindingdb,0,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"3-[5-[3-[3-[[ethyl(methyl)sulfamoyl]amino]-2,6-difluorobenzoyl]-1H-pyrrolo[2,3-b]pyridin-5-yl]thiophen-2-yl]-5-methyl-1,2,4-oxadiazole",PUBCHEM.COMPOUND:60164446,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,8,0.944,0.944,0.0,0.0,0.472,94.4,False,-0.0,False,0.944,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,8,medik:edge#249,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,biolink:gene_associated_with_condition,[],one-hop,,,,,,,,,['PMID:16439621'],DEFAULT PHRASE,infores:disgenet,1,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"5-[[3-(Ethylsulfonylamino)-2-fluorophenyl]methyl]-3,4-difluoro-2-(2-fluoro-4-iodoanilino)benzamide",PUBCHEM.COMPOUND:156808798,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,9,0.936,0.936,0.0,0.0,0.468,93.6,False,-0.0,False,0.936,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,9,medik:creative_edge#109,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,PUBCHEM.COMPOUND:156808798,"5-[[3-(Ethylsulfonylamino)-2-fluorophenyl]methyl]-3,4-difluoro-2-(2-fluoro-4-iodoanilino)benzamide",['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:treats,[],creative,,,,,,,,,[],DEFAULT PHRASE,infores:unsecret-agent,0,
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"5-[[3-(Ethylsulfonylamino)-2-fluorophenyl]methyl]-3,4-difluoro-2-(2-fluoro-4-iodoanilino)benzamide",PUBCHEM.COMPOUND:156808798,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,9,0.936,0.936,0.0,0.0,0.468,93.6,False,-0.0,False,0.936,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,9,medik:edge#218,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,PUBCHEM.COMPOUND:156808798,"5-[[3-(Ethylsulfonylamino)-2-fluorophenyl]methyl]-3,4-difluoro-2-(2-fluoro-4-iodoanilino)benzamide",['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:affects,"[{'qualifier_type_id': 'biolink:object_aspect_qualifier', 'qualifier_value': 'activity'}, {'qualifier_type_id': 'biolink:object_direction_qualifier', 'qualifier_value': 'decreased'}, {'qualifier_type_id': 'biolink:qualified_predicate', 'qualifier_value': 'biolink:causes'}]",one-hop,causes,,,,,decreased,activity,,[],"5-[[3-(Ethylsulfonylamino)-2-fluorophenyl]methyl]-3,4-difluoro-2-(2-fluoro-4-iodoanilino)benzamide causes decreased activity of BRAF",infores:bindingdb,0,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"5-[[3-(Ethylsulfonylamino)-2-fluorophenyl]methyl]-3,4-difluoro-2-(2-fluoro-4-iodoanilino)benzamide",PUBCHEM.COMPOUND:156808798,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,9,0.936,0.936,0.0,0.0,0.468,93.6,False,-0.0,False,0.936,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,9,medik:edge#219,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,biolink:gene_associated_with_condition,[],one-hop,,,,,,,,,['PMID:16439621'],DEFAULT PHRASE,infores:disgenet,1,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,Anticancer agent 124,PUBCHEM.COMPOUND:118948409,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,10,0.928,0.928,0.0,0.0,0.464,92.8,False,-0.0,False,0.928,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,10,medik:creative_edge#17,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,PUBCHEM.COMPOUND:118948409,Anticancer agent 124,['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:treats,[],creative,,,,,,,,,[],DEFAULT PHRASE,infores:unsecret-agent,0,
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,Anticancer agent 124,PUBCHEM.COMPOUND:118948409,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,10,0.928,0.928,0.0,0.0,0.464,92.8,False,-0.0,False,0.928,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,10,medik:edge#34,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,PUBCHEM.COMPOUND:118948409,Anticancer agent 124,['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:affects,"[{'qualifier_type_id': 'biolink:object_aspect_qualifier', 'qualifier_value': 'activity'}, {'qualifier_type_id': 'biolink:object_direction_qualifier', 'qualifier_value': 'decreased'}, {'qualifier_type_id': 'biolink:qualified_predicate', 'qualifier_value': 'biolink:causes'}]",one-hop,causes,,,,,decreased,activity,,[],Anticancer agent 124 causes decreased activity of BRAF,infores:bindingdb,0,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,Anticancer agent 124,PUBCHEM.COMPOUND:118948409,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,10,0.928,0.928,0.0,0.0,0.464,92.8,False,-0.0,False,0.928,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,10,medik:edge#35,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,biolink:gene_associated_with_condition,[],one-hop,,,,,,,,,['PMID:16439621'],DEFAULT PHRASE,infores:disgenet,1,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,N-[2-chloro-3-[2-cyclopropyl-5-[2-(methylamino)pyrimidin-4-yl]-1H-imidazol-4-yl]-5-fluorophenyl]methanesulfonamide,PUBCHEM.COMPOUND:58164489,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,11,0.92,0.92,0.0,0.0,0.46,92.0,False,-0.0,False,0.92,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,11,medik:creative_edge#41,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,PUBCHEM.COMPOUND:58164489,N-[2-chloro-3-[2-cyclopropyl-5-[2-(methylamino)pyrimidin-4-yl]-1H-imidazol-4-yl]-5-fluorophenyl]methanesulfonamide,['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:treats,[],creative,,,,,,,,,[],DEFAULT PHRASE,infores:unsecret-agent,0,
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,N-[2-chloro-3-[2-cyclopropyl-5-[2-(methylamino)pyrimidin-4-yl]-1H-imidazol-4-yl]-5-fluorophenyl]methanesulfonamide,PUBCHEM.COMPOUND:58164489,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,11,0.92,0.92,0.0,0.0,0.46,92.0,False,-0.0,False,0.92,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,11,medik:edge#82,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,PUBCHEM.COMPOUND:58164489,N-[2-chloro-3-[2-cyclopropyl-5-[2-(methylamino)pyrimidin-4-yl]-1H-imidazol-4-yl]-5-fluorophenyl]methanesulfonamide,['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:affects,"[{'qualifier_type_id': 'biolink:object_aspect_qualifier', 'qualifier_value': 'activity'}, {'qualifier_type_id': 'biolink:object_direction_qualifier', 'qualifier_value': 'decreased'}, {'qualifier_type_id': 'biolink:qualified_predicate', 'qualifier_value': 'biolink:causes'}]",one-hop,causes,,,,,decreased,activity,,[],N-[2-chloro-3-[2-cyclopropyl-5-[2-(methylamino)pyrimidin-4-yl]-1H-imidazol-4-yl]-5-fluorophenyl]methanesulfonamide causes decreased activity of BRAF,infores:bindingdb,0,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,N-[2-chloro-3-[2-cyclopropyl-5-[2-(methylamino)pyrimidin-4-yl]-1H-imidazol-4-yl]-5-fluorophenyl]methanesulfonamide,PUBCHEM.COMPOUND:58164489,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,11,0.92,0.92,0.0,0.0,0.46,92.0,False,-0.0,False,0.92,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,11,medik:edge#83,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,biolink:gene_associated_with_condition,[],one-hop,,,,,,,,,['PMID:16439621'],DEFAULT PHRASE,infores:disgenet,1,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"N-[(1S,1aS,6bS)-5-[(2-oxo-3,4-dihydro-1H-pyrido[2,3-d]pyrimidin-5-yl)oxy]-1a,6b-dihydro-1H-cyclopropa[b][1]benzofuran-1-yl]-4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)benzamide",PUBCHEM.COMPOUND:129189442,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,12,0.912,0.912,0.0,0.0,0.456,91.2,False,-0.0,False,0.912,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,12,medik:creative_edge#19,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,PUBCHEM.COMPOUND:129189442,"N-[(1S,1aS,6bS)-5-[(2-oxo-3,4-dihydro-1H-pyrido[2,3-d]pyrimidin-5-yl)oxy]-1a,6b-dihydro-1H-cyclopropa[b][1]benzofuran-1-yl]-4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)benzamide",['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:treats,[],creative,,,,,,,,,[],DEFAULT PHRASE,infores:unsecret-agent,0,
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"N-[(1S,1aS,6bS)-5-[(2-oxo-3,4-dihydro-1H-pyrido[2,3-d]pyrimidin-5-yl)oxy]-1a,6b-dihydro-1H-cyclopropa[b][1]benzofuran-1-yl]-4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)benzamide",PUBCHEM.COMPOUND:129189442,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,12,0.912,0.912,0.0,0.0,0.456,91.2,False,-0.0,False,0.912,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,12,medik:edge#38,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,PUBCHEM.COMPOUND:129189442,"N-[(1S,1aS,6bS)-5-[(2-oxo-3,4-dihydro-1H-pyrido[2,3-d]pyrimidin-5-yl)oxy]-1a,6b-dihydro-1H-cyclopropa[b][1]benzofuran-1-yl]-4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)benzamide",['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:affects,"[{'qualifier_type_id': 'biolink:object_aspect_qualifier', 'qualifier_value': 'activity'}, {'qualifier_type_id': 'biolink:object_direction_qualifier', 'qualifier_value': 'decreased'}, {'qualifier_type_id': 'biolink:qualified_predicate', 'qualifier_value': 'biolink:causes'}]",one-hop,causes,,,,,decreased,activity,,[],"N-[(1S,1aS,6bS)-5-[(2-oxo-3,4-dihydro-1H-pyrido[2,3-d]pyrimidin-5-yl)oxy]-1a,6b-dihydro-1H-cyclopropa[b][1]benzofuran-1-yl]-4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)benzamide causes decreased activity of BRAF",infores:bindingdb,0,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"N-[(1S,1aS,6bS)-5-[(2-oxo-3,4-dihydro-1H-pyrido[2,3-d]pyrimidin-5-yl)oxy]-1a,6b-dihydro-1H-cyclopropa[b][1]benzofuran-1-yl]-4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)benzamide",PUBCHEM.COMPOUND:129189442,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,12,0.912,0.912,0.0,0.0,0.456,91.2,False,-0.0,False,0.912,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,12,medik:edge#39,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,biolink:gene_associated_with_condition,[],one-hop,,,,,,,,,['PMID:16439621'],DEFAULT PHRASE,infores:disgenet,1,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"(E)-N-[(1S,1aS,6bS)-5-[(7-oxo-6,8-dihydro-5H-1,8-naphthyridin-4-yl)oxy]-1a,6b-dihydro-1H-cyclopropa[b][1]benzofuran-1-yl]-3-[3-(trifluoromethyl)phenyl]prop-2-enamide",PUBCHEM.COMPOUND:129189472,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,13,0.904,0.904,0.0,0.0,0.452,90.4,False,-0.0,False,0.904,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,13,medik:creative_edge#101,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,PUBCHEM.COMPOUND:129189472,"(E)-N-[(1S,1aS,6bS)-5-[(7-oxo-6,8-dihydro-5H-1,8-naphthyridin-4-yl)oxy]-1a,6b-dihydro-1H-cyclopropa[b][1]benzofuran-1-yl]-3-[3-(trifluoromethyl)phenyl]prop-2-enamide",['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:treats,[],creative,,,,,,,,,[],DEFAULT PHRASE,infores:unsecret-agent,0,
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"(E)-N-[(1S,1aS,6bS)-5-[(7-oxo-6,8-dihydro-5H-1,8-naphthyridin-4-yl)oxy]-1a,6b-dihydro-1H-cyclopropa[b][1]benzofuran-1-yl]-3-[3-(trifluoromethyl)phenyl]prop-2-enamide",PUBCHEM.COMPOUND:129189472,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,13,0.904,0.904,0.0,0.0,0.452,90.4,False,-0.0,False,0.904,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,13,medik:edge#202,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,PUBCHEM.COMPOUND:129189472,"(E)-N-[(1S,1aS,6bS)-5-[(7-oxo-6,8-dihydro-5H-1,8-naphthyridin-4-yl)oxy]-1a,6b-dihydro-1H-cyclopropa[b][1]benzofuran-1-yl]-3-[3-(trifluoromethyl)phenyl]prop-2-enamide",['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:affects,"[{'qualifier_type_id': 'biolink:object_aspect_qualifier', 'qualifier_value': 'activity'}, {'qualifier_type_id': 'biolink:object_direction_qualifier', 'qualifier_value': 'decreased'}, {'qualifier_type_id': 'biolink:qualified_predicate', 'qualifier_value': 'biolink:causes'}]",one-hop,causes,,,,,decreased,activity,,[],"(E)-N-[(1S,1aS,6bS)-5-[(7-oxo-6,8-dihydro-5H-1,8-naphthyridin-4-yl)oxy]-1a,6b-dihydro-1H-cyclopropa[b][1]benzofuran-1-yl]-3-[3-(trifluoromethyl)phenyl]prop-2-enamide causes decreased activity of BRAF",infores:bindingdb,0,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"(E)-N-[(1S,1aS,6bS)-5-[(7-oxo-6,8-dihydro-5H-1,8-naphthyridin-4-yl)oxy]-1a,6b-dihydro-1H-cyclopropa[b][1]benzofuran-1-yl]-3-[3-(trifluoromethyl)phenyl]prop-2-enamide",PUBCHEM.COMPOUND:129189472,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,13,0.904,0.904,0.0,0.0,0.452,90.4,False,-0.0,False,0.904,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,13,medik:edge#203,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,biolink:gene_associated_with_condition,[],one-hop,,,,,,,,,['PMID:16439621'],DEFAULT PHRASE,infores:disgenet,1,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"3,4-Difluoro-2-(2-fluoro-4-iodoanilino)-5-[[6-(methylsulfamoylamino)pyridin-2-yl]methyl]benzamide",PUBCHEM.COMPOUND:156808821,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,14,0.896,0.896,0.0,0.0,0.448,89.6,False,-0.0,False,0.896,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,14,medik:creative_edge#110,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,PUBCHEM.COMPOUND:156808821,"3,4-Difluoro-2-(2-fluoro-4-iodoanilino)-5-[[6-(methylsulfamoylamino)pyridin-2-yl]methyl]benzamide",['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:treats,[],creative,,,,,,,,,[],DEFAULT PHRASE,infores:unsecret-agent,0,
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"3,4-Difluoro-2-(2-fluoro-4-iodoanilino)-5-[[6-(methylsulfamoylamino)pyridin-2-yl]methyl]benzamide",PUBCHEM.COMPOUND:156808821,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,14,0.896,0.896,0.0,0.0,0.448,89.6,False,-0.0,False,0.896,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,14,medik:edge#220,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,PUBCHEM.COMPOUND:156808821,"3,4-Difluoro-2-(2-fluoro-4-iodoanilino)-5-[[6-(methylsulfamoylamino)pyridin-2-yl]methyl]benzamide",['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:affects,"[{'qualifier_type_id': 'biolink:object_aspect_qualifier', 'qualifier_value': 'activity'}, {'qualifier_type_id': 'biolink:object_direction_qualifier', 'qualifier_value': 'decreased'}, {'qualifier_type_id': 'biolink:qualified_predicate', 'qualifier_value': 'biolink:causes'}]",one-hop,causes,,,,,decreased,activity,,[],"3,4-Difluoro-2-(2-fluoro-4-iodoanilino)-5-[[6-(methylsulfamoylamino)pyridin-2-yl]methyl]benzamide causes decreased activity of BRAF",infores:bindingdb,0,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"3,4-Difluoro-2-(2-fluoro-4-iodoanilino)-5-[[6-(methylsulfamoylamino)pyridin-2-yl]methyl]benzamide",PUBCHEM.COMPOUND:156808821,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,14,0.896,0.896,0.0,0.0,0.448,89.6,False,-0.0,False,0.896,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,14,medik:edge#221,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,biolink:gene_associated_with_condition,[],one-hop,,,,,,,,,['PMID:16439621'],DEFAULT PHRASE,infores:disgenet,1,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"US8653087, III-204",PUBCHEM.COMPOUND:68035906,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,15,0.888,0.888,0.0,0.0,0.444,88.8,False,-0.0,False,0.888,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,15,medik:creative_edge#55,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,PUBCHEM.COMPOUND:68035906,"US8653087, III-204",['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:treats,[],creative,,,,,,,,,[],DEFAULT PHRASE,infores:unsecret-agent,0,
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"US8653087, III-204",PUBCHEM.COMPOUND:68035906,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,15,0.888,0.888,0.0,0.0,0.444,88.8,False,-0.0,False,0.888,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,15,medik:edge#110,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,PUBCHEM.COMPOUND:68035906,"US8653087, III-204",['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:affects,"[{'qualifier_type_id': 'biolink:object_aspect_qualifier', 'qualifier_value': 'activity'}, {'qualifier_type_id': 'biolink:object_direction_qualifier', 'qualifier_value': 'decreased'}, {'qualifier_type_id': 'biolink:qualified_predicate', 'qualifier_value': 'biolink:causes'}]",one-hop,causes,,,,,decreased,activity,,[],"US8653087, III-204 causes decreased activity of BRAF",infores:bindingdb,0,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"US8653087, III-204",PUBCHEM.COMPOUND:68035906,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,15,0.888,0.888,0.0,0.0,0.444,88.8,False,-0.0,False,0.888,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,15,medik:edge#111,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,biolink:gene_associated_with_condition,[],one-hop,,,,,,,,,['PMID:16439621'],DEFAULT PHRASE,infores:disgenet,1,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"US8653087, III-139",PUBCHEM.COMPOUND:68035831,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,16,0.88,0.88,0.0,0.0,0.44,88.0,False,-0.0,False,0.88,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,16,medik:creative_edge#53,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,PUBCHEM.COMPOUND:68035831,"US8653087, III-139",['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:treats,[],creative,,,,,,,,,[],DEFAULT PHRASE,infores:unsecret-agent,0,
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"US8653087, III-139",PUBCHEM.COMPOUND:68035831,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,16,0.88,0.88,0.0,0.0,0.44,88.0,False,-0.0,False,0.88,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,16,medik:edge#106,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,PUBCHEM.COMPOUND:68035831,"US8653087, III-139",['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:affects,"[{'qualifier_type_id': 'biolink:object_aspect_qualifier', 'qualifier_value': 'activity'}, {'qualifier_type_id': 'biolink:object_direction_qualifier', 'qualifier_value': 'decreased'}, {'qualifier_type_id': 'biolink:qualified_predicate', 'qualifier_value': 'biolink:causes'}]",one-hop,causes,,,,,decreased,activity,,[],"US8653087, III-139 causes decreased activity of BRAF",infores:bindingdb,0,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"US8653087, III-139",PUBCHEM.COMPOUND:68035831,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,16,0.88,0.88,0.0,0.0,0.44,88.0,False,-0.0,False,0.88,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,16,medik:edge#107,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,biolink:gene_associated_with_condition,[],one-hop,,,,,,,,,['PMID:16439621'],DEFAULT PHRASE,infores:disgenet,1,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"US8653087, III-17",PUBCHEM.COMPOUND:68035635,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,17,0.872,0.872,0.0,0.0,0.436,87.2,False,-0.0,False,0.872,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,17,medik:creative_edge#50,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,PUBCHEM.COMPOUND:68035635,"US8653087, III-17",['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:treats,[],creative,,,,,,,,,[],DEFAULT PHRASE,infores:unsecret-agent,0,
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"US8653087, III-17",PUBCHEM.COMPOUND:68035635,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,17,0.872,0.872,0.0,0.0,0.436,87.2,False,-0.0,False,0.872,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,17,medik:edge#100,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,PUBCHEM.COMPOUND:68035635,"US8653087, III-17",['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:affects,"[{'qualifier_type_id': 'biolink:object_aspect_qualifier', 'qualifier_value': 'activity'}, {'qualifier_type_id': 'biolink:object_direction_qualifier', 'qualifier_value': 'decreased'}, {'qualifier_type_id': 'biolink:qualified_predicate', 'qualifier_value': 'biolink:causes'}]",one-hop,causes,,,,,decreased,activity,,[],"US8653087, III-17 causes decreased activity of BRAF",infores:bindingdb,0,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"US8653087, III-17",PUBCHEM.COMPOUND:68035635,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,17,0.872,0.872,0.0,0.0,0.436,87.2,False,-0.0,False,0.872,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,17,medik:edge#101,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,biolink:gene_associated_with_condition,[],one-hop,,,,,,,,,['PMID:16439621'],DEFAULT PHRASE,infores:disgenet,1,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"US8653087, III-16",PUBCHEM.COMPOUND:68035633,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,18,0.864,0.864,0.0,0.0,0.432,86.4,False,-0.0,False,0.864,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,18,medik:creative_edge#49,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,PUBCHEM.COMPOUND:68035633,"US8653087, III-16",['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:treats,[],creative,,,,,,,,,[],DEFAULT PHRASE,infores:unsecret-agent,0,
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"US8653087, III-16",PUBCHEM.COMPOUND:68035633,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,18,0.864,0.864,0.0,0.0,0.432,86.4,False,-0.0,False,0.864,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,18,medik:edge#98,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,PUBCHEM.COMPOUND:68035633,"US8653087, III-16",['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:affects,"[{'qualifier_type_id': 'biolink:object_aspect_qualifier', 'qualifier_value': 'activity'}, {'qualifier_type_id': 'biolink:object_direction_qualifier', 'qualifier_value': 'decreased'}, {'qualifier_type_id': 'biolink:qualified_predicate', 'qualifier_value': 'biolink:causes'}]",one-hop,causes,,,,,decreased,activity,,[],"US8653087, III-16 causes decreased activity of BRAF",infores:bindingdb,0,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"US8653087, III-16",PUBCHEM.COMPOUND:68035633,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,18,0.864,0.864,0.0,0.0,0.432,86.4,False,-0.0,False,0.864,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,18,medik:edge#99,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,biolink:gene_associated_with_condition,[],one-hop,,,,,,,,,['PMID:16439621'],DEFAULT PHRASE,infores:disgenet,1,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"N-(3-(3-(9H-purin-6-yl)pyridin-2-ylamino)-2,4-difluorophenyl)-3-chlorobenzenesulfonamide",PUBCHEM.COMPOUND:57343974,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,19,0.856,0.856,0.0,0.0,0.428,85.6,False,-0.0,False,0.856,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,19,medik:creative_edge#38,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,PUBCHEM.COMPOUND:57343974,"N-(3-(3-(9H-purin-6-yl)pyridin-2-ylamino)-2,4-difluorophenyl)-3-chlorobenzenesulfonamide",['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:treats,[],creative,,,,,,,,,[],DEFAULT PHRASE,infores:unsecret-agent,0,
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"N-(3-(3-(9H-purin-6-yl)pyridin-2-ylamino)-2,4-difluorophenyl)-3-chlorobenzenesulfonamide",PUBCHEM.COMPOUND:57343974,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,19,0.856,0.856,0.0,0.0,0.428,85.6,False,-0.0,False,0.856,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,19,medik:edge#76,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,PUBCHEM.COMPOUND:57343974,"N-(3-(3-(9H-purin-6-yl)pyridin-2-ylamino)-2,4-difluorophenyl)-3-chlorobenzenesulfonamide",['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:affects,"[{'qualifier_type_id': 'biolink:object_aspect_qualifier', 'qualifier_value': 'activity'}, {'qualifier_type_id': 'biolink:object_direction_qualifier', 'qualifier_value': 'increased'}, {'qualifier_type_id': 'biolink:qualified_predicate', 'qualifier_value': 'biolink:causes'}]",one-hop,causes,,,,,increased,activity,,[],"N-(3-(3-(9H-purin-6-yl)pyridin-2-ylamino)-2,4-difluorophenyl)-3-chlorobenzenesulfonamide causes increased activity of BRAF",infores:bindingdb,0,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"N-(3-(3-(9H-purin-6-yl)pyridin-2-ylamino)-2,4-difluorophenyl)-3-chlorobenzenesulfonamide",PUBCHEM.COMPOUND:57343974,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,19,0.856,0.856,0.0,0.0,0.428,85.6,False,-0.0,False,0.856,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,19,medik:edge#77,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,biolink:gene_associated_with_condition,[],one-hop,,,,,,,,,['PMID:16439621'],DEFAULT PHRASE,infores:disgenet,1,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"US10167279, Example 43",PUBCHEM.COMPOUND:134609379,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,20,0.848,0.848,0.0,0.0,0.424,84.8,False,-0.0,False,0.848,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,20,medik:creative_edge#21,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,PUBCHEM.COMPOUND:134609379,"US10167279, Example 43",['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:treats,[],creative,,,,,,,,,[],DEFAULT PHRASE,infores:unsecret-agent,0,
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"US10167279, Example 43",PUBCHEM.COMPOUND:134609379,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,20,0.848,0.848,0.0,0.0,0.424,84.8,False,-0.0,False,0.848,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,20,medik:edge#42,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,PUBCHEM.COMPOUND:134609379,"US10167279, Example 43",['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:affects,"[{'qualifier_type_id': 'biolink:object_aspect_qualifier', 'qualifier_value': 'activity'}, {'qualifier_type_id': 'biolink:object_direction_qualifier', 'qualifier_value': 'decreased'}, {'qualifier_type_id': 'biolink:qualified_predicate', 'qualifier_value': 'biolink:causes'}]",one-hop,causes,,,,,decreased,activity,,[],"US10167279, Example 43 causes decreased activity of BRAF",infores:bindingdb,0,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"US10167279, Example 43",PUBCHEM.COMPOUND:134609379,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,20,0.848,0.848,0.0,0.0,0.424,84.8,False,-0.0,False,0.848,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,20,medik:edge#43,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,biolink:gene_associated_with_condition,[],one-hop,,,,,,,,,['PMID:16439621'],DEFAULT PHRASE,infores:disgenet,1,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"4-amino-N-(1-((4-((dimethylamino)methyl)-3-(trifluoromethyl)phenyl)amino)-6-methylisoquinolin-5-yl)imidazo[2,1-f][1,2,4]triazine-7-carboxamide",PUBCHEM.COMPOUND:163272140,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,21,0.84,0.84,0.0,0.0,0.42,84.0,False,-0.0,False,0.84,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,21,medik:creative_edge#30,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,PUBCHEM.COMPOUND:163272140,"4-amino-N-(1-((4-((dimethylamino)methyl)-3-(trifluoromethyl)phenyl)amino)-6-methylisoquinolin-5-yl)imidazo[2,1-f][1,2,4]triazine-7-carboxamide",['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:treats,[],creative,,,,,,,,,[],DEFAULT PHRASE,infores:unsecret-agent,0,
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"4-amino-N-(1-((4-((dimethylamino)methyl)-3-(trifluoromethyl)phenyl)amino)-6-methylisoquinolin-5-yl)imidazo[2,1-f][1,2,4]triazine-7-carboxamide",PUBCHEM.COMPOUND:163272140,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,21,0.84,0.84,0.0,0.0,0.42,84.0,False,-0.0,False,0.84,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,21,medik:edge#60,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,PUBCHEM.COMPOUND:163272140,"4-amino-N-(1-((4-((dimethylamino)methyl)-3-(trifluoromethyl)phenyl)amino)-6-methylisoquinolin-5-yl)imidazo[2,1-f][1,2,4]triazine-7-carboxamide",['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:affects,"[{'qualifier_type_id': 'biolink:object_aspect_qualifier', 'qualifier_value': 'activity'}, {'qualifier_type_id': 'biolink:object_direction_qualifier', 'qualifier_value': 'decreased'}, {'qualifier_type_id': 'biolink:qualified_predicate', 'qualifier_value': 'biolink:causes'}]",one-hop,causes,,,,,decreased,activity,,[],"4-amino-N-(1-((4-((dimethylamino)methyl)-3-(trifluoromethyl)phenyl)amino)-6-methylisoquinolin-5-yl)imidazo[2,1-f][1,2,4]triazine-7-carboxamide causes decreased activity of BRAF",infores:bindingdb,0,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"4-amino-N-(1-((4-((dimethylamino)methyl)-3-(trifluoromethyl)phenyl)amino)-6-methylisoquinolin-5-yl)imidazo[2,1-f][1,2,4]triazine-7-carboxamide",PUBCHEM.COMPOUND:163272140,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,21,0.84,0.84,0.0,0.0,0.42,84.0,False,-0.0,False,0.84,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,21,medik:edge#61,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,biolink:gene_associated_with_condition,[],one-hop,,,,,,,,,['PMID:16439621'],DEFAULT PHRASE,infores:disgenet,1,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"4-amino-N-(6-methyl-1-((2-methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)amino)isoquinolin-5-yl)quinazoline-8-carboxamide",PUBCHEM.COMPOUND:163272170,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,22,0.832,0.832,0.0,0.0,0.416,83.2,False,-0.0,False,0.832,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,22,medik:creative_edge#31,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,PUBCHEM.COMPOUND:163272170,"4-amino-N-(6-methyl-1-((2-methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)amino)isoquinolin-5-yl)quinazoline-8-carboxamide",['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:treats,[],creative,,,,,,,,,[],DEFAULT PHRASE,infores:unsecret-agent,0,
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"4-amino-N-(6-methyl-1-((2-methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)amino)isoquinolin-5-yl)quinazoline-8-carboxamide",PUBCHEM.COMPOUND:163272170,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,22,0.832,0.832,0.0,0.0,0.416,83.2,False,-0.0,False,0.832,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,22,medik:edge#62,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,PUBCHEM.COMPOUND:163272170,"4-amino-N-(6-methyl-1-((2-methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)amino)isoquinolin-5-yl)quinazoline-8-carboxamide",['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:affects,"[{'qualifier_type_id': 'biolink:object_aspect_qualifier', 'qualifier_value': 'activity'}, {'qualifier_type_id': 'biolink:object_direction_qualifier', 'qualifier_value': 'decreased'}, {'qualifier_type_id': 'biolink:qualified_predicate', 'qualifier_value': 'biolink:causes'}]",one-hop,causes,,,,,decreased,activity,,[],"4-amino-N-(6-methyl-1-((2-methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)amino)isoquinolin-5-yl)quinazoline-8-carboxamide causes decreased activity of BRAF",infores:bindingdb,0,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"4-amino-N-(6-methyl-1-((2-methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)amino)isoquinolin-5-yl)quinazoline-8-carboxamide",PUBCHEM.COMPOUND:163272170,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,22,0.832,0.832,0.0,0.0,0.416,83.2,False,-0.0,False,0.832,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,22,medik:edge#63,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,biolink:gene_associated_with_condition,[],one-hop,,,,,,,,,['PMID:16439621'],DEFAULT PHRASE,infores:disgenet,1,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,2-(2-fluoropropan-2-yl)-N-[3-(6-methoxy-5-morpholin-4-ylpyridazin-3-yl)-4-methylphenyl]pyridine-4-carboxamide,PUBCHEM.COMPOUND:90461011,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,23,0.824,0.824,0.0,0.0,0.412,82.4,False,-0.0,False,0.824,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,23,medik:creative_edge#78,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,PUBCHEM.COMPOUND:90461011,2-(2-fluoropropan-2-yl)-N-[3-(6-methoxy-5-morpholin-4-ylpyridazin-3-yl)-4-methylphenyl]pyridine-4-carboxamide,['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:treats,[],creative,,,,,,,,,[],DEFAULT PHRASE,infores:unsecret-agent,0,
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,2-(2-fluoropropan-2-yl)-N-[3-(6-methoxy-5-morpholin-4-ylpyridazin-3-yl)-4-methylphenyl]pyridine-4-carboxamide,PUBCHEM.COMPOUND:90461011,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,23,0.824,0.824,0.0,0.0,0.412,82.4,False,-0.0,False,0.824,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,23,medik:edge#156,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,PUBCHEM.COMPOUND:90461011,2-(2-fluoropropan-2-yl)-N-[3-(6-methoxy-5-morpholin-4-ylpyridazin-3-yl)-4-methylphenyl]pyridine-4-carboxamide,['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:affects,"[{'qualifier_type_id': 'biolink:object_aspect_qualifier', 'qualifier_value': 'activity'}, {'qualifier_type_id': 'biolink:object_direction_qualifier', 'qualifier_value': 'decreased'}, {'qualifier_type_id': 'biolink:qualified_predicate', 'qualifier_value': 'biolink:causes'}]",one-hop,causes,,,,,decreased,activity,,[],2-(2-fluoropropan-2-yl)-N-[3-(6-methoxy-5-morpholin-4-ylpyridazin-3-yl)-4-methylphenyl]pyridine-4-carboxamide causes decreased activity of BRAF,infores:bindingdb,0,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,2-(2-fluoropropan-2-yl)-N-[3-(6-methoxy-5-morpholin-4-ylpyridazin-3-yl)-4-methylphenyl]pyridine-4-carboxamide,PUBCHEM.COMPOUND:90461011,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,23,0.824,0.824,0.0,0.0,0.412,82.4,False,-0.0,False,0.824,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,23,medik:edge#157,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,biolink:gene_associated_with_condition,[],one-hop,,,,,,,,,['PMID:16439621'],DEFAULT PHRASE,infores:disgenet,1,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,4-[4-(4-Fluorophenyl)-1-[4-(trifluoromethyl)phenyl]pyrazol-3-yl]pyridine,PUBCHEM.COMPOUND:56951008,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,24,0.816,0.816,0.0,0.0,0.408,81.6,False,-0.0,False,0.816,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,24,medik:creative_edge#120,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,PUBCHEM.COMPOUND:56951008,4-[4-(4-Fluorophenyl)-1-[4-(trifluoromethyl)phenyl]pyrazol-3-yl]pyridine,['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:treats,[],creative,,,,,,,,,[],DEFAULT PHRASE,infores:unsecret-agent,0,
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,4-[4-(4-Fluorophenyl)-1-[4-(trifluoromethyl)phenyl]pyrazol-3-yl]pyridine,PUBCHEM.COMPOUND:56951008,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,24,0.816,0.816,0.0,0.0,0.408,81.6,False,-0.0,False,0.816,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,24,medik:edge#240,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,PUBCHEM.COMPOUND:56951008,4-[4-(4-Fluorophenyl)-1-[4-(trifluoromethyl)phenyl]pyrazol-3-yl]pyridine,['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:affects,"[{'qualifier_type_id': 'biolink:object_aspect_qualifier', 'qualifier_value': 'activity'}, {'qualifier_type_id': 'biolink:object_direction_qualifier', 'qualifier_value': 'decreased'}, {'qualifier_type_id': 'biolink:qualified_predicate', 'qualifier_value': 'biolink:causes'}]",one-hop,causes,,,,,decreased,activity,,[],4-[4-(4-Fluorophenyl)-1-[4-(trifluoromethyl)phenyl]pyrazol-3-yl]pyridine causes decreased activity of BRAF,infores:bindingdb,0,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,4-[4-(4-Fluorophenyl)-1-[4-(trifluoromethyl)phenyl]pyrazol-3-yl]pyridine,PUBCHEM.COMPOUND:56951008,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,24,0.816,0.816,0.0,0.0,0.408,81.6,False,-0.0,False,0.816,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,24,medik:edge#241,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,biolink:gene_associated_with_condition,[],one-hop,,,,,,,,,['PMID:16439621'],DEFAULT PHRASE,infores:disgenet,1,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"5-((1-(6-(trifluoromethyl)-1H-benzo[d]imidazol-2-yl)-1a,6b-dihydro-1H-cyclopropa[b]benzofuran-5-yl)oxy)-3,4-dihydro-1,8-naphthyridin-2(1H)-one",PUBCHEM.COMPOUND:71622942,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,25,0.808,0.808,0.0,0.0,0.404,80.8,False,-0.0,False,0.808,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,25,medik:creative_edge#70,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,PUBCHEM.COMPOUND:71622942,"5-((1-(6-(trifluoromethyl)-1H-benzo[d]imidazol-2-yl)-1a,6b-dihydro-1H-cyclopropa[b]benzofuran-5-yl)oxy)-3,4-dihydro-1,8-naphthyridin-2(1H)-one",['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:treats,[],creative,,,,,,,,,[],DEFAULT PHRASE,infores:unsecret-agent,0,
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"5-((1-(6-(trifluoromethyl)-1H-benzo[d]imidazol-2-yl)-1a,6b-dihydro-1H-cyclopropa[b]benzofuran-5-yl)oxy)-3,4-dihydro-1,8-naphthyridin-2(1H)-one",PUBCHEM.COMPOUND:71622942,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,25,0.808,0.808,0.0,0.0,0.404,80.8,False,-0.0,False,0.808,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,25,medik:edge#140,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,PUBCHEM.COMPOUND:71622942,"5-((1-(6-(trifluoromethyl)-1H-benzo[d]imidazol-2-yl)-1a,6b-dihydro-1H-cyclopropa[b]benzofuran-5-yl)oxy)-3,4-dihydro-1,8-naphthyridin-2(1H)-one",['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:affects,"[{'qualifier_type_id': 'biolink:object_aspect_qualifier', 'qualifier_value': 'activity'}, {'qualifier_type_id': 'biolink:object_direction_qualifier', 'qualifier_value': 'decreased'}, {'qualifier_type_id': 'biolink:qualified_predicate', 'qualifier_value': 'biolink:causes'}]",one-hop,causes,,,,,decreased,activity,,[],"5-((1-(6-(trifluoromethyl)-1H-benzo[d]imidazol-2-yl)-1a,6b-dihydro-1H-cyclopropa[b]benzofuran-5-yl)oxy)-3,4-dihydro-1,8-naphthyridin-2(1H)-one causes decreased activity of BRAF",infores:bindingdb,0,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"5-((1-(6-(trifluoromethyl)-1H-benzo[d]imidazol-2-yl)-1a,6b-dihydro-1H-cyclopropa[b]benzofuran-5-yl)oxy)-3,4-dihydro-1,8-naphthyridin-2(1H)-one",PUBCHEM.COMPOUND:71622942,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,25,0.808,0.808,0.0,0.0,0.404,80.8,False,-0.0,False,0.808,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,25,medik:edge#141,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,biolink:gene_associated_with_condition,[],one-hop,,,,,,,,,['PMID:16439621'],DEFAULT PHRASE,infores:disgenet,1,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,N-[2-chloro-3-(2-cyclopropyl-5-pyrimidin-4-yl-1H-imidazol-4-yl)-5-fluorophenyl]methanesulfonamide,PUBCHEM.COMPOUND:50997149,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,26,0.8,0.8,0.0,0.0,0.4,80.0,False,-0.0,False,0.8,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,26,medik:creative_edge#35,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,PUBCHEM.COMPOUND:50997149,N-[2-chloro-3-(2-cyclopropyl-5-pyrimidin-4-yl-1H-imidazol-4-yl)-5-fluorophenyl]methanesulfonamide,['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:treats,[],creative,,,,,,,,,[],DEFAULT PHRASE,infores:unsecret-agent,0,
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,N-[2-chloro-3-(2-cyclopropyl-5-pyrimidin-4-yl-1H-imidazol-4-yl)-5-fluorophenyl]methanesulfonamide,PUBCHEM.COMPOUND:50997149,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,26,0.8,0.8,0.0,0.0,0.4,80.0,False,-0.0,False,0.8,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,26,medik:edge#70,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,PUBCHEM.COMPOUND:50997149,N-[2-chloro-3-(2-cyclopropyl-5-pyrimidin-4-yl-1H-imidazol-4-yl)-5-fluorophenyl]methanesulfonamide,['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:affects,"[{'qualifier_type_id': 'biolink:object_aspect_qualifier', 'qualifier_value': 'activity'}, {'qualifier_type_id': 'biolink:object_direction_qualifier', 'qualifier_value': 'decreased'}, {'qualifier_type_id': 'biolink:qualified_predicate', 'qualifier_value': 'biolink:causes'}]",one-hop,causes,,,,,decreased,activity,,[],N-[2-chloro-3-(2-cyclopropyl-5-pyrimidin-4-yl-1H-imidazol-4-yl)-5-fluorophenyl]methanesulfonamide causes decreased activity of BRAF,infores:bindingdb,0,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,N-[2-chloro-3-(2-cyclopropyl-5-pyrimidin-4-yl-1H-imidazol-4-yl)-5-fluorophenyl]methanesulfonamide,PUBCHEM.COMPOUND:50997149,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,26,0.8,0.8,0.0,0.0,0.4,80.0,False,-0.0,False,0.8,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,26,medik:edge#71,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,biolink:gene_associated_with_condition,[],one-hop,,,,,,,,,['PMID:16439621'],DEFAULT PHRASE,infores:disgenet,1,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"N-[5-chloro-3-(3,5-dimethyl-4-oxoquinazolin-6-yl)oxy-2-fluorophenyl]propane-1-sulfonamide",PUBCHEM.COMPOUND:155434917,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,27,0.792,0.792,0.0,0.0,0.396,79.2,False,-0.0,False,0.792,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,27,medik:creative_edge#107,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,PUBCHEM.COMPOUND:155434917,"N-[5-chloro-3-(3,5-dimethyl-4-oxoquinazolin-6-yl)oxy-2-fluorophenyl]propane-1-sulfonamide",['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:treats,[],creative,,,,,,,,,[],DEFAULT PHRASE,infores:unsecret-agent,0,
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"N-[5-chloro-3-(3,5-dimethyl-4-oxoquinazolin-6-yl)oxy-2-fluorophenyl]propane-1-sulfonamide",PUBCHEM.COMPOUND:155434917,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,27,0.792,0.792,0.0,0.0,0.396,79.2,False,-0.0,False,0.792,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,27,medik:edge#214,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,PUBCHEM.COMPOUND:155434917,"N-[5-chloro-3-(3,5-dimethyl-4-oxoquinazolin-6-yl)oxy-2-fluorophenyl]propane-1-sulfonamide",['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:affects,"[{'qualifier_type_id': 'biolink:object_aspect_qualifier', 'qualifier_value': 'activity'}, {'qualifier_type_id': 'biolink:object_direction_qualifier', 'qualifier_value': 'decreased'}, {'qualifier_type_id': 'biolink:qualified_predicate', 'qualifier_value': 'biolink:causes'}]",one-hop,causes,,,,,decreased,activity,,[],"N-[5-chloro-3-(3,5-dimethyl-4-oxoquinazolin-6-yl)oxy-2-fluorophenyl]propane-1-sulfonamide causes decreased activity of BRAF",infores:bindingdb,0,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"N-[5-chloro-3-(3,5-dimethyl-4-oxoquinazolin-6-yl)oxy-2-fluorophenyl]propane-1-sulfonamide",PUBCHEM.COMPOUND:155434917,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,27,0.792,0.792,0.0,0.0,0.396,79.2,False,-0.0,False,0.792,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,27,medik:edge#215,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,biolink:gene_associated_with_condition,[],one-hop,,,,,,,,,['PMID:16439621'],DEFAULT PHRASE,infores:disgenet,1,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,methyl N-[(2S)-1-[[4-[4-[2-fluoro-3-(methanesulfonamido)-5-methylphenyl]-2-(1-methylcyclopropyl)-1H-imidazol-5-yl]pyrimidin-2-yl]amino]propan-2-yl]carbamate,PUBCHEM.COMPOUND:50996975,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,28,0.784,0.784,0.0,0.0,0.392,78.4,False,-0.0,False,0.784,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,28,medik:creative_edge#34,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,PUBCHEM.COMPOUND:50996975,methyl N-[(2S)-1-[[4-[4-[2-fluoro-3-(methanesulfonamido)-5-methylphenyl]-2-(1-methylcyclopropyl)-1H-imidazol-5-yl]pyrimidin-2-yl]amino]propan-2-yl]carbamate,['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:treats,[],creative,,,,,,,,,[],DEFAULT PHRASE,infores:unsecret-agent,0,
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,methyl N-[(2S)-1-[[4-[4-[2-fluoro-3-(methanesulfonamido)-5-methylphenyl]-2-(1-methylcyclopropyl)-1H-imidazol-5-yl]pyrimidin-2-yl]amino]propan-2-yl]carbamate,PUBCHEM.COMPOUND:50996975,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,28,0.784,0.784,0.0,0.0,0.392,78.4,False,-0.0,False,0.784,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,28,medik:edge#68,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,PUBCHEM.COMPOUND:50996975,methyl N-[(2S)-1-[[4-[4-[2-fluoro-3-(methanesulfonamido)-5-methylphenyl]-2-(1-methylcyclopropyl)-1H-imidazol-5-yl]pyrimidin-2-yl]amino]propan-2-yl]carbamate,['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:affects,"[{'qualifier_type_id': 'biolink:object_aspect_qualifier', 'qualifier_value': 'activity'}, {'qualifier_type_id': 'biolink:object_direction_qualifier', 'qualifier_value': 'decreased'}, {'qualifier_type_id': 'biolink:qualified_predicate', 'qualifier_value': 'biolink:causes'}]",one-hop,causes,,,,,decreased,activity,,[],methyl N-[(2S)-1-[[4-[4-[2-fluoro-3-(methanesulfonamido)-5-methylphenyl]-2-(1-methylcyclopropyl)-1H-imidazol-5-yl]pyrimidin-2-yl]amino]propan-2-yl]carbamate causes decreased activity of BRAF,infores:bindingdb,0,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,methyl N-[(2S)-1-[[4-[4-[2-fluoro-3-(methanesulfonamido)-5-methylphenyl]-2-(1-methylcyclopropyl)-1H-imidazol-5-yl]pyrimidin-2-yl]amino]propan-2-yl]carbamate,PUBCHEM.COMPOUND:50996975,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,28,0.784,0.784,0.0,0.0,0.392,78.4,False,-0.0,False,0.784,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,28,medik:edge#69,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,biolink:gene_associated_with_condition,[],one-hop,,,,,,,,,['PMID:16439621'],DEFAULT PHRASE,infores:disgenet,1,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"3,4-difluoro-2-(2-fluoro-4-iodoanilino)-5-[[3-fluoro-2-(methylsulfamoylamino)pyridin-4-yl]methyl]-N-(2-methoxyethoxy)benzamide",PUBCHEM.COMPOUND:156808884,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,29,0.776,0.776,0.0,0.0,0.388,77.6,False,-0.0,False,0.776,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,29,medik:creative_edge#28,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,PUBCHEM.COMPOUND:156808884,"3,4-difluoro-2-(2-fluoro-4-iodoanilino)-5-[[3-fluoro-2-(methylsulfamoylamino)pyridin-4-yl]methyl]-N-(2-methoxyethoxy)benzamide",['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:treats,[],creative,,,,,,,,,[],DEFAULT PHRASE,infores:unsecret-agent,0,
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"3,4-difluoro-2-(2-fluoro-4-iodoanilino)-5-[[3-fluoro-2-(methylsulfamoylamino)pyridin-4-yl]methyl]-N-(2-methoxyethoxy)benzamide",PUBCHEM.COMPOUND:156808884,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,29,0.776,0.776,0.0,0.0,0.388,77.6,False,-0.0,False,0.776,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,29,medik:edge#56,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,PUBCHEM.COMPOUND:156808884,"3,4-difluoro-2-(2-fluoro-4-iodoanilino)-5-[[3-fluoro-2-(methylsulfamoylamino)pyridin-4-yl]methyl]-N-(2-methoxyethoxy)benzamide",['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:affects,"[{'qualifier_type_id': 'biolink:object_aspect_qualifier', 'qualifier_value': 'activity'}, {'qualifier_type_id': 'biolink:object_direction_qualifier', 'qualifier_value': 'decreased'}, {'qualifier_type_id': 'biolink:qualified_predicate', 'qualifier_value': 'biolink:causes'}]",one-hop,causes,,,,,decreased,activity,,[],"3,4-difluoro-2-(2-fluoro-4-iodoanilino)-5-[[3-fluoro-2-(methylsulfamoylamino)pyridin-4-yl]methyl]-N-(2-methoxyethoxy)benzamide causes decreased activity of BRAF",infores:bindingdb,0,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"3,4-difluoro-2-(2-fluoro-4-iodoanilino)-5-[[3-fluoro-2-(methylsulfamoylamino)pyridin-4-yl]methyl]-N-(2-methoxyethoxy)benzamide",PUBCHEM.COMPOUND:156808884,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,29,0.776,0.776,0.0,0.0,0.388,77.6,False,-0.0,False,0.776,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,29,medik:edge#57,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,biolink:gene_associated_with_condition,[],one-hop,,,,,,,,,['PMID:16439621'],DEFAULT PHRASE,infores:disgenet,1,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"5-[(2-Amino-3-fluoropyridin-4-yl)methyl]-3,4-difluoro-2-(2-fluoro-4-iodoanilino)benzoic acid",PUBCHEM.COMPOUND:156808894,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,30,0.768,0.768,0.0,0.0,0.384,76.8,False,-0.0,False,0.768,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,30,medik:creative_edge#29,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,PUBCHEM.COMPOUND:156808894,"5-[(2-Amino-3-fluoropyridin-4-yl)methyl]-3,4-difluoro-2-(2-fluoro-4-iodoanilino)benzoic acid",['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:treats,[],creative,,,,,,,,,[],DEFAULT PHRASE,infores:unsecret-agent,0,
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"5-[(2-Amino-3-fluoropyridin-4-yl)methyl]-3,4-difluoro-2-(2-fluoro-4-iodoanilino)benzoic acid",PUBCHEM.COMPOUND:156808894,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,30,0.768,0.768,0.0,0.0,0.384,76.8,False,-0.0,False,0.768,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,30,medik:edge#58,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,PUBCHEM.COMPOUND:156808894,"5-[(2-Amino-3-fluoropyridin-4-yl)methyl]-3,4-difluoro-2-(2-fluoro-4-iodoanilino)benzoic acid",['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:affects,"[{'qualifier_type_id': 'biolink:object_aspect_qualifier', 'qualifier_value': 'activity'}, {'qualifier_type_id': 'biolink:object_direction_qualifier', 'qualifier_value': 'decreased'}, {'qualifier_type_id': 'biolink:qualified_predicate', 'qualifier_value': 'biolink:causes'}]",one-hop,causes,,,,,decreased,activity,,[],"5-[(2-Amino-3-fluoropyridin-4-yl)methyl]-3,4-difluoro-2-(2-fluoro-4-iodoanilino)benzoic acid causes decreased activity of BRAF",infores:bindingdb,0,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"5-[(2-Amino-3-fluoropyridin-4-yl)methyl]-3,4-difluoro-2-(2-fluoro-4-iodoanilino)benzoic acid",PUBCHEM.COMPOUND:156808894,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,30,0.768,0.768,0.0,0.0,0.384,76.8,False,-0.0,False,0.768,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,30,medik:edge#59,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,biolink:gene_associated_with_condition,[],one-hop,,,,,,,,,['PMID:16439621'],DEFAULT PHRASE,infores:disgenet,1,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"N-[2-fluoro-3-[5-[6-(4-methylpiperazin-1-yl)pyrimidin-4-yl]-1H-pyrrolo[2,3-b]pyridine-3-carbonyl]phenyl]pyrrolidine-1-sulfonamide",PUBCHEM.COMPOUND:60164773,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,31,0.76,0.76,0.0,0.0,0.38,76.0,False,-0.0,False,0.76,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,31,medik:creative_edge#44,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,PUBCHEM.COMPOUND:60164773,"N-[2-fluoro-3-[5-[6-(4-methylpiperazin-1-yl)pyrimidin-4-yl]-1H-pyrrolo[2,3-b]pyridine-3-carbonyl]phenyl]pyrrolidine-1-sulfonamide",['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:treats,[],creative,,,,,,,,,[],DEFAULT PHRASE,infores:unsecret-agent,0,
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"N-[2-fluoro-3-[5-[6-(4-methylpiperazin-1-yl)pyrimidin-4-yl]-1H-pyrrolo[2,3-b]pyridine-3-carbonyl]phenyl]pyrrolidine-1-sulfonamide",PUBCHEM.COMPOUND:60164773,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,31,0.76,0.76,0.0,0.0,0.38,76.0,False,-0.0,False,0.76,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,31,medik:edge#88,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,PUBCHEM.COMPOUND:60164773,"N-[2-fluoro-3-[5-[6-(4-methylpiperazin-1-yl)pyrimidin-4-yl]-1H-pyrrolo[2,3-b]pyridine-3-carbonyl]phenyl]pyrrolidine-1-sulfonamide",['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:affects,"[{'qualifier_type_id': 'biolink:object_aspect_qualifier', 'qualifier_value': 'activity'}, {'qualifier_type_id': 'biolink:object_direction_qualifier', 'qualifier_value': 'decreased'}, {'qualifier_type_id': 'biolink:qualified_predicate', 'qualifier_value': 'biolink:causes'}]",one-hop,causes,,,,,decreased,activity,,[],"N-[2-fluoro-3-[5-[6-(4-methylpiperazin-1-yl)pyrimidin-4-yl]-1H-pyrrolo[2,3-b]pyridine-3-carbonyl]phenyl]pyrrolidine-1-sulfonamide causes decreased activity of BRAF",infores:bindingdb,0,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"N-[2-fluoro-3-[5-[6-(4-methylpiperazin-1-yl)pyrimidin-4-yl]-1H-pyrrolo[2,3-b]pyridine-3-carbonyl]phenyl]pyrrolidine-1-sulfonamide",PUBCHEM.COMPOUND:60164773,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,31,0.76,0.76,0.0,0.0,0.38,76.0,False,-0.0,False,0.76,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,31,medik:edge#89,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,biolink:gene_associated_with_condition,[],one-hop,,,,,,,,,['PMID:16439621'],DEFAULT PHRASE,infores:disgenet,1,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,5-tert-butyl-N-[4-methyl-3-[4-[5-(4-prop-2-enylpiperazin-1-yl)pyridin-3-yl]triazol-1-yl]phenyl]furan-2-carboxamide,PUBCHEM.COMPOUND:89708498,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,32,0.752,0.752,0.0,0.0,0.376,75.2,False,-0.0,False,0.752,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,32,medik:creative_edge#73,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,PUBCHEM.COMPOUND:89708498,5-tert-butyl-N-[4-methyl-3-[4-[5-(4-prop-2-enylpiperazin-1-yl)pyridin-3-yl]triazol-1-yl]phenyl]furan-2-carboxamide,['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:treats,[],creative,,,,,,,,,[],DEFAULT PHRASE,infores:unsecret-agent,0,
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,5-tert-butyl-N-[4-methyl-3-[4-[5-(4-prop-2-enylpiperazin-1-yl)pyridin-3-yl]triazol-1-yl]phenyl]furan-2-carboxamide,PUBCHEM.COMPOUND:89708498,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,32,0.752,0.752,0.0,0.0,0.376,75.2,False,-0.0,False,0.752,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,32,medik:edge#146,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,PUBCHEM.COMPOUND:89708498,5-tert-butyl-N-[4-methyl-3-[4-[5-(4-prop-2-enylpiperazin-1-yl)pyridin-3-yl]triazol-1-yl]phenyl]furan-2-carboxamide,['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:affects,"[{'qualifier_type_id': 'biolink:object_aspect_qualifier', 'qualifier_value': 'activity'}, {'qualifier_type_id': 'biolink:object_direction_qualifier', 'qualifier_value': 'decreased'}, {'qualifier_type_id': 'biolink:qualified_predicate', 'qualifier_value': 'biolink:causes'}]",one-hop,causes,,,,,decreased,activity,,[],5-tert-butyl-N-[4-methyl-3-[4-[5-(4-prop-2-enylpiperazin-1-yl)pyridin-3-yl]triazol-1-yl]phenyl]furan-2-carboxamide causes decreased activity of BRAF,infores:bindingdb,0,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,5-tert-butyl-N-[4-methyl-3-[4-[5-(4-prop-2-enylpiperazin-1-yl)pyridin-3-yl]triazol-1-yl]phenyl]furan-2-carboxamide,PUBCHEM.COMPOUND:89708498,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,32,0.752,0.752,0.0,0.0,0.376,75.2,False,-0.0,False,0.752,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,32,medik:edge#147,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,biolink:gene_associated_with_condition,[],one-hop,,,,,,,,,['PMID:16439621'],DEFAULT PHRASE,infores:disgenet,1,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,2-cyclopropyl-N-[3-[2-(2-hydroxyethoxy)-6-morpholin-4-ylpyridin-4-yl]-4-methylphenyl]pyridine-4-carboxamide,PUBCHEM.COMPOUND:90463671,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,33,0.744,0.744,0.0,0.0,0.372,74.4,False,-0.0,False,0.744,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,33,medik:creative_edge#80,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,PUBCHEM.COMPOUND:90463671,2-cyclopropyl-N-[3-[2-(2-hydroxyethoxy)-6-morpholin-4-ylpyridin-4-yl]-4-methylphenyl]pyridine-4-carboxamide,['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:treats,[],creative,,,,,,,,,[],DEFAULT PHRASE,infores:unsecret-agent,0,
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,2-cyclopropyl-N-[3-[2-(2-hydroxyethoxy)-6-morpholin-4-ylpyridin-4-yl]-4-methylphenyl]pyridine-4-carboxamide,PUBCHEM.COMPOUND:90463671,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,33,0.744,0.744,0.0,0.0,0.372,74.4,False,-0.0,False,0.744,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,33,medik:edge#160,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,PUBCHEM.COMPOUND:90463671,2-cyclopropyl-N-[3-[2-(2-hydroxyethoxy)-6-morpholin-4-ylpyridin-4-yl]-4-methylphenyl]pyridine-4-carboxamide,['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:affects,"[{'qualifier_type_id': 'biolink:object_aspect_qualifier', 'qualifier_value': 'activity'}, {'qualifier_type_id': 'biolink:object_direction_qualifier', 'qualifier_value': 'decreased'}, {'qualifier_type_id': 'biolink:qualified_predicate', 'qualifier_value': 'biolink:causes'}]",one-hop,causes,,,,,decreased,activity,,[],2-cyclopropyl-N-[3-[2-(2-hydroxyethoxy)-6-morpholin-4-ylpyridin-4-yl]-4-methylphenyl]pyridine-4-carboxamide causes decreased activity of BRAF,infores:bindingdb,0,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,2-cyclopropyl-N-[3-[2-(2-hydroxyethoxy)-6-morpholin-4-ylpyridin-4-yl]-4-methylphenyl]pyridine-4-carboxamide,PUBCHEM.COMPOUND:90463671,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,33,0.744,0.744,0.0,0.0,0.372,74.4,False,-0.0,False,0.744,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,33,medik:edge#161,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,biolink:gene_associated_with_condition,[],one-hop,,,,,,,,,['PMID:16439621'],DEFAULT PHRASE,infores:disgenet,1,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"US8653087, III-276",PUBCHEM.COMPOUND:68036023,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,34,0.736,0.736,0.0,0.0,0.368,73.6,False,-0.0,False,0.736,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,34,medik:creative_edge#56,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,PUBCHEM.COMPOUND:68036023,"US8653087, III-276",['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:treats,[],creative,,,,,,,,,[],DEFAULT PHRASE,infores:unsecret-agent,0,
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"US8653087, III-276",PUBCHEM.COMPOUND:68036023,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,34,0.736,0.736,0.0,0.0,0.368,73.6,False,-0.0,False,0.736,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,34,medik:edge#112,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,PUBCHEM.COMPOUND:68036023,"US8653087, III-276",['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:affects,"[{'qualifier_type_id': 'biolink:object_aspect_qualifier', 'qualifier_value': 'activity'}, {'qualifier_type_id': 'biolink:object_direction_qualifier', 'qualifier_value': 'decreased'}, {'qualifier_type_id': 'biolink:qualified_predicate', 'qualifier_value': 'biolink:causes'}]",one-hop,causes,,,,,decreased,activity,,[],"US8653087, III-276 causes decreased activity of BRAF",infores:bindingdb,0,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"US8653087, III-276",PUBCHEM.COMPOUND:68036023,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,34,0.736,0.736,0.0,0.0,0.368,73.6,False,-0.0,False,0.736,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,34,medik:edge#113,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,biolink:gene_associated_with_condition,[],one-hop,,,,,,,,,['PMID:16439621'],DEFAULT PHRASE,infores:disgenet,1,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"US10245267, Example 877",PUBCHEM.COMPOUND:130416857,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,35,0.728,0.728,0.0,0.0,0.364,72.8,False,-0.0,False,0.728,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,35,medik:creative_edge#102,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,PUBCHEM.COMPOUND:130416857,"US10245267, Example 877",['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:treats,[],creative,,,,,,,,,[],DEFAULT PHRASE,infores:unsecret-agent,0,
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"US10245267, Example 877",PUBCHEM.COMPOUND:130416857,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,35,0.728,0.728,0.0,0.0,0.364,72.8,False,-0.0,False,0.728,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,35,medik:edge#204,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,PUBCHEM.COMPOUND:130416857,"US10245267, Example 877",['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:affects,"[{'qualifier_type_id': 'biolink:object_aspect_qualifier', 'qualifier_value': 'activity'}, {'qualifier_type_id': 'biolink:object_direction_qualifier', 'qualifier_value': 'decreased'}, {'qualifier_type_id': 'biolink:qualified_predicate', 'qualifier_value': 'biolink:causes'}]",one-hop,causes,,,,,decreased,activity,,[],"US10245267, Example 877 causes decreased activity of BRAF",infores:bindingdb,0,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"US10245267, Example 877",PUBCHEM.COMPOUND:130416857,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,35,0.728,0.728,0.0,0.0,0.364,72.8,False,-0.0,False,0.728,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,35,medik:edge#205,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,biolink:gene_associated_with_condition,[],one-hop,,,,,,,,,['PMID:16439621'],DEFAULT PHRASE,infores:disgenet,1,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,N-[5-[2-(2-hydroxyethylamino)-6-morpholin-4-ylpyridin-4-yl]-6-methylpyridin-3-yl]-2-(2-hydroxypropan-2-yl)pyridine-4-carboxamide,PUBCHEM.COMPOUND:117609825,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,36,0.72,0.72,0.0,0.0,0.36,72.0,False,-0.0,False,0.72,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,36,medik:creative_edge#9,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,PUBCHEM.COMPOUND:117609825,N-[5-[2-(2-hydroxyethylamino)-6-morpholin-4-ylpyridin-4-yl]-6-methylpyridin-3-yl]-2-(2-hydroxypropan-2-yl)pyridine-4-carboxamide,['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:treats,[],creative,,,,,,,,,[],DEFAULT PHRASE,infores:unsecret-agent,0,
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,N-[5-[2-(2-hydroxyethylamino)-6-morpholin-4-ylpyridin-4-yl]-6-methylpyridin-3-yl]-2-(2-hydroxypropan-2-yl)pyridine-4-carboxamide,PUBCHEM.COMPOUND:117609825,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,36,0.72,0.72,0.0,0.0,0.36,72.0,False,-0.0,False,0.72,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,36,medik:edge#18,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,PUBCHEM.COMPOUND:117609825,N-[5-[2-(2-hydroxyethylamino)-6-morpholin-4-ylpyridin-4-yl]-6-methylpyridin-3-yl]-2-(2-hydroxypropan-2-yl)pyridine-4-carboxamide,['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:affects,"[{'qualifier_type_id': 'biolink:object_aspect_qualifier', 'qualifier_value': 'activity'}, {'qualifier_type_id': 'biolink:object_direction_qualifier', 'qualifier_value': 'decreased'}, {'qualifier_type_id': 'biolink:qualified_predicate', 'qualifier_value': 'biolink:causes'}]",one-hop,causes,,,,,decreased,activity,,[],N-[5-[2-(2-hydroxyethylamino)-6-morpholin-4-ylpyridin-4-yl]-6-methylpyridin-3-yl]-2-(2-hydroxypropan-2-yl)pyridine-4-carboxamide causes decreased activity of BRAF,infores:bindingdb,0,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,N-[5-[2-(2-hydroxyethylamino)-6-morpholin-4-ylpyridin-4-yl]-6-methylpyridin-3-yl]-2-(2-hydroxypropan-2-yl)pyridine-4-carboxamide,PUBCHEM.COMPOUND:117609825,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,36,0.72,0.72,0.0,0.0,0.36,72.0,False,-0.0,False,0.72,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,36,medik:edge#19,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,biolink:gene_associated_with_condition,[],one-hop,,,,,,,,,['PMID:16439621'],DEFAULT PHRASE,infores:disgenet,1,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,N-[4-methyl-3-(5-morpholin-4-yl-6-propan-2-yloxypyridazin-3-yl)phenyl]-4-(trifluoromethyl)pyridine-2-carboxamide,PUBCHEM.COMPOUND:90456617,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,37,0.712,0.712,0.0,0.0,0.356,71.2,False,-0.0,False,0.712,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,37,medik:creative_edge#75,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,PUBCHEM.COMPOUND:90456617,N-[4-methyl-3-(5-morpholin-4-yl-6-propan-2-yloxypyridazin-3-yl)phenyl]-4-(trifluoromethyl)pyridine-2-carboxamide,['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:treats,[],creative,,,,,,,,,[],DEFAULT PHRASE,infores:unsecret-agent,0,
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,N-[4-methyl-3-(5-morpholin-4-yl-6-propan-2-yloxypyridazin-3-yl)phenyl]-4-(trifluoromethyl)pyridine-2-carboxamide,PUBCHEM.COMPOUND:90456617,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,37,0.712,0.712,0.0,0.0,0.356,71.2,False,-0.0,False,0.712,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,37,medik:edge#150,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,PUBCHEM.COMPOUND:90456617,N-[4-methyl-3-(5-morpholin-4-yl-6-propan-2-yloxypyridazin-3-yl)phenyl]-4-(trifluoromethyl)pyridine-2-carboxamide,['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:affects,"[{'qualifier_type_id': 'biolink:object_aspect_qualifier', 'qualifier_value': 'activity'}, {'qualifier_type_id': 'biolink:object_direction_qualifier', 'qualifier_value': 'decreased'}, {'qualifier_type_id': 'biolink:qualified_predicate', 'qualifier_value': 'biolink:causes'}]",one-hop,causes,,,,,decreased,activity,,[],N-[4-methyl-3-(5-morpholin-4-yl-6-propan-2-yloxypyridazin-3-yl)phenyl]-4-(trifluoromethyl)pyridine-2-carboxamide causes decreased activity of BRAF,infores:bindingdb,0,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,N-[4-methyl-3-(5-morpholin-4-yl-6-propan-2-yloxypyridazin-3-yl)phenyl]-4-(trifluoromethyl)pyridine-2-carboxamide,PUBCHEM.COMPOUND:90456617,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,37,0.712,0.712,0.0,0.0,0.356,71.2,False,-0.0,False,0.712,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,37,medik:edge#151,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,biolink:gene_associated_with_condition,[],one-hop,,,,,,,,,['PMID:16439621'],DEFAULT PHRASE,infores:disgenet,1,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"tert-butyl 2,6-dimethyl-4-(4-(((1S,1aS,6bS)-5-((7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-4-yl)oxy)-1a,6b-dihydro-1H-cyclopropa[b]benzofuran-1-yl)carbamoyl)-2-(trifluoromethyl)benzyl)piperazine-1-carboxylate",PUBCHEM.COMPOUND:117807504,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,38,0.704,0.704,0.0,0.0,0.352,70.4,False,-0.0,False,0.704,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,38,medik:creative_edge#89,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,PUBCHEM.COMPOUND:117807504,"tert-butyl 2,6-dimethyl-4-(4-(((1S,1aS,6bS)-5-((7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-4-yl)oxy)-1a,6b-dihydro-1H-cyclopropa[b]benzofuran-1-yl)carbamoyl)-2-(trifluoromethyl)benzyl)piperazine-1-carboxylate",['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:treats,[],creative,,,,,,,,,[],DEFAULT PHRASE,infores:unsecret-agent,0,
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"tert-butyl 2,6-dimethyl-4-(4-(((1S,1aS,6bS)-5-((7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-4-yl)oxy)-1a,6b-dihydro-1H-cyclopropa[b]benzofuran-1-yl)carbamoyl)-2-(trifluoromethyl)benzyl)piperazine-1-carboxylate",PUBCHEM.COMPOUND:117807504,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,38,0.704,0.704,0.0,0.0,0.352,70.4,False,-0.0,False,0.704,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,38,medik:edge#178,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,PUBCHEM.COMPOUND:117807504,"tert-butyl 2,6-dimethyl-4-(4-(((1S,1aS,6bS)-5-((7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-4-yl)oxy)-1a,6b-dihydro-1H-cyclopropa[b]benzofuran-1-yl)carbamoyl)-2-(trifluoromethyl)benzyl)piperazine-1-carboxylate",['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:affects,"[{'qualifier_type_id': 'biolink:object_aspect_qualifier', 'qualifier_value': 'activity'}, {'qualifier_type_id': 'biolink:object_direction_qualifier', 'qualifier_value': 'decreased'}, {'qualifier_type_id': 'biolink:qualified_predicate', 'qualifier_value': 'biolink:causes'}]",one-hop,causes,,,,,decreased,activity,,[],"tert-butyl 2,6-dimethyl-4-(4-(((1S,1aS,6bS)-5-((7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-4-yl)oxy)-1a,6b-dihydro-1H-cyclopropa[b]benzofuran-1-yl)carbamoyl)-2-(trifluoromethyl)benzyl)piperazine-1-carboxylate causes decreased activity of BRAF",infores:bindingdb,0,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"tert-butyl 2,6-dimethyl-4-(4-(((1S,1aS,6bS)-5-((7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-4-yl)oxy)-1a,6b-dihydro-1H-cyclopropa[b]benzofuran-1-yl)carbamoyl)-2-(trifluoromethyl)benzyl)piperazine-1-carboxylate",PUBCHEM.COMPOUND:117807504,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,38,0.704,0.704,0.0,0.0,0.352,70.4,False,-0.0,False,0.704,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,38,medik:edge#179,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,biolink:gene_associated_with_condition,[],one-hop,,,,,,,,,['PMID:16439621'],DEFAULT PHRASE,infores:disgenet,1,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"2-(1,1-difluoropropyl)-N-[4-methyl-3-(1-methyl-5-morpholin-4-yl-6-oxopyridazin-3-yl)phenyl]pyridine-4-carboxamide",PUBCHEM.COMPOUND:90460980,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,39,0.696,0.696,0.0,0.0,0.348,69.6,False,-0.0,False,0.696,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,39,medik:creative_edge#77,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,PUBCHEM.COMPOUND:90460980,"2-(1,1-difluoropropyl)-N-[4-methyl-3-(1-methyl-5-morpholin-4-yl-6-oxopyridazin-3-yl)phenyl]pyridine-4-carboxamide",['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:treats,[],creative,,,,,,,,,[],DEFAULT PHRASE,infores:unsecret-agent,0,
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"2-(1,1-difluoropropyl)-N-[4-methyl-3-(1-methyl-5-morpholin-4-yl-6-oxopyridazin-3-yl)phenyl]pyridine-4-carboxamide",PUBCHEM.COMPOUND:90460980,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,39,0.696,0.696,0.0,0.0,0.348,69.6,False,-0.0,False,0.696,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,39,medik:edge#154,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,PUBCHEM.COMPOUND:90460980,"2-(1,1-difluoropropyl)-N-[4-methyl-3-(1-methyl-5-morpholin-4-yl-6-oxopyridazin-3-yl)phenyl]pyridine-4-carboxamide",['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:affects,"[{'qualifier_type_id': 'biolink:object_aspect_qualifier', 'qualifier_value': 'activity'}, {'qualifier_type_id': 'biolink:object_direction_qualifier', 'qualifier_value': 'decreased'}, {'qualifier_type_id': 'biolink:qualified_predicate', 'qualifier_value': 'biolink:causes'}]",one-hop,causes,,,,,decreased,activity,,[],"2-(1,1-difluoropropyl)-N-[4-methyl-3-(1-methyl-5-morpholin-4-yl-6-oxopyridazin-3-yl)phenyl]pyridine-4-carboxamide causes decreased activity of BRAF",infores:bindingdb,0,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"2-(1,1-difluoropropyl)-N-[4-methyl-3-(1-methyl-5-morpholin-4-yl-6-oxopyridazin-3-yl)phenyl]pyridine-4-carboxamide",PUBCHEM.COMPOUND:90460980,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,39,0.696,0.696,0.0,0.0,0.348,69.6,False,-0.0,False,0.696,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,39,medik:edge#155,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,biolink:gene_associated_with_condition,[],one-hop,,,,,,,,,['PMID:16439621'],DEFAULT PHRASE,infores:disgenet,1,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"US8653087, III-174",PUBCHEM.COMPOUND:68035874,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,40,0.688,0.688,0.0,0.0,0.344,68.8,False,-0.0,False,0.688,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,40,medik:creative_edge#54,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,PUBCHEM.COMPOUND:68035874,"US8653087, III-174",['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:treats,[],creative,,,,,,,,,[],DEFAULT PHRASE,infores:unsecret-agent,0,
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"US8653087, III-174",PUBCHEM.COMPOUND:68035874,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,40,0.688,0.688,0.0,0.0,0.344,68.8,False,-0.0,False,0.688,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,40,medik:edge#108,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,PUBCHEM.COMPOUND:68035874,"US8653087, III-174",['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:affects,"[{'qualifier_type_id': 'biolink:object_aspect_qualifier', 'qualifier_value': 'activity'}, {'qualifier_type_id': 'biolink:object_direction_qualifier', 'qualifier_value': 'decreased'}, {'qualifier_type_id': 'biolink:qualified_predicate', 'qualifier_value': 'biolink:causes'}]",one-hop,causes,,,,,decreased,activity,,[],"US8653087, III-174 causes decreased activity of BRAF",infores:bindingdb,0,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"US8653087, III-174",PUBCHEM.COMPOUND:68035874,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,40,0.688,0.688,0.0,0.0,0.344,68.8,False,-0.0,False,0.688,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,40,medik:edge#109,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,biolink:gene_associated_with_condition,[],one-hop,,,,,,,,,['PMID:16439621'],DEFAULT PHRASE,infores:disgenet,1,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"N-[3-[5,5-dimethyl-4-oxo-2-(2-sulfanylidene-1H-pyrimidin-6-yl)furan-3-yl]-2-fluorophenyl]-2,6-difluorobenzenesulfonamide",PUBCHEM.COMPOUND:121265197,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,41,0.68,0.68,0.0,0.0,0.34,68.0,False,-0.0,False,0.68,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,41,medik:creative_edge#97,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,PUBCHEM.COMPOUND:121265197,"N-[3-[5,5-dimethyl-4-oxo-2-(2-sulfanylidene-1H-pyrimidin-6-yl)furan-3-yl]-2-fluorophenyl]-2,6-difluorobenzenesulfonamide",['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:treats,[],creative,,,,,,,,,[],DEFAULT PHRASE,infores:unsecret-agent,0,
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"N-[3-[5,5-dimethyl-4-oxo-2-(2-sulfanylidene-1H-pyrimidin-6-yl)furan-3-yl]-2-fluorophenyl]-2,6-difluorobenzenesulfonamide",PUBCHEM.COMPOUND:121265197,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,41,0.68,0.68,0.0,0.0,0.34,68.0,False,-0.0,False,0.68,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,41,medik:edge#194,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,PUBCHEM.COMPOUND:121265197,"N-[3-[5,5-dimethyl-4-oxo-2-(2-sulfanylidene-1H-pyrimidin-6-yl)furan-3-yl]-2-fluorophenyl]-2,6-difluorobenzenesulfonamide",['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:affects,"[{'qualifier_type_id': 'biolink:object_aspect_qualifier', 'qualifier_value': 'activity'}, {'qualifier_type_id': 'biolink:object_direction_qualifier', 'qualifier_value': 'decreased'}, {'qualifier_type_id': 'biolink:qualified_predicate', 'qualifier_value': 'biolink:causes'}]",one-hop,causes,,,,,decreased,activity,,[],"N-[3-[5,5-dimethyl-4-oxo-2-(2-sulfanylidene-1H-pyrimidin-6-yl)furan-3-yl]-2-fluorophenyl]-2,6-difluorobenzenesulfonamide causes decreased activity of BRAF",infores:bindingdb,0,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"N-[3-[5,5-dimethyl-4-oxo-2-(2-sulfanylidene-1H-pyrimidin-6-yl)furan-3-yl]-2-fluorophenyl]-2,6-difluorobenzenesulfonamide",PUBCHEM.COMPOUND:121265197,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,41,0.68,0.68,0.0,0.0,0.34,68.0,False,-0.0,False,0.68,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,41,medik:edge#195,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,biolink:gene_associated_with_condition,[],one-hop,,,,,,,,,['PMID:16439621'],DEFAULT PHRASE,infores:disgenet,1,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"US8653087, III-296",PUBCHEM.COMPOUND:68036047,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,42,0.672,0.672,0.0,0.0,0.336,67.2,False,-0.0,False,0.672,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,42,medik:creative_edge#57,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,PUBCHEM.COMPOUND:68036047,"US8653087, III-296",['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:treats,[],creative,,,,,,,,,[],DEFAULT PHRASE,infores:unsecret-agent,0,
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"US8653087, III-296",PUBCHEM.COMPOUND:68036047,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,42,0.672,0.672,0.0,0.0,0.336,67.2,False,-0.0,False,0.672,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,42,medik:edge#114,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,PUBCHEM.COMPOUND:68036047,"US8653087, III-296",['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:affects,"[{'qualifier_type_id': 'biolink:object_aspect_qualifier', 'qualifier_value': 'activity'}, {'qualifier_type_id': 'biolink:object_direction_qualifier', 'qualifier_value': 'decreased'}, {'qualifier_type_id': 'biolink:qualified_predicate', 'qualifier_value': 'biolink:causes'}]",one-hop,causes,,,,,decreased,activity,,[],"US8653087, III-296 causes decreased activity of BRAF",infores:bindingdb,0,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"US8653087, III-296",PUBCHEM.COMPOUND:68036047,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,42,0.672,0.672,0.0,0.0,0.336,67.2,False,-0.0,False,0.672,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,42,medik:edge#115,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,biolink:gene_associated_with_condition,[],one-hop,,,,,,,,,['PMID:16439621'],DEFAULT PHRASE,infores:disgenet,1,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,N-[6-methyl-5-[5-morpholin-4-yl-6-(oxan-4-yloxy)pyridin-3-yl]pyridin-3-yl]-N-propyl-3-(trifluoromethyl)benzamide,PUBCHEM.COMPOUND:117609823,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,43,0.664,0.664,0.0,0.0,0.332,66.4,False,-0.0,False,0.664,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,43,medik:creative_edge#8,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,PUBCHEM.COMPOUND:117609823,N-[6-methyl-5-[5-morpholin-4-yl-6-(oxan-4-yloxy)pyridin-3-yl]pyridin-3-yl]-N-propyl-3-(trifluoromethyl)benzamide,['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:treats,[],creative,,,,,,,,,[],DEFAULT PHRASE,infores:unsecret-agent,0,
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,N-[6-methyl-5-[5-morpholin-4-yl-6-(oxan-4-yloxy)pyridin-3-yl]pyridin-3-yl]-N-propyl-3-(trifluoromethyl)benzamide,PUBCHEM.COMPOUND:117609823,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,43,0.664,0.664,0.0,0.0,0.332,66.4,False,-0.0,False,0.664,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,43,medik:edge#16,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,PUBCHEM.COMPOUND:117609823,N-[6-methyl-5-[5-morpholin-4-yl-6-(oxan-4-yloxy)pyridin-3-yl]pyridin-3-yl]-N-propyl-3-(trifluoromethyl)benzamide,['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:affects,"[{'qualifier_type_id': 'biolink:object_aspect_qualifier', 'qualifier_value': 'activity'}, {'qualifier_type_id': 'biolink:object_direction_qualifier', 'qualifier_value': 'decreased'}, {'qualifier_type_id': 'biolink:qualified_predicate', 'qualifier_value': 'biolink:causes'}]",one-hop,causes,,,,,decreased,activity,,[],N-[6-methyl-5-[5-morpholin-4-yl-6-(oxan-4-yloxy)pyridin-3-yl]pyridin-3-yl]-N-propyl-3-(trifluoromethyl)benzamide causes decreased activity of BRAF,infores:bindingdb,0,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,N-[6-methyl-5-[5-morpholin-4-yl-6-(oxan-4-yloxy)pyridin-3-yl]pyridin-3-yl]-N-propyl-3-(trifluoromethyl)benzamide,PUBCHEM.COMPOUND:117609823,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,43,0.664,0.664,0.0,0.0,0.332,66.4,False,-0.0,False,0.664,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,43,medik:edge#17,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,biolink:gene_associated_with_condition,[],one-hop,,,,,,,,,['PMID:16439621'],DEFAULT PHRASE,infores:disgenet,1,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"1-[(1S,1aS,6bS)-5-[(7-oxo-6,8-dihydro-5H-1,8-naphthyridin-4-yl)oxy]-1a,6b-dihydro-1H-cyclopropa[b][1]benzofuran-1-yl]-3-(2,3,6-trifluorophenyl)urea",PUBCHEM.COMPOUND:117806793,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,44,0.656,0.656,0.0,0.0,0.328,65.6,False,-0.0,False,0.656,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,44,medik:creative_edge#11,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,PUBCHEM.COMPOUND:117806793,"1-[(1S,1aS,6bS)-5-[(7-oxo-6,8-dihydro-5H-1,8-naphthyridin-4-yl)oxy]-1a,6b-dihydro-1H-cyclopropa[b][1]benzofuran-1-yl]-3-(2,3,6-trifluorophenyl)urea",['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:treats,[],creative,,,,,,,,,[],DEFAULT PHRASE,infores:unsecret-agent,0,
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"1-[(1S,1aS,6bS)-5-[(7-oxo-6,8-dihydro-5H-1,8-naphthyridin-4-yl)oxy]-1a,6b-dihydro-1H-cyclopropa[b][1]benzofuran-1-yl]-3-(2,3,6-trifluorophenyl)urea",PUBCHEM.COMPOUND:117806793,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,44,0.656,0.656,0.0,0.0,0.328,65.6,False,-0.0,False,0.656,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,44,medik:edge#22,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,PUBCHEM.COMPOUND:117806793,"1-[(1S,1aS,6bS)-5-[(7-oxo-6,8-dihydro-5H-1,8-naphthyridin-4-yl)oxy]-1a,6b-dihydro-1H-cyclopropa[b][1]benzofuran-1-yl]-3-(2,3,6-trifluorophenyl)urea",['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:affects,"[{'qualifier_type_id': 'biolink:object_aspect_qualifier', 'qualifier_value': 'activity'}, {'qualifier_type_id': 'biolink:object_direction_qualifier', 'qualifier_value': 'decreased'}, {'qualifier_type_id': 'biolink:qualified_predicate', 'qualifier_value': 'biolink:causes'}]",one-hop,causes,,,,,decreased,activity,,[],"1-[(1S,1aS,6bS)-5-[(7-oxo-6,8-dihydro-5H-1,8-naphthyridin-4-yl)oxy]-1a,6b-dihydro-1H-cyclopropa[b][1]benzofuran-1-yl]-3-(2,3,6-trifluorophenyl)urea causes decreased activity of BRAF",infores:bindingdb,0,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"1-[(1S,1aS,6bS)-5-[(7-oxo-6,8-dihydro-5H-1,8-naphthyridin-4-yl)oxy]-1a,6b-dihydro-1H-cyclopropa[b][1]benzofuran-1-yl]-3-(2,3,6-trifluorophenyl)urea",PUBCHEM.COMPOUND:117806793,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,44,0.656,0.656,0.0,0.0,0.328,65.6,False,-0.0,False,0.656,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,44,medik:edge#23,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,biolink:gene_associated_with_condition,[],one-hop,,,,,,,,,['PMID:16439621'],DEFAULT PHRASE,infores:disgenet,1,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"(2S,4R)-N-[3-[2-(1,4-dioxan-2-yl)-6-morpholin-4-ylpyridin-4-yl]-4-methylphenyl]-2-(trifluoromethyl)piperidine-4-carboxamide",PUBCHEM.COMPOUND:117609723,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,45,0.648,0.648,0.0,0.0,0.324,64.8,False,-0.0,False,0.648,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,45,medik:creative_edge#5,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,PUBCHEM.COMPOUND:117609723,"(2S,4R)-N-[3-[2-(1,4-dioxan-2-yl)-6-morpholin-4-ylpyridin-4-yl]-4-methylphenyl]-2-(trifluoromethyl)piperidine-4-carboxamide",['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:treats,[],creative,,,,,,,,,[],DEFAULT PHRASE,infores:unsecret-agent,0,
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"(2S,4R)-N-[3-[2-(1,4-dioxan-2-yl)-6-morpholin-4-ylpyridin-4-yl]-4-methylphenyl]-2-(trifluoromethyl)piperidine-4-carboxamide",PUBCHEM.COMPOUND:117609723,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,45,0.648,0.648,0.0,0.0,0.324,64.8,False,-0.0,False,0.648,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,45,medik:edge#10,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,PUBCHEM.COMPOUND:117609723,"(2S,4R)-N-[3-[2-(1,4-dioxan-2-yl)-6-morpholin-4-ylpyridin-4-yl]-4-methylphenyl]-2-(trifluoromethyl)piperidine-4-carboxamide",['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:affects,"[{'qualifier_type_id': 'biolink:object_aspect_qualifier', 'qualifier_value': 'activity'}, {'qualifier_type_id': 'biolink:object_direction_qualifier', 'qualifier_value': 'decreased'}, {'qualifier_type_id': 'biolink:qualified_predicate', 'qualifier_value': 'biolink:causes'}]",one-hop,causes,,,,,decreased,activity,,[],"(2S,4R)-N-[3-[2-(1,4-dioxan-2-yl)-6-morpholin-4-ylpyridin-4-yl]-4-methylphenyl]-2-(trifluoromethyl)piperidine-4-carboxamide causes decreased activity of BRAF",infores:bindingdb,0,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"(2S,4R)-N-[3-[2-(1,4-dioxan-2-yl)-6-morpholin-4-ylpyridin-4-yl]-4-methylphenyl]-2-(trifluoromethyl)piperidine-4-carboxamide",PUBCHEM.COMPOUND:117609723,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,45,0.648,0.648,0.0,0.0,0.324,64.8,False,-0.0,False,0.648,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,45,medik:edge#11,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,biolink:gene_associated_with_condition,[],one-hop,,,,,,,,,['PMID:16439621'],DEFAULT PHRASE,infores:disgenet,1,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"3-[[4-amino-2-(4-methyl-1,4-diazepan-1-yl)pyrimido[5,4-d]pyrimidin-8-yl]amino]-4-bromo-N-[3-(trifluoromethyl)phenyl]benzamide",PUBCHEM.COMPOUND:68035516,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,46,0.64,0.64,0.0,0.0,0.32,64.0,False,-0.0,False,0.64,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,46,medik:creative_edge#46,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,PUBCHEM.COMPOUND:68035516,"3-[[4-amino-2-(4-methyl-1,4-diazepan-1-yl)pyrimido[5,4-d]pyrimidin-8-yl]amino]-4-bromo-N-[3-(trifluoromethyl)phenyl]benzamide",['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:treats,[],creative,,,,,,,,,[],DEFAULT PHRASE,infores:unsecret-agent,0,
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"3-[[4-amino-2-(4-methyl-1,4-diazepan-1-yl)pyrimido[5,4-d]pyrimidin-8-yl]amino]-4-bromo-N-[3-(trifluoromethyl)phenyl]benzamide",PUBCHEM.COMPOUND:68035516,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,46,0.64,0.64,0.0,0.0,0.32,64.0,False,-0.0,False,0.64,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,46,medik:edge#92,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,PUBCHEM.COMPOUND:68035516,"3-[[4-amino-2-(4-methyl-1,4-diazepan-1-yl)pyrimido[5,4-d]pyrimidin-8-yl]amino]-4-bromo-N-[3-(trifluoromethyl)phenyl]benzamide",['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:affects,"[{'qualifier_type_id': 'biolink:object_aspect_qualifier', 'qualifier_value': 'activity'}, {'qualifier_type_id': 'biolink:object_direction_qualifier', 'qualifier_value': 'decreased'}, {'qualifier_type_id': 'biolink:qualified_predicate', 'qualifier_value': 'biolink:causes'}]",one-hop,causes,,,,,decreased,activity,,[],"3-[[4-amino-2-(4-methyl-1,4-diazepan-1-yl)pyrimido[5,4-d]pyrimidin-8-yl]amino]-4-bromo-N-[3-(trifluoromethyl)phenyl]benzamide causes decreased activity of BRAF",infores:bindingdb,0,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"3-[[4-amino-2-(4-methyl-1,4-diazepan-1-yl)pyrimido[5,4-d]pyrimidin-8-yl]amino]-4-bromo-N-[3-(trifluoromethyl)phenyl]benzamide",PUBCHEM.COMPOUND:68035516,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,46,0.64,0.64,0.0,0.0,0.32,64.0,False,-0.0,False,0.64,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,46,medik:edge#93,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,biolink:gene_associated_with_condition,[],one-hop,,,,,,,,,['PMID:16439621'],DEFAULT PHRASE,infores:disgenet,1,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"3-[[4-amino-2-[4-(1-methylpiperidin-4-yl)piperazin-1-yl]pyrimido[5,4-d]pyrimidin-8-yl]amino]-4-chloro-N-[3-(trifluoromethyl)phenyl]benzamide",PUBCHEM.COMPOUND:68035514,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,47,0.632,0.632,0.0,0.0,0.316,63.2,False,-0.0,False,0.632,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,47,medik:creative_edge#45,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,PUBCHEM.COMPOUND:68035514,"3-[[4-amino-2-[4-(1-methylpiperidin-4-yl)piperazin-1-yl]pyrimido[5,4-d]pyrimidin-8-yl]amino]-4-chloro-N-[3-(trifluoromethyl)phenyl]benzamide",['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:treats,[],creative,,,,,,,,,[],DEFAULT PHRASE,infores:unsecret-agent,0,
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"3-[[4-amino-2-[4-(1-methylpiperidin-4-yl)piperazin-1-yl]pyrimido[5,4-d]pyrimidin-8-yl]amino]-4-chloro-N-[3-(trifluoromethyl)phenyl]benzamide",PUBCHEM.COMPOUND:68035514,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,47,0.632,0.632,0.0,0.0,0.316,63.2,False,-0.0,False,0.632,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,47,medik:edge#90,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,PUBCHEM.COMPOUND:68035514,"3-[[4-amino-2-[4-(1-methylpiperidin-4-yl)piperazin-1-yl]pyrimido[5,4-d]pyrimidin-8-yl]amino]-4-chloro-N-[3-(trifluoromethyl)phenyl]benzamide",['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:affects,"[{'qualifier_type_id': 'biolink:object_aspect_qualifier', 'qualifier_value': 'activity'}, {'qualifier_type_id': 'biolink:object_direction_qualifier', 'qualifier_value': 'decreased'}, {'qualifier_type_id': 'biolink:qualified_predicate', 'qualifier_value': 'biolink:causes'}]",one-hop,causes,,,,,decreased,activity,,[],"3-[[4-amino-2-[4-(1-methylpiperidin-4-yl)piperazin-1-yl]pyrimido[5,4-d]pyrimidin-8-yl]amino]-4-chloro-N-[3-(trifluoromethyl)phenyl]benzamide causes decreased activity of BRAF",infores:bindingdb,0,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"3-[[4-amino-2-[4-(1-methylpiperidin-4-yl)piperazin-1-yl]pyrimido[5,4-d]pyrimidin-8-yl]amino]-4-chloro-N-[3-(trifluoromethyl)phenyl]benzamide",PUBCHEM.COMPOUND:68035514,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,47,0.632,0.632,0.0,0.0,0.316,63.2,False,-0.0,False,0.632,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,47,medik:edge#91,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,biolink:gene_associated_with_condition,[],one-hop,,,,,,,,,['PMID:16439621'],DEFAULT PHRASE,infores:disgenet,1,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"US10167279, Example 25",PUBCHEM.COMPOUND:134609572,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,48,0.624,0.624,0.0,0.0,0.312,62.4,False,-0.0,False,0.624,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,48,medik:creative_edge#104,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,PUBCHEM.COMPOUND:134609572,"US10167279, Example 25",['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:treats,[],creative,,,,,,,,,[],DEFAULT PHRASE,infores:unsecret-agent,0,
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"US10167279, Example 25",PUBCHEM.COMPOUND:134609572,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,48,0.624,0.624,0.0,0.0,0.312,62.4,False,-0.0,False,0.624,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,48,medik:edge#208,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,PUBCHEM.COMPOUND:134609572,"US10167279, Example 25",['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:affects,"[{'qualifier_type_id': 'biolink:object_aspect_qualifier', 'qualifier_value': 'activity'}, {'qualifier_type_id': 'biolink:object_direction_qualifier', 'qualifier_value': 'decreased'}, {'qualifier_type_id': 'biolink:qualified_predicate', 'qualifier_value': 'biolink:causes'}]",one-hop,causes,,,,,decreased,activity,,[],"US10167279, Example 25 causes decreased activity of BRAF",infores:bindingdb,0,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"US10167279, Example 25",PUBCHEM.COMPOUND:134609572,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,48,0.624,0.624,0.0,0.0,0.312,62.4,False,-0.0,False,0.624,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,48,medik:edge#209,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,biolink:gene_associated_with_condition,[],one-hop,,,,,,,,,['PMID:16439621'],DEFAULT PHRASE,infores:disgenet,1,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,2-ethyl-N-[4-methyl-3-(1-methyl-5-morpholin-4-yl-6-oxopyridazin-3-yl)phenyl]pyridine-4-carboxamide,PUBCHEM.COMPOUND:90456589,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,49,0.616,0.616,0.0,0.0,0.308,61.6,False,-0.0,False,0.616,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,49,medik:creative_edge#74,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,PUBCHEM.COMPOUND:90456589,2-ethyl-N-[4-methyl-3-(1-methyl-5-morpholin-4-yl-6-oxopyridazin-3-yl)phenyl]pyridine-4-carboxamide,['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:treats,[],creative,,,,,,,,,[],DEFAULT PHRASE,infores:unsecret-agent,0,
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,2-ethyl-N-[4-methyl-3-(1-methyl-5-morpholin-4-yl-6-oxopyridazin-3-yl)phenyl]pyridine-4-carboxamide,PUBCHEM.COMPOUND:90456589,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,49,0.616,0.616,0.0,0.0,0.308,61.6,False,-0.0,False,0.616,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,49,medik:edge#148,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,PUBCHEM.COMPOUND:90456589,2-ethyl-N-[4-methyl-3-(1-methyl-5-morpholin-4-yl-6-oxopyridazin-3-yl)phenyl]pyridine-4-carboxamide,['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:affects,"[{'qualifier_type_id': 'biolink:object_aspect_qualifier', 'qualifier_value': 'activity'}, {'qualifier_type_id': 'biolink:object_direction_qualifier', 'qualifier_value': 'decreased'}, {'qualifier_type_id': 'biolink:qualified_predicate', 'qualifier_value': 'biolink:causes'}]",one-hop,causes,,,,,decreased,activity,,[],2-ethyl-N-[4-methyl-3-(1-methyl-5-morpholin-4-yl-6-oxopyridazin-3-yl)phenyl]pyridine-4-carboxamide causes decreased activity of BRAF,infores:bindingdb,0,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,2-ethyl-N-[4-methyl-3-(1-methyl-5-morpholin-4-yl-6-oxopyridazin-3-yl)phenyl]pyridine-4-carboxamide,PUBCHEM.COMPOUND:90456589,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,49,0.616,0.616,0.0,0.0,0.308,61.6,False,-0.0,False,0.616,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,49,medik:edge#149,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,biolink:gene_associated_with_condition,[],one-hop,,,,,,,,,['PMID:16439621'],DEFAULT PHRASE,infores:disgenet,1,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,N-[3-[6-(2-hydroxyethoxy)-5-morpholin-4-ylpyridin-3-yl]-4-methylphenyl]-2-(trifluoromethyl)pyridine-4-carboxamide,PUBCHEM.COMPOUND:117609994,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,50,0.608,0.608,0.0,0.0,0.304,60.8,False,-0.0,False,0.608,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,50,medik:creative_edge#10,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,PUBCHEM.COMPOUND:117609994,N-[3-[6-(2-hydroxyethoxy)-5-morpholin-4-ylpyridin-3-yl]-4-methylphenyl]-2-(trifluoromethyl)pyridine-4-carboxamide,['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:treats,[],creative,,,,,,,,,[],DEFAULT PHRASE,infores:unsecret-agent,0,
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,N-[3-[6-(2-hydroxyethoxy)-5-morpholin-4-ylpyridin-3-yl]-4-methylphenyl]-2-(trifluoromethyl)pyridine-4-carboxamide,PUBCHEM.COMPOUND:117609994,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,50,0.608,0.608,0.0,0.0,0.304,60.8,False,-0.0,False,0.608,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,50,medik:edge#20,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,PUBCHEM.COMPOUND:117609994,N-[3-[6-(2-hydroxyethoxy)-5-morpholin-4-ylpyridin-3-yl]-4-methylphenyl]-2-(trifluoromethyl)pyridine-4-carboxamide,['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:affects,"[{'qualifier_type_id': 'biolink:object_aspect_qualifier', 'qualifier_value': 'activity'}, {'qualifier_type_id': 'biolink:object_direction_qualifier', 'qualifier_value': 'decreased'}, {'qualifier_type_id': 'biolink:qualified_predicate', 'qualifier_value': 'biolink:causes'}]",one-hop,causes,,,,,decreased,activity,,[],N-[3-[6-(2-hydroxyethoxy)-5-morpholin-4-ylpyridin-3-yl]-4-methylphenyl]-2-(trifluoromethyl)pyridine-4-carboxamide causes decreased activity of BRAF,infores:bindingdb,0,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,N-[3-[6-(2-hydroxyethoxy)-5-morpholin-4-ylpyridin-3-yl]-4-methylphenyl]-2-(trifluoromethyl)pyridine-4-carboxamide,PUBCHEM.COMPOUND:117609994,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,50,0.608,0.608,0.0,0.0,0.304,60.8,False,-0.0,False,0.608,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,50,medik:edge#21,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,biolink:gene_associated_with_condition,[],one-hop,,,,,,,,,['PMID:16439621'],DEFAULT PHRASE,infores:disgenet,1,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,N-[2-chloro-3-[2-cyclopropyl-5-[2-(ethylamino)pyrimidin-4-yl]-1H-imidazol-4-yl]-5-fluorophenyl]propane-1-sulfonamide,PUBCHEM.COMPOUND:58164427,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,51,0.6,0.6,0.0,0.0,0.3,60.0,False,-0.0,False,0.6,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,51,medik:creative_edge#121,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,PUBCHEM.COMPOUND:58164427,N-[2-chloro-3-[2-cyclopropyl-5-[2-(ethylamino)pyrimidin-4-yl]-1H-imidazol-4-yl]-5-fluorophenyl]propane-1-sulfonamide,['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:treats,[],creative,,,,,,,,,[],DEFAULT PHRASE,infores:unsecret-agent,0,
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,N-[2-chloro-3-[2-cyclopropyl-5-[2-(ethylamino)pyrimidin-4-yl]-1H-imidazol-4-yl]-5-fluorophenyl]propane-1-sulfonamide,PUBCHEM.COMPOUND:58164427,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,51,0.6,0.6,0.0,0.0,0.3,60.0,False,-0.0,False,0.6,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,51,medik:edge#242,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,PUBCHEM.COMPOUND:58164427,N-[2-chloro-3-[2-cyclopropyl-5-[2-(ethylamino)pyrimidin-4-yl]-1H-imidazol-4-yl]-5-fluorophenyl]propane-1-sulfonamide,['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:affects,"[{'qualifier_type_id': 'biolink:object_aspect_qualifier', 'qualifier_value': 'activity'}, {'qualifier_type_id': 'biolink:object_direction_qualifier', 'qualifier_value': 'decreased'}, {'qualifier_type_id': 'biolink:qualified_predicate', 'qualifier_value': 'biolink:causes'}]",one-hop,causes,,,,,decreased,activity,,[],N-[2-chloro-3-[2-cyclopropyl-5-[2-(ethylamino)pyrimidin-4-yl]-1H-imidazol-4-yl]-5-fluorophenyl]propane-1-sulfonamide causes decreased activity of BRAF,infores:bindingdb,0,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,N-[2-chloro-3-[2-cyclopropyl-5-[2-(ethylamino)pyrimidin-4-yl]-1H-imidazol-4-yl]-5-fluorophenyl]propane-1-sulfonamide,PUBCHEM.COMPOUND:58164427,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,51,0.6,0.6,0.0,0.0,0.3,60.0,False,-0.0,False,0.6,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,51,medik:edge#243,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,biolink:gene_associated_with_condition,[],one-hop,,,,,,,,,['PMID:16439621'],DEFAULT PHRASE,infores:disgenet,1,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"N-{2,4-Difluoro-3-[4-(2-methoxy-ethylamino)-7H-pyrrolo[2,3-d]pyrimidine-5-carbonyl]-phenyl}-4-trifluoromethyl-benzenesulfonamide",PUBCHEM.COMPOUND:58316985,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,52,0.592,0.592,0.0,0.0,0.296,59.2,False,-0.0,False,0.592,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,52,medik:creative_edge#42,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,PUBCHEM.COMPOUND:58316985,"N-{2,4-Difluoro-3-[4-(2-methoxy-ethylamino)-7H-pyrrolo[2,3-d]pyrimidine-5-carbonyl]-phenyl}-4-trifluoromethyl-benzenesulfonamide",['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:treats,[],creative,,,,,,,,,[],DEFAULT PHRASE,infores:unsecret-agent,0,
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"N-{2,4-Difluoro-3-[4-(2-methoxy-ethylamino)-7H-pyrrolo[2,3-d]pyrimidine-5-carbonyl]-phenyl}-4-trifluoromethyl-benzenesulfonamide",PUBCHEM.COMPOUND:58316985,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,52,0.592,0.592,0.0,0.0,0.296,59.2,False,-0.0,False,0.592,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,52,medik:edge#84,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,PUBCHEM.COMPOUND:58316985,"N-{2,4-Difluoro-3-[4-(2-methoxy-ethylamino)-7H-pyrrolo[2,3-d]pyrimidine-5-carbonyl]-phenyl}-4-trifluoromethyl-benzenesulfonamide",['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:affects,"[{'qualifier_type_id': 'biolink:object_aspect_qualifier', 'qualifier_value': 'activity'}, {'qualifier_type_id': 'biolink:object_direction_qualifier', 'qualifier_value': 'decreased'}, {'qualifier_type_id': 'biolink:qualified_predicate', 'qualifier_value': 'biolink:causes'}]",one-hop,causes,,,,,decreased,activity,,[],"N-{2,4-Difluoro-3-[4-(2-methoxy-ethylamino)-7H-pyrrolo[2,3-d]pyrimidine-5-carbonyl]-phenyl}-4-trifluoromethyl-benzenesulfonamide causes decreased activity of BRAF",infores:bindingdb,0,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"N-{2,4-Difluoro-3-[4-(2-methoxy-ethylamino)-7H-pyrrolo[2,3-d]pyrimidine-5-carbonyl]-phenyl}-4-trifluoromethyl-benzenesulfonamide",PUBCHEM.COMPOUND:58316985,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,52,0.592,0.592,0.0,0.0,0.296,59.2,False,-0.0,False,0.592,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,52,medik:edge#85,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,biolink:gene_associated_with_condition,[],one-hop,,,,,,,,,['PMID:16439621'],DEFAULT PHRASE,infores:disgenet,1,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"US10167279, Example 94",PUBCHEM.COMPOUND:134609471,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,53,0.584,0.584,0.0,0.0,0.292,58.4,False,-0.0,False,0.584,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,53,medik:creative_edge#22,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,PUBCHEM.COMPOUND:134609471,"US10167279, Example 94",['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:treats,[],creative,,,,,,,,,[],DEFAULT PHRASE,infores:unsecret-agent,0,
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"US10167279, Example 94",PUBCHEM.COMPOUND:134609471,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,53,0.584,0.584,0.0,0.0,0.292,58.4,False,-0.0,False,0.584,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,53,medik:edge#44,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,PUBCHEM.COMPOUND:134609471,"US10167279, Example 94",['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:affects,"[{'qualifier_type_id': 'biolink:object_aspect_qualifier', 'qualifier_value': 'activity'}, {'qualifier_type_id': 'biolink:object_direction_qualifier', 'qualifier_value': 'decreased'}, {'qualifier_type_id': 'biolink:qualified_predicate', 'qualifier_value': 'biolink:causes'}]",one-hop,causes,,,,,decreased,activity,,[],"US10167279, Example 94 causes decreased activity of BRAF",infores:bindingdb,0,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"US10167279, Example 94",PUBCHEM.COMPOUND:134609471,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,53,0.584,0.584,0.0,0.0,0.292,58.4,False,-0.0,False,0.584,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,53,medik:edge#45,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,biolink:gene_associated_with_condition,[],one-hop,,,,,,,,,['PMID:16439621'],DEFAULT PHRASE,infores:disgenet,1,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"1-[4-[3-[2-fluoro-3-(pyrrolidin-1-ylsulfonylamino)benzoyl]-1H-pyrrolo[2,3-b]pyridin-5-yl]phenyl]cyclopropane-1-carboxylic acid",PUBCHEM.COMPOUND:60164209,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,54,0.576,0.576,0.0,0.0,0.288,57.6,False,-0.0,False,0.576,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,54,medik:creative_edge#43,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,PUBCHEM.COMPOUND:60164209,"1-[4-[3-[2-fluoro-3-(pyrrolidin-1-ylsulfonylamino)benzoyl]-1H-pyrrolo[2,3-b]pyridin-5-yl]phenyl]cyclopropane-1-carboxylic acid",['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:treats,[],creative,,,,,,,,,[],DEFAULT PHRASE,infores:unsecret-agent,0,
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"1-[4-[3-[2-fluoro-3-(pyrrolidin-1-ylsulfonylamino)benzoyl]-1H-pyrrolo[2,3-b]pyridin-5-yl]phenyl]cyclopropane-1-carboxylic acid",PUBCHEM.COMPOUND:60164209,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,54,0.576,0.576,0.0,0.0,0.288,57.6,False,-0.0,False,0.576,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,54,medik:edge#86,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,PUBCHEM.COMPOUND:60164209,"1-[4-[3-[2-fluoro-3-(pyrrolidin-1-ylsulfonylamino)benzoyl]-1H-pyrrolo[2,3-b]pyridin-5-yl]phenyl]cyclopropane-1-carboxylic acid",['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:affects,"[{'qualifier_type_id': 'biolink:object_aspect_qualifier', 'qualifier_value': 'activity'}, {'qualifier_type_id': 'biolink:object_direction_qualifier', 'qualifier_value': 'decreased'}, {'qualifier_type_id': 'biolink:qualified_predicate', 'qualifier_value': 'biolink:causes'}]",one-hop,causes,,,,,decreased,activity,,[],"1-[4-[3-[2-fluoro-3-(pyrrolidin-1-ylsulfonylamino)benzoyl]-1H-pyrrolo[2,3-b]pyridin-5-yl]phenyl]cyclopropane-1-carboxylic acid causes decreased activity of BRAF",infores:bindingdb,0,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"1-[4-[3-[2-fluoro-3-(pyrrolidin-1-ylsulfonylamino)benzoyl]-1H-pyrrolo[2,3-b]pyridin-5-yl]phenyl]cyclopropane-1-carboxylic acid",PUBCHEM.COMPOUND:60164209,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,54,0.576,0.576,0.0,0.0,0.288,57.6,False,-0.0,False,0.576,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,54,medik:edge#87,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,biolink:gene_associated_with_condition,[],one-hop,,,,,,,,,['PMID:16439621'],DEFAULT PHRASE,infores:disgenet,1,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,N-[3-(6-ethoxy-5-morpholin-4-ylpyridin-3-yl)-4-methylphenyl]-2-(2-hydroxypropan-2-yl)pyridine-4-carboxamide,PUBCHEM.COMPOUND:117609553,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,55,0.568,0.568,0.0,0.0,0.284,56.8,False,-0.0,False,0.568,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,55,medik:creative_edge#81,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,PUBCHEM.COMPOUND:117609553,N-[3-(6-ethoxy-5-morpholin-4-ylpyridin-3-yl)-4-methylphenyl]-2-(2-hydroxypropan-2-yl)pyridine-4-carboxamide,['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:treats,[],creative,,,,,,,,,[],DEFAULT PHRASE,infores:unsecret-agent,0,
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,N-[3-(6-ethoxy-5-morpholin-4-ylpyridin-3-yl)-4-methylphenyl]-2-(2-hydroxypropan-2-yl)pyridine-4-carboxamide,PUBCHEM.COMPOUND:117609553,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,55,0.568,0.568,0.0,0.0,0.284,56.8,False,-0.0,False,0.568,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,55,medik:edge#162,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,PUBCHEM.COMPOUND:117609553,N-[3-(6-ethoxy-5-morpholin-4-ylpyridin-3-yl)-4-methylphenyl]-2-(2-hydroxypropan-2-yl)pyridine-4-carboxamide,['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:affects,"[{'qualifier_type_id': 'biolink:object_aspect_qualifier', 'qualifier_value': 'activity'}, {'qualifier_type_id': 'biolink:object_direction_qualifier', 'qualifier_value': 'decreased'}, {'qualifier_type_id': 'biolink:qualified_predicate', 'qualifier_value': 'biolink:causes'}]",one-hop,causes,,,,,decreased,activity,,[],N-[3-(6-ethoxy-5-morpholin-4-ylpyridin-3-yl)-4-methylphenyl]-2-(2-hydroxypropan-2-yl)pyridine-4-carboxamide causes decreased activity of BRAF,infores:bindingdb,0,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,N-[3-(6-ethoxy-5-morpholin-4-ylpyridin-3-yl)-4-methylphenyl]-2-(2-hydroxypropan-2-yl)pyridine-4-carboxamide,PUBCHEM.COMPOUND:117609553,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,55,0.568,0.568,0.0,0.0,0.284,56.8,False,-0.0,False,0.568,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,55,medik:edge#163,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,biolink:gene_associated_with_condition,[],one-hop,,,,,,,,,['PMID:16439621'],DEFAULT PHRASE,infores:disgenet,1,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,N-[5-(6-ethoxy-5-morpholin-4-ylpyridin-3-yl)-6-methylpyridin-3-yl]-2-(2-hydroxypropan-2-yl)pyridine-4-carboxamide,PUBCHEM.COMPOUND:117609566,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,56,0.56,0.56,0.0,0.0,0.28,56.0,False,-0.0,False,0.56,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,56,medik:creative_edge#82,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,PUBCHEM.COMPOUND:117609566,N-[5-(6-ethoxy-5-morpholin-4-ylpyridin-3-yl)-6-methylpyridin-3-yl]-2-(2-hydroxypropan-2-yl)pyridine-4-carboxamide,['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:treats,[],creative,,,,,,,,,[],DEFAULT PHRASE,infores:unsecret-agent,0,
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,N-[5-(6-ethoxy-5-morpholin-4-ylpyridin-3-yl)-6-methylpyridin-3-yl]-2-(2-hydroxypropan-2-yl)pyridine-4-carboxamide,PUBCHEM.COMPOUND:117609566,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,56,0.56,0.56,0.0,0.0,0.28,56.0,False,-0.0,False,0.56,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,56,medik:edge#164,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,PUBCHEM.COMPOUND:117609566,N-[5-(6-ethoxy-5-morpholin-4-ylpyridin-3-yl)-6-methylpyridin-3-yl]-2-(2-hydroxypropan-2-yl)pyridine-4-carboxamide,['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:affects,"[{'qualifier_type_id': 'biolink:object_aspect_qualifier', 'qualifier_value': 'activity'}, {'qualifier_type_id': 'biolink:object_direction_qualifier', 'qualifier_value': 'decreased'}, {'qualifier_type_id': 'biolink:qualified_predicate', 'qualifier_value': 'biolink:causes'}]",one-hop,causes,,,,,decreased,activity,,[],N-[5-(6-ethoxy-5-morpholin-4-ylpyridin-3-yl)-6-methylpyridin-3-yl]-2-(2-hydroxypropan-2-yl)pyridine-4-carboxamide causes decreased activity of BRAF,infores:bindingdb,0,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,N-[5-(6-ethoxy-5-morpholin-4-ylpyridin-3-yl)-6-methylpyridin-3-yl]-2-(2-hydroxypropan-2-yl)pyridine-4-carboxamide,PUBCHEM.COMPOUND:117609566,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,56,0.56,0.56,0.0,0.0,0.28,56.0,False,-0.0,False,0.56,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,56,medik:edge#165,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,biolink:gene_associated_with_condition,[],one-hop,,,,,,,,,['PMID:16439621'],DEFAULT PHRASE,infores:disgenet,1,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"N-[(1S,1aS,6bS)-5-[(7-oxo-6,8-dihydro-5H-1,8-naphthyridin-4-yl)oxy]-1a,6b-dihydro-1H-cyclopropa[b][1]benzofuran-1-yl]-3-[(dimethylamino)methyl]-5-(trifluoromethyl)benzamide",PUBCHEM.COMPOUND:117807506,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,57,0.552,0.552,0.0,0.0,0.276,55.2,False,-0.0,False,0.552,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,57,medik:creative_edge#90,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,PUBCHEM.COMPOUND:117807506,"N-[(1S,1aS,6bS)-5-[(7-oxo-6,8-dihydro-5H-1,8-naphthyridin-4-yl)oxy]-1a,6b-dihydro-1H-cyclopropa[b][1]benzofuran-1-yl]-3-[(dimethylamino)methyl]-5-(trifluoromethyl)benzamide",['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:treats,[],creative,,,,,,,,,[],DEFAULT PHRASE,infores:unsecret-agent,0,
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"N-[(1S,1aS,6bS)-5-[(7-oxo-6,8-dihydro-5H-1,8-naphthyridin-4-yl)oxy]-1a,6b-dihydro-1H-cyclopropa[b][1]benzofuran-1-yl]-3-[(dimethylamino)methyl]-5-(trifluoromethyl)benzamide",PUBCHEM.COMPOUND:117807506,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,57,0.552,0.552,0.0,0.0,0.276,55.2,False,-0.0,False,0.552,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,57,medik:edge#180,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,PUBCHEM.COMPOUND:117807506,"N-[(1S,1aS,6bS)-5-[(7-oxo-6,8-dihydro-5H-1,8-naphthyridin-4-yl)oxy]-1a,6b-dihydro-1H-cyclopropa[b][1]benzofuran-1-yl]-3-[(dimethylamino)methyl]-5-(trifluoromethyl)benzamide",['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:affects,"[{'qualifier_type_id': 'biolink:object_aspect_qualifier', 'qualifier_value': 'activity'}, {'qualifier_type_id': 'biolink:object_direction_qualifier', 'qualifier_value': 'decreased'}, {'qualifier_type_id': 'biolink:qualified_predicate', 'qualifier_value': 'biolink:causes'}]",one-hop,causes,,,,,decreased,activity,,[],"N-[(1S,1aS,6bS)-5-[(7-oxo-6,8-dihydro-5H-1,8-naphthyridin-4-yl)oxy]-1a,6b-dihydro-1H-cyclopropa[b][1]benzofuran-1-yl]-3-[(dimethylamino)methyl]-5-(trifluoromethyl)benzamide causes decreased activity of BRAF",infores:bindingdb,0,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"N-[(1S,1aS,6bS)-5-[(7-oxo-6,8-dihydro-5H-1,8-naphthyridin-4-yl)oxy]-1a,6b-dihydro-1H-cyclopropa[b][1]benzofuran-1-yl]-3-[(dimethylamino)methyl]-5-(trifluoromethyl)benzamide",PUBCHEM.COMPOUND:117807506,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,57,0.552,0.552,0.0,0.0,0.276,55.2,False,-0.0,False,0.552,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,57,medik:edge#181,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,biolink:gene_associated_with_condition,[],one-hop,,,,,,,,,['PMID:16439621'],DEFAULT PHRASE,infores:disgenet,1,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"N-[3-[5-(2-aminopyrimidin-4-yl)-2-tert-butyl-1H-imidazol-4-yl]-2-chlorophenyl]-2,6-difluorobenzenesulfonamide",PUBCHEM.COMPOUND:58164438,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,58,0.544,0.544,0.0,0.0,0.272,54.4,False,-0.0,False,0.544,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,58,medik:creative_edge#40,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,PUBCHEM.COMPOUND:58164438,"N-[3-[5-(2-aminopyrimidin-4-yl)-2-tert-butyl-1H-imidazol-4-yl]-2-chlorophenyl]-2,6-difluorobenzenesulfonamide",['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:treats,[],creative,,,,,,,,,[],DEFAULT PHRASE,infores:unsecret-agent,0,
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"N-[3-[5-(2-aminopyrimidin-4-yl)-2-tert-butyl-1H-imidazol-4-yl]-2-chlorophenyl]-2,6-difluorobenzenesulfonamide",PUBCHEM.COMPOUND:58164438,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,58,0.544,0.544,0.0,0.0,0.272,54.4,False,-0.0,False,0.544,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,58,medik:edge#80,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,PUBCHEM.COMPOUND:58164438,"N-[3-[5-(2-aminopyrimidin-4-yl)-2-tert-butyl-1H-imidazol-4-yl]-2-chlorophenyl]-2,6-difluorobenzenesulfonamide",['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:affects,"[{'qualifier_type_id': 'biolink:object_aspect_qualifier', 'qualifier_value': 'activity'}, {'qualifier_type_id': 'biolink:object_direction_qualifier', 'qualifier_value': 'decreased'}, {'qualifier_type_id': 'biolink:qualified_predicate', 'qualifier_value': 'biolink:causes'}]",one-hop,causes,,,,,decreased,activity,,[],"N-[3-[5-(2-aminopyrimidin-4-yl)-2-tert-butyl-1H-imidazol-4-yl]-2-chlorophenyl]-2,6-difluorobenzenesulfonamide causes decreased activity of BRAF",infores:bindingdb,0,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"N-[3-[5-(2-aminopyrimidin-4-yl)-2-tert-butyl-1H-imidazol-4-yl]-2-chlorophenyl]-2,6-difluorobenzenesulfonamide",PUBCHEM.COMPOUND:58164438,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,58,0.544,0.544,0.0,0.0,0.272,54.4,False,-0.0,False,0.544,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,58,medik:edge#81,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,biolink:gene_associated_with_condition,[],one-hop,,,,,,,,,['PMID:16439621'],DEFAULT PHRASE,infores:disgenet,1,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"1-[(1S,1aS,6bS)-5-[(7-oxo-6,8-dihydro-5H-1,8-naphthyridin-4-yl)oxy]-1a,6b-dihydro-1H-cyclopropa[b][1]benzofuran-1-yl]-3-[3-(trifluoromethoxy)phenyl]urea",PUBCHEM.COMPOUND:124149060,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,59,0.536,0.536,0.0,0.0,0.268,53.6,False,-0.0,False,0.536,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,59,medik:creative_edge#99,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,PUBCHEM.COMPOUND:124149060,"1-[(1S,1aS,6bS)-5-[(7-oxo-6,8-dihydro-5H-1,8-naphthyridin-4-yl)oxy]-1a,6b-dihydro-1H-cyclopropa[b][1]benzofuran-1-yl]-3-[3-(trifluoromethoxy)phenyl]urea",['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:treats,[],creative,,,,,,,,,[],DEFAULT PHRASE,infores:unsecret-agent,0,
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"1-[(1S,1aS,6bS)-5-[(7-oxo-6,8-dihydro-5H-1,8-naphthyridin-4-yl)oxy]-1a,6b-dihydro-1H-cyclopropa[b][1]benzofuran-1-yl]-3-[3-(trifluoromethoxy)phenyl]urea",PUBCHEM.COMPOUND:124149060,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,59,0.536,0.536,0.0,0.0,0.268,53.6,False,-0.0,False,0.536,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,59,medik:edge#198,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,PUBCHEM.COMPOUND:124149060,"1-[(1S,1aS,6bS)-5-[(7-oxo-6,8-dihydro-5H-1,8-naphthyridin-4-yl)oxy]-1a,6b-dihydro-1H-cyclopropa[b][1]benzofuran-1-yl]-3-[3-(trifluoromethoxy)phenyl]urea",['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:affects,"[{'qualifier_type_id': 'biolink:object_aspect_qualifier', 'qualifier_value': 'activity'}, {'qualifier_type_id': 'biolink:object_direction_qualifier', 'qualifier_value': 'decreased'}, {'qualifier_type_id': 'biolink:qualified_predicate', 'qualifier_value': 'biolink:causes'}]",one-hop,causes,,,,,decreased,activity,,[],"1-[(1S,1aS,6bS)-5-[(7-oxo-6,8-dihydro-5H-1,8-naphthyridin-4-yl)oxy]-1a,6b-dihydro-1H-cyclopropa[b][1]benzofuran-1-yl]-3-[3-(trifluoromethoxy)phenyl]urea causes decreased activity of BRAF",infores:bindingdb,0,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"1-[(1S,1aS,6bS)-5-[(7-oxo-6,8-dihydro-5H-1,8-naphthyridin-4-yl)oxy]-1a,6b-dihydro-1H-cyclopropa[b][1]benzofuran-1-yl]-3-[3-(trifluoromethoxy)phenyl]urea",PUBCHEM.COMPOUND:124149060,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,59,0.536,0.536,0.0,0.0,0.268,53.6,False,-0.0,False,0.536,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,59,medik:edge#199,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,biolink:gene_associated_with_condition,[],one-hop,,,,,,,,,['PMID:16439621'],DEFAULT PHRASE,infores:disgenet,1,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,N-[3-[5-(2-aminopyrimidin-4-yl)-2-cyclopropyl-1H-imidazol-4-yl]-5-chloro-2-fluorophenyl]methanesulfonamide,PUBCHEM.COMPOUND:58164433,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,60,0.528,0.528,0.0,0.0,0.264,52.8,False,-0.0,False,0.528,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,60,medik:creative_edge#122,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,PUBCHEM.COMPOUND:58164433,N-[3-[5-(2-aminopyrimidin-4-yl)-2-cyclopropyl-1H-imidazol-4-yl]-5-chloro-2-fluorophenyl]methanesulfonamide,['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:treats,[],creative,,,,,,,,,[],DEFAULT PHRASE,infores:unsecret-agent,0,
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,N-[3-[5-(2-aminopyrimidin-4-yl)-2-cyclopropyl-1H-imidazol-4-yl]-5-chloro-2-fluorophenyl]methanesulfonamide,PUBCHEM.COMPOUND:58164433,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,60,0.528,0.528,0.0,0.0,0.264,52.8,False,-0.0,False,0.528,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,60,medik:edge#244,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,PUBCHEM.COMPOUND:58164433,N-[3-[5-(2-aminopyrimidin-4-yl)-2-cyclopropyl-1H-imidazol-4-yl]-5-chloro-2-fluorophenyl]methanesulfonamide,['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:affects,"[{'qualifier_type_id': 'biolink:object_aspect_qualifier', 'qualifier_value': 'activity'}, {'qualifier_type_id': 'biolink:object_direction_qualifier', 'qualifier_value': 'decreased'}, {'qualifier_type_id': 'biolink:qualified_predicate', 'qualifier_value': 'biolink:causes'}]",one-hop,causes,,,,,decreased,activity,,[],N-[3-[5-(2-aminopyrimidin-4-yl)-2-cyclopropyl-1H-imidazol-4-yl]-5-chloro-2-fluorophenyl]methanesulfonamide causes decreased activity of BRAF,infores:bindingdb,0,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,N-[3-[5-(2-aminopyrimidin-4-yl)-2-cyclopropyl-1H-imidazol-4-yl]-5-chloro-2-fluorophenyl]methanesulfonamide,PUBCHEM.COMPOUND:58164433,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,60,0.528,0.528,0.0,0.0,0.264,52.8,False,-0.0,False,0.528,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,60,medik:edge#245,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,biolink:gene_associated_with_condition,[],one-hop,,,,,,,,,['PMID:16439621'],DEFAULT PHRASE,infores:disgenet,1,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,6-(5-amino-2-fluorophenyl)-N-(1H-indazol-4-yl)quinazolin-4-amine,PUBCHEM.COMPOUND:86766672,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,61,0.52,0.52,0.0,0.0,0.26,52.0,False,-0.0,False,0.52,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,61,medik:creative_edge#72,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,PUBCHEM.COMPOUND:86766672,6-(5-amino-2-fluorophenyl)-N-(1H-indazol-4-yl)quinazolin-4-amine,['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:treats,[],creative,,,,,,,,,[],DEFAULT PHRASE,infores:unsecret-agent,0,
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,6-(5-amino-2-fluorophenyl)-N-(1H-indazol-4-yl)quinazolin-4-amine,PUBCHEM.COMPOUND:86766672,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,61,0.52,0.52,0.0,0.0,0.26,52.0,False,-0.0,False,0.52,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,61,medik:edge#144,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,PUBCHEM.COMPOUND:86766672,6-(5-amino-2-fluorophenyl)-N-(1H-indazol-4-yl)quinazolin-4-amine,['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:affects,"[{'qualifier_type_id': 'biolink:object_aspect_qualifier', 'qualifier_value': 'activity'}, {'qualifier_type_id': 'biolink:object_direction_qualifier', 'qualifier_value': 'decreased'}, {'qualifier_type_id': 'biolink:qualified_predicate', 'qualifier_value': 'biolink:causes'}]",one-hop,causes,,,,,decreased,activity,,[],6-(5-amino-2-fluorophenyl)-N-(1H-indazol-4-yl)quinazolin-4-amine causes decreased activity of BRAF,infores:bindingdb,0,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,6-(5-amino-2-fluorophenyl)-N-(1H-indazol-4-yl)quinazolin-4-amine,PUBCHEM.COMPOUND:86766672,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,61,0.52,0.52,0.0,0.0,0.26,52.0,False,-0.0,False,0.52,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,61,medik:edge#145,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,biolink:gene_associated_with_condition,[],one-hop,,,,,,,,,['PMID:16439621'],DEFAULT PHRASE,infores:disgenet,1,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"N-[3-[[4-[6-(4-fluoro-3-hydroxyphenyl)imidazo[2,1-b][1,3]oxazol-5-yl]pyrimidin-2-yl]amino]propyl]-4-methoxybenzenesulfonamide",PUBCHEM.COMPOUND:146501316,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,62,0.512,0.512,0.0,0.0,0.256,51.2,False,-0.0,False,0.512,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,62,medik:creative_edge#106,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,PUBCHEM.COMPOUND:146501316,"N-[3-[[4-[6-(4-fluoro-3-hydroxyphenyl)imidazo[2,1-b][1,3]oxazol-5-yl]pyrimidin-2-yl]amino]propyl]-4-methoxybenzenesulfonamide",['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:treats,[],creative,,,,,,,,,[],DEFAULT PHRASE,infores:unsecret-agent,0,
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"N-[3-[[4-[6-(4-fluoro-3-hydroxyphenyl)imidazo[2,1-b][1,3]oxazol-5-yl]pyrimidin-2-yl]amino]propyl]-4-methoxybenzenesulfonamide",PUBCHEM.COMPOUND:146501316,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,62,0.512,0.512,0.0,0.0,0.256,51.2,False,-0.0,False,0.512,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,62,medik:edge#212,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,PUBCHEM.COMPOUND:146501316,"N-[3-[[4-[6-(4-fluoro-3-hydroxyphenyl)imidazo[2,1-b][1,3]oxazol-5-yl]pyrimidin-2-yl]amino]propyl]-4-methoxybenzenesulfonamide",['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:affects,"[{'qualifier_type_id': 'biolink:object_aspect_qualifier', 'qualifier_value': 'activity'}, {'qualifier_type_id': 'biolink:object_direction_qualifier', 'qualifier_value': 'decreased'}, {'qualifier_type_id': 'biolink:qualified_predicate', 'qualifier_value': 'biolink:causes'}]",one-hop,causes,,,,,decreased,activity,,[],"N-[3-[[4-[6-(4-fluoro-3-hydroxyphenyl)imidazo[2,1-b][1,3]oxazol-5-yl]pyrimidin-2-yl]amino]propyl]-4-methoxybenzenesulfonamide causes decreased activity of BRAF",infores:bindingdb,0,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"N-[3-[[4-[6-(4-fluoro-3-hydroxyphenyl)imidazo[2,1-b][1,3]oxazol-5-yl]pyrimidin-2-yl]amino]propyl]-4-methoxybenzenesulfonamide",PUBCHEM.COMPOUND:146501316,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,62,0.512,0.512,0.0,0.0,0.256,51.2,False,-0.0,False,0.512,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,62,medik:edge#213,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,biolink:gene_associated_with_condition,[],one-hop,,,,,,,,,['PMID:16439621'],DEFAULT PHRASE,infores:disgenet,1,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"US10167279, Example 21",PUBCHEM.COMPOUND:135133624,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,63,0.504,0.504,0.0,0.0,0.252,50.4,False,-0.0,False,0.504,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,63,medik:creative_edge#24,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,PUBCHEM.COMPOUND:135133624,"US10167279, Example 21",['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:treats,[],creative,,,,,,,,,[],DEFAULT PHRASE,infores:unsecret-agent,0,
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"US10167279, Example 21",PUBCHEM.COMPOUND:135133624,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,63,0.504,0.504,0.0,0.0,0.252,50.4,False,-0.0,False,0.504,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,63,medik:edge#48,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,PUBCHEM.COMPOUND:135133624,"US10167279, Example 21",['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:affects,"[{'qualifier_type_id': 'biolink:object_aspect_qualifier', 'qualifier_value': 'activity'}, {'qualifier_type_id': 'biolink:object_direction_qualifier', 'qualifier_value': 'decreased'}, {'qualifier_type_id': 'biolink:qualified_predicate', 'qualifier_value': 'biolink:causes'}]",one-hop,causes,,,,,decreased,activity,,[],"US10167279, Example 21 causes decreased activity of BRAF",infores:bindingdb,0,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"US10167279, Example 21",PUBCHEM.COMPOUND:135133624,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,63,0.504,0.504,0.0,0.0,0.252,50.4,False,-0.0,False,0.504,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,63,medik:edge#49,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,biolink:gene_associated_with_condition,[],one-hop,,,,,,,,,['PMID:16439621'],DEFAULT PHRASE,infores:disgenet,1,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,6-(2-cyanopropan-2-yl)-N-[3-[2-(2-hydroxyethylamino)-6-morpholin-4-ylpyrimidin-4-yl]-4-methylphenyl]pyridazine-4-carboxamide,PUBCHEM.COMPOUND:90463199,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,64,0.496,0.496,0.0,0.0,0.248,49.6,False,-0.0,False,0.496,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,64,medik:creative_edge#79,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,PUBCHEM.COMPOUND:90463199,6-(2-cyanopropan-2-yl)-N-[3-[2-(2-hydroxyethylamino)-6-morpholin-4-ylpyrimidin-4-yl]-4-methylphenyl]pyridazine-4-carboxamide,['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:treats,[],creative,,,,,,,,,[],DEFAULT PHRASE,infores:unsecret-agent,0,
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,6-(2-cyanopropan-2-yl)-N-[3-[2-(2-hydroxyethylamino)-6-morpholin-4-ylpyrimidin-4-yl]-4-methylphenyl]pyridazine-4-carboxamide,PUBCHEM.COMPOUND:90463199,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,64,0.496,0.496,0.0,0.0,0.248,49.6,False,-0.0,False,0.496,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,64,medik:edge#158,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,PUBCHEM.COMPOUND:90463199,6-(2-cyanopropan-2-yl)-N-[3-[2-(2-hydroxyethylamino)-6-morpholin-4-ylpyrimidin-4-yl]-4-methylphenyl]pyridazine-4-carboxamide,['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:affects,"[{'qualifier_type_id': 'biolink:object_aspect_qualifier', 'qualifier_value': 'activity'}, {'qualifier_type_id': 'biolink:object_direction_qualifier', 'qualifier_value': 'decreased'}, {'qualifier_type_id': 'biolink:qualified_predicate', 'qualifier_value': 'biolink:causes'}]",one-hop,causes,,,,,decreased,activity,,[],6-(2-cyanopropan-2-yl)-N-[3-[2-(2-hydroxyethylamino)-6-morpholin-4-ylpyrimidin-4-yl]-4-methylphenyl]pyridazine-4-carboxamide causes decreased activity of BRAF,infores:bindingdb,0,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,6-(2-cyanopropan-2-yl)-N-[3-[2-(2-hydroxyethylamino)-6-morpholin-4-ylpyrimidin-4-yl]-4-methylphenyl]pyridazine-4-carboxamide,PUBCHEM.COMPOUND:90463199,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,64,0.496,0.496,0.0,0.0,0.248,49.6,False,-0.0,False,0.496,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,64,medik:edge#159,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,biolink:gene_associated_with_condition,[],one-hop,,,,,,,,,['PMID:16439621'],DEFAULT PHRASE,infores:disgenet,1,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,4-[4-(2-Hydroxyanilino)quinazolin-6-yl]-2-methoxyphenol,PUBCHEM.COMPOUND:86766626,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,65,0.488,0.488,0.0,0.0,0.244,48.8,False,-0.0,False,0.488,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,65,medik:creative_edge#71,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,PUBCHEM.COMPOUND:86766626,4-[4-(2-Hydroxyanilino)quinazolin-6-yl]-2-methoxyphenol,['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:treats,[],creative,,,,,,,,,[],DEFAULT PHRASE,infores:unsecret-agent,0,
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,4-[4-(2-Hydroxyanilino)quinazolin-6-yl]-2-methoxyphenol,PUBCHEM.COMPOUND:86766626,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,65,0.488,0.488,0.0,0.0,0.244,48.8,False,-0.0,False,0.488,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,65,medik:edge#142,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,PUBCHEM.COMPOUND:86766626,4-[4-(2-Hydroxyanilino)quinazolin-6-yl]-2-methoxyphenol,['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:affects,"[{'qualifier_type_id': 'biolink:object_aspect_qualifier', 'qualifier_value': 'activity'}, {'qualifier_type_id': 'biolink:object_direction_qualifier', 'qualifier_value': 'decreased'}, {'qualifier_type_id': 'biolink:qualified_predicate', 'qualifier_value': 'biolink:causes'}]",one-hop,causes,,,,,decreased,activity,,[],4-[4-(2-Hydroxyanilino)quinazolin-6-yl]-2-methoxyphenol causes decreased activity of BRAF,infores:bindingdb,0,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,4-[4-(2-Hydroxyanilino)quinazolin-6-yl]-2-methoxyphenol,PUBCHEM.COMPOUND:86766626,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,65,0.488,0.488,0.0,0.0,0.244,48.8,False,-0.0,False,0.488,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,65,medik:edge#143,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,biolink:gene_associated_with_condition,[],one-hop,,,,,,,,,['PMID:16439621'],DEFAULT PHRASE,infores:disgenet,1,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,1-ethyl-N-[6-methyl-5-(1-methyl-2-morpholin-4-yl-6-oxopyridin-4-yl)pyridin-3-yl]-6-oxo-5-(trifluoromethyl)pyridine-3-carboxamide,PUBCHEM.COMPOUND:117609621,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,66,0.48,0.48,0.0,0.0,0.24,48.0,False,-0.0,False,0.48,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,66,medik:creative_edge#84,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,PUBCHEM.COMPOUND:117609621,1-ethyl-N-[6-methyl-5-(1-methyl-2-morpholin-4-yl-6-oxopyridin-4-yl)pyridin-3-yl]-6-oxo-5-(trifluoromethyl)pyridine-3-carboxamide,['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:treats,[],creative,,,,,,,,,[],DEFAULT PHRASE,infores:unsecret-agent,0,
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,1-ethyl-N-[6-methyl-5-(1-methyl-2-morpholin-4-yl-6-oxopyridin-4-yl)pyridin-3-yl]-6-oxo-5-(trifluoromethyl)pyridine-3-carboxamide,PUBCHEM.COMPOUND:117609621,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,66,0.48,0.48,0.0,0.0,0.24,48.0,False,-0.0,False,0.48,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,66,medik:edge#168,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,PUBCHEM.COMPOUND:117609621,1-ethyl-N-[6-methyl-5-(1-methyl-2-morpholin-4-yl-6-oxopyridin-4-yl)pyridin-3-yl]-6-oxo-5-(trifluoromethyl)pyridine-3-carboxamide,['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:affects,"[{'qualifier_type_id': 'biolink:object_aspect_qualifier', 'qualifier_value': 'activity'}, {'qualifier_type_id': 'biolink:object_direction_qualifier', 'qualifier_value': 'decreased'}, {'qualifier_type_id': 'biolink:qualified_predicate', 'qualifier_value': 'biolink:causes'}]",one-hop,causes,,,,,decreased,activity,,[],1-ethyl-N-[6-methyl-5-(1-methyl-2-morpholin-4-yl-6-oxopyridin-4-yl)pyridin-3-yl]-6-oxo-5-(trifluoromethyl)pyridine-3-carboxamide causes decreased activity of BRAF,infores:bindingdb,0,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,1-ethyl-N-[6-methyl-5-(1-methyl-2-morpholin-4-yl-6-oxopyridin-4-yl)pyridin-3-yl]-6-oxo-5-(trifluoromethyl)pyridine-3-carboxamide,PUBCHEM.COMPOUND:117609621,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,66,0.48,0.48,0.0,0.0,0.24,48.0,False,-0.0,False,0.48,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,66,medik:edge#169,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,biolink:gene_associated_with_condition,[],one-hop,,,,,,,,,['PMID:16439621'],DEFAULT PHRASE,infores:disgenet,1,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"US9359338, Exe. 141",PUBCHEM.COMPOUND:118233986,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,67,0.472,0.472,0.0,0.0,0.236,47.2,False,-0.0,False,0.472,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,67,medik:creative_edge#94,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,PUBCHEM.COMPOUND:118233986,"US9359338, Exe. 141",['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:treats,[],creative,,,,,,,,,[],DEFAULT PHRASE,infores:unsecret-agent,0,
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"US9359338, Exe. 141",PUBCHEM.COMPOUND:118233986,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,67,0.472,0.472,0.0,0.0,0.236,47.2,False,-0.0,False,0.472,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,67,medik:edge#188,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,PUBCHEM.COMPOUND:118233986,"US9359338, Exe. 141",['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:affects,"[{'qualifier_type_id': 'biolink:object_aspect_qualifier', 'qualifier_value': 'activity'}, {'qualifier_type_id': 'biolink:object_direction_qualifier', 'qualifier_value': 'decreased'}, {'qualifier_type_id': 'biolink:qualified_predicate', 'qualifier_value': 'biolink:causes'}]",one-hop,causes,,,,,decreased,activity,,[],"US9359338, Exe. 141 causes decreased activity of BRAF",infores:bindingdb,0,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"US9359338, Exe. 141",PUBCHEM.COMPOUND:118233986,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,67,0.472,0.472,0.0,0.0,0.236,47.2,False,-0.0,False,0.472,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,67,medik:edge#189,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,biolink:gene_associated_with_condition,[],one-hop,,,,,,,,,['PMID:16439621'],DEFAULT PHRASE,infores:disgenet,1,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"3-[[4-amino-2-[(1R,4R)-5-methyl-2,5-diazabicyclo[2.2.1]heptan-2-yl]pyrimido[5,4-d]pyrimidin-8-yl]amino]-4-methyl-N-[3-(trifluoromethyl)phenyl]benzamide",PUBCHEM.COMPOUND:68035561,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,68,0.464,0.464,0.0,0.0,0.232,46.4,False,-0.0,False,0.464,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,68,medik:creative_edge#47,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,PUBCHEM.COMPOUND:68035561,"3-[[4-amino-2-[(1R,4R)-5-methyl-2,5-diazabicyclo[2.2.1]heptan-2-yl]pyrimido[5,4-d]pyrimidin-8-yl]amino]-4-methyl-N-[3-(trifluoromethyl)phenyl]benzamide",['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:treats,[],creative,,,,,,,,,[],DEFAULT PHRASE,infores:unsecret-agent,0,
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"3-[[4-amino-2-[(1R,4R)-5-methyl-2,5-diazabicyclo[2.2.1]heptan-2-yl]pyrimido[5,4-d]pyrimidin-8-yl]amino]-4-methyl-N-[3-(trifluoromethyl)phenyl]benzamide",PUBCHEM.COMPOUND:68035561,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,68,0.464,0.464,0.0,0.0,0.232,46.4,False,-0.0,False,0.464,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,68,medik:edge#94,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,PUBCHEM.COMPOUND:68035561,"3-[[4-amino-2-[(1R,4R)-5-methyl-2,5-diazabicyclo[2.2.1]heptan-2-yl]pyrimido[5,4-d]pyrimidin-8-yl]amino]-4-methyl-N-[3-(trifluoromethyl)phenyl]benzamide",['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:affects,"[{'qualifier_type_id': 'biolink:object_aspect_qualifier', 'qualifier_value': 'activity'}, {'qualifier_type_id': 'biolink:object_direction_qualifier', 'qualifier_value': 'decreased'}, {'qualifier_type_id': 'biolink:qualified_predicate', 'qualifier_value': 'biolink:causes'}]",one-hop,causes,,,,,decreased,activity,,[],"3-[[4-amino-2-[(1R,4R)-5-methyl-2,5-diazabicyclo[2.2.1]heptan-2-yl]pyrimido[5,4-d]pyrimidin-8-yl]amino]-4-methyl-N-[3-(trifluoromethyl)phenyl]benzamide causes decreased activity of BRAF",infores:bindingdb,0,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"3-[[4-amino-2-[(1R,4R)-5-methyl-2,5-diazabicyclo[2.2.1]heptan-2-yl]pyrimido[5,4-d]pyrimidin-8-yl]amino]-4-methyl-N-[3-(trifluoromethyl)phenyl]benzamide",PUBCHEM.COMPOUND:68035561,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,68,0.464,0.464,0.0,0.0,0.232,46.4,False,-0.0,False,0.464,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,68,medik:edge#95,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,biolink:gene_associated_with_condition,[],one-hop,,,,,,,,,['PMID:16439621'],DEFAULT PHRASE,infores:disgenet,1,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"US9359338, Exe. 152",PUBCHEM.COMPOUND:118233989,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,69,0.456,0.456,0.0,0.0,0.228,45.6,False,-0.0,False,0.456,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,69,medik:creative_edge#95,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,PUBCHEM.COMPOUND:118233989,"US9359338, Exe. 152",['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:treats,[],creative,,,,,,,,,[],DEFAULT PHRASE,infores:unsecret-agent,0,
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"US9359338, Exe. 152",PUBCHEM.COMPOUND:118233989,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,69,0.456,0.456,0.0,0.0,0.228,45.6,False,-0.0,False,0.456,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,69,medik:edge#190,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,PUBCHEM.COMPOUND:118233989,"US9359338, Exe. 152",['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:affects,"[{'qualifier_type_id': 'biolink:object_aspect_qualifier', 'qualifier_value': 'activity'}, {'qualifier_type_id': 'biolink:object_direction_qualifier', 'qualifier_value': 'decreased'}, {'qualifier_type_id': 'biolink:qualified_predicate', 'qualifier_value': 'biolink:causes'}]",one-hop,causes,,,,,decreased,activity,,[],"US9359338, Exe. 152 causes decreased activity of BRAF",infores:bindingdb,0,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"US9359338, Exe. 152",PUBCHEM.COMPOUND:118233989,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,69,0.456,0.456,0.0,0.0,0.228,45.6,False,-0.0,False,0.456,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,69,medik:edge#191,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,biolink:gene_associated_with_condition,[],one-hop,,,,,,,,,['PMID:16439621'],DEFAULT PHRASE,infores:disgenet,1,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"US10167279, Example 64",PUBCHEM.COMPOUND:134609516,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,70,0.448,0.448,0.0,0.0,0.224,44.8,False,-0.0,False,0.448,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,70,medik:creative_edge#103,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,PUBCHEM.COMPOUND:134609516,"US10167279, Example 64",['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:treats,[],creative,,,,,,,,,[],DEFAULT PHRASE,infores:unsecret-agent,0,
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"US10167279, Example 64",PUBCHEM.COMPOUND:134609516,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,70,0.448,0.448,0.0,0.0,0.224,44.8,False,-0.0,False,0.448,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,70,medik:edge#206,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,PUBCHEM.COMPOUND:134609516,"US10167279, Example 64",['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:affects,"[{'qualifier_type_id': 'biolink:object_aspect_qualifier', 'qualifier_value': 'activity'}, {'qualifier_type_id': 'biolink:object_direction_qualifier', 'qualifier_value': 'decreased'}, {'qualifier_type_id': 'biolink:qualified_predicate', 'qualifier_value': 'biolink:causes'}]",one-hop,causes,,,,,decreased,activity,,[],"US10167279, Example 64 causes decreased activity of BRAF",infores:bindingdb,0,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"US10167279, Example 64",PUBCHEM.COMPOUND:134609516,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,70,0.448,0.448,0.0,0.0,0.224,44.8,False,-0.0,False,0.448,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,70,medik:edge#207,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,biolink:gene_associated_with_condition,[],one-hop,,,,,,,,,['PMID:16439621'],DEFAULT PHRASE,infores:disgenet,1,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"N-(2-cyano-3-((3,5-dimethyl-4-oxo-3,4-dihdyroquinazolin-6-yl)amino)phenyl)propane-1-sulfonamide",PUBCHEM.COMPOUND:155434721,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,71,0.44,0.44,0.0,0.0,0.22,44.0,False,-0.0,False,0.44,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,71,medik:creative_edge#26,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,PUBCHEM.COMPOUND:155434721,"N-(2-cyano-3-((3,5-dimethyl-4-oxo-3,4-dihdyroquinazolin-6-yl)amino)phenyl)propane-1-sulfonamide",['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:treats,[],creative,,,,,,,,,[],DEFAULT PHRASE,infores:unsecret-agent,0,
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"N-(2-cyano-3-((3,5-dimethyl-4-oxo-3,4-dihdyroquinazolin-6-yl)amino)phenyl)propane-1-sulfonamide",PUBCHEM.COMPOUND:155434721,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,71,0.44,0.44,0.0,0.0,0.22,44.0,False,-0.0,False,0.44,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,71,medik:edge#52,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,PUBCHEM.COMPOUND:155434721,"N-(2-cyano-3-((3,5-dimethyl-4-oxo-3,4-dihdyroquinazolin-6-yl)amino)phenyl)propane-1-sulfonamide",['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:affects,"[{'qualifier_type_id': 'biolink:object_aspect_qualifier', 'qualifier_value': 'activity'}, {'qualifier_type_id': 'biolink:object_direction_qualifier', 'qualifier_value': 'decreased'}, {'qualifier_type_id': 'biolink:qualified_predicate', 'qualifier_value': 'biolink:causes'}]",one-hop,causes,,,,,decreased,activity,,[],"N-(2-cyano-3-((3,5-dimethyl-4-oxo-3,4-dihdyroquinazolin-6-yl)amino)phenyl)propane-1-sulfonamide causes decreased activity of BRAF",infores:bindingdb,0,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"N-(2-cyano-3-((3,5-dimethyl-4-oxo-3,4-dihdyroquinazolin-6-yl)amino)phenyl)propane-1-sulfonamide",PUBCHEM.COMPOUND:155434721,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,71,0.44,0.44,0.0,0.0,0.22,44.0,False,-0.0,False,0.44,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,71,medik:edge#53,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,biolink:gene_associated_with_condition,[],one-hop,,,,,,,,,['PMID:16439621'],DEFAULT PHRASE,infores:disgenet,1,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"US8653087, III-387",PUBCHEM.COMPOUND:68036165,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,72,0.432,0.432,0.0,0.0,0.216,43.2,False,-0.0,False,0.432,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,72,medik:creative_edge#58,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,PUBCHEM.COMPOUND:68036165,"US8653087, III-387",['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:treats,[],creative,,,,,,,,,[],DEFAULT PHRASE,infores:unsecret-agent,0,
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"US8653087, III-387",PUBCHEM.COMPOUND:68036165,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,72,0.432,0.432,0.0,0.0,0.216,43.2,False,-0.0,False,0.432,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,72,medik:edge#116,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,PUBCHEM.COMPOUND:68036165,"US8653087, III-387",['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:affects,"[{'qualifier_type_id': 'biolink:object_aspect_qualifier', 'qualifier_value': 'activity'}, {'qualifier_type_id': 'biolink:object_direction_qualifier', 'qualifier_value': 'decreased'}, {'qualifier_type_id': 'biolink:qualified_predicate', 'qualifier_value': 'biolink:causes'}]",one-hop,causes,,,,,decreased,activity,,[],"US8653087, III-387 causes decreased activity of BRAF",infores:bindingdb,0,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"US8653087, III-387",PUBCHEM.COMPOUND:68036165,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,72,0.432,0.432,0.0,0.0,0.216,43.2,False,-0.0,False,0.432,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,72,medik:edge#117,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,biolink:gene_associated_with_condition,[],one-hop,,,,,,,,,['PMID:16439621'],DEFAULT PHRASE,infores:disgenet,1,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"US10167279, Example 39",PUBCHEM.COMPOUND:135133708,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,73,0.424,0.424,0.0,0.0,0.212,42.4,False,-0.0,False,0.424,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,73,medik:creative_edge#25,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,PUBCHEM.COMPOUND:135133708,"US10167279, Example 39",['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:treats,[],creative,,,,,,,,,[],DEFAULT PHRASE,infores:unsecret-agent,0,
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"US10167279, Example 39",PUBCHEM.COMPOUND:135133708,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,73,0.424,0.424,0.0,0.0,0.212,42.4,False,-0.0,False,0.424,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,73,medik:edge#50,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,PUBCHEM.COMPOUND:135133708,"US10167279, Example 39",['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:affects,"[{'qualifier_type_id': 'biolink:object_aspect_qualifier', 'qualifier_value': 'activity'}, {'qualifier_type_id': 'biolink:object_direction_qualifier', 'qualifier_value': 'decreased'}, {'qualifier_type_id': 'biolink:qualified_predicate', 'qualifier_value': 'biolink:causes'}]",one-hop,causes,,,,,decreased,activity,,[],"US10167279, Example 39 causes decreased activity of BRAF",infores:bindingdb,0,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"US10167279, Example 39",PUBCHEM.COMPOUND:135133708,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,73,0.424,0.424,0.0,0.0,0.212,42.4,False,-0.0,False,0.424,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,73,medik:edge#51,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,biolink:gene_associated_with_condition,[],one-hop,,,,,,,,,['PMID:16439621'],DEFAULT PHRASE,infores:disgenet,1,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"US9359338, Exe. 021",PUBCHEM.COMPOUND:118233957,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,74,0.416,0.416,0.0,0.0,0.208,41.6,False,-0.0,False,0.416,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,74,medik:creative_edge#93,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,PUBCHEM.COMPOUND:118233957,"US9359338, Exe. 021",['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:treats,[],creative,,,,,,,,,[],DEFAULT PHRASE,infores:unsecret-agent,0,
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"US9359338, Exe. 021",PUBCHEM.COMPOUND:118233957,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,74,0.416,0.416,0.0,0.0,0.208,41.6,False,-0.0,False,0.416,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,74,medik:edge#186,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,PUBCHEM.COMPOUND:118233957,"US9359338, Exe. 021",['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:affects,"[{'qualifier_type_id': 'biolink:object_aspect_qualifier', 'qualifier_value': 'activity'}, {'qualifier_type_id': 'biolink:object_direction_qualifier', 'qualifier_value': 'decreased'}, {'qualifier_type_id': 'biolink:qualified_predicate', 'qualifier_value': 'biolink:causes'}]",one-hop,causes,,,,,decreased,activity,,[],"US9359338, Exe. 021 causes decreased activity of BRAF",infores:bindingdb,0,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"US9359338, Exe. 021",PUBCHEM.COMPOUND:118233957,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,74,0.416,0.416,0.0,0.0,0.208,41.6,False,-0.0,False,0.416,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,74,medik:edge#187,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,biolink:gene_associated_with_condition,[],one-hop,,,,,,,,,['PMID:16439621'],DEFAULT PHRASE,infores:disgenet,1,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,5-tert-butyl-N-[4-methyl-3-[4-[5-[4-(2-methylpropyl)piperazin-1-yl]pyridin-3-yl]triazol-1-yl]phenyl]thiophene-2-carboxamide,PUBCHEM.COMPOUND:53464474,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,75,0.408,0.408,0.0,0.0,0.204,40.8,False,-0.0,False,0.408,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,75,medik:creative_edge#118,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,PUBCHEM.COMPOUND:53464474,5-tert-butyl-N-[4-methyl-3-[4-[5-[4-(2-methylpropyl)piperazin-1-yl]pyridin-3-yl]triazol-1-yl]phenyl]thiophene-2-carboxamide,['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:treats,[],creative,,,,,,,,,[],DEFAULT PHRASE,infores:unsecret-agent,0,
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,5-tert-butyl-N-[4-methyl-3-[4-[5-[4-(2-methylpropyl)piperazin-1-yl]pyridin-3-yl]triazol-1-yl]phenyl]thiophene-2-carboxamide,PUBCHEM.COMPOUND:53464474,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,75,0.408,0.408,0.0,0.0,0.204,40.8,False,-0.0,False,0.408,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,75,medik:edge#236,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,PUBCHEM.COMPOUND:53464474,5-tert-butyl-N-[4-methyl-3-[4-[5-[4-(2-methylpropyl)piperazin-1-yl]pyridin-3-yl]triazol-1-yl]phenyl]thiophene-2-carboxamide,['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:affects,"[{'qualifier_type_id': 'biolink:object_aspect_qualifier', 'qualifier_value': 'activity'}, {'qualifier_type_id': 'biolink:object_direction_qualifier', 'qualifier_value': 'decreased'}, {'qualifier_type_id': 'biolink:qualified_predicate', 'qualifier_value': 'biolink:causes'}]",one-hop,causes,,,,,decreased,activity,,[],5-tert-butyl-N-[4-methyl-3-[4-[5-[4-(2-methylpropyl)piperazin-1-yl]pyridin-3-yl]triazol-1-yl]phenyl]thiophene-2-carboxamide causes decreased activity of BRAF,infores:bindingdb,0,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,5-tert-butyl-N-[4-methyl-3-[4-[5-[4-(2-methylpropyl)piperazin-1-yl]pyridin-3-yl]triazol-1-yl]phenyl]thiophene-2-carboxamide,PUBCHEM.COMPOUND:53464474,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,75,0.408,0.408,0.0,0.0,0.204,40.8,False,-0.0,False,0.408,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,75,medik:edge#237,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,biolink:gene_associated_with_condition,[],one-hop,,,,,,,,,['PMID:16439621'],DEFAULT PHRASE,infores:disgenet,1,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"3,4-Difluoro-2-(2-fluoro-4-iodoanilino)-5-[[2-fluoro-3-(propylsulfonylamino)phenyl]methyl]benzamide",PUBCHEM.COMPOUND:156808781,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,76,0.4,0.4,0.0,0.0,0.2,40.0,False,-0.0,False,0.4,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,76,medik:creative_edge#108,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,PUBCHEM.COMPOUND:156808781,"3,4-Difluoro-2-(2-fluoro-4-iodoanilino)-5-[[2-fluoro-3-(propylsulfonylamino)phenyl]methyl]benzamide",['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:treats,[],creative,,,,,,,,,[],DEFAULT PHRASE,infores:unsecret-agent,0,
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"3,4-Difluoro-2-(2-fluoro-4-iodoanilino)-5-[[2-fluoro-3-(propylsulfonylamino)phenyl]methyl]benzamide",PUBCHEM.COMPOUND:156808781,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,76,0.4,0.4,0.0,0.0,0.2,40.0,False,-0.0,False,0.4,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,76,medik:edge#216,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,PUBCHEM.COMPOUND:156808781,"3,4-Difluoro-2-(2-fluoro-4-iodoanilino)-5-[[2-fluoro-3-(propylsulfonylamino)phenyl]methyl]benzamide",['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:affects,"[{'qualifier_type_id': 'biolink:object_aspect_qualifier', 'qualifier_value': 'activity'}, {'qualifier_type_id': 'biolink:object_direction_qualifier', 'qualifier_value': 'decreased'}, {'qualifier_type_id': 'biolink:qualified_predicate', 'qualifier_value': 'biolink:causes'}]",one-hop,causes,,,,,decreased,activity,,[],"3,4-Difluoro-2-(2-fluoro-4-iodoanilino)-5-[[2-fluoro-3-(propylsulfonylamino)phenyl]methyl]benzamide causes decreased activity of BRAF",infores:bindingdb,0,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"3,4-Difluoro-2-(2-fluoro-4-iodoanilino)-5-[[2-fluoro-3-(propylsulfonylamino)phenyl]methyl]benzamide",PUBCHEM.COMPOUND:156808781,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,76,0.4,0.4,0.0,0.0,0.2,40.0,False,-0.0,False,0.4,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,76,medik:edge#217,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,biolink:gene_associated_with_condition,[],one-hop,,,,,,,,,['PMID:16439621'],DEFAULT PHRASE,infores:disgenet,1,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"1-[(1S,1aS,6bS)-5-[(7-oxo-6,8-dihydro-5H-1,8-naphthyridin-4-yl)oxy]-1a,6b-dihydro-1H-cyclopropa[b][1]benzofuran-1-yl]-3-[[4-(trifluoromethyl)phenyl]methyl]urea",PUBCHEM.COMPOUND:117807085,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,77,0.392,0.392,0.0,0.0,0.196,39.2,False,-0.0,False,0.392,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,77,medik:creative_edge#13,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,PUBCHEM.COMPOUND:117807085,"1-[(1S,1aS,6bS)-5-[(7-oxo-6,8-dihydro-5H-1,8-naphthyridin-4-yl)oxy]-1a,6b-dihydro-1H-cyclopropa[b][1]benzofuran-1-yl]-3-[[4-(trifluoromethyl)phenyl]methyl]urea",['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:treats,[],creative,,,,,,,,,[],DEFAULT PHRASE,infores:unsecret-agent,0,
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"1-[(1S,1aS,6bS)-5-[(7-oxo-6,8-dihydro-5H-1,8-naphthyridin-4-yl)oxy]-1a,6b-dihydro-1H-cyclopropa[b][1]benzofuran-1-yl]-3-[[4-(trifluoromethyl)phenyl]methyl]urea",PUBCHEM.COMPOUND:117807085,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,77,0.392,0.392,0.0,0.0,0.196,39.2,False,-0.0,False,0.392,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,77,medik:edge#26,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,PUBCHEM.COMPOUND:117807085,"1-[(1S,1aS,6bS)-5-[(7-oxo-6,8-dihydro-5H-1,8-naphthyridin-4-yl)oxy]-1a,6b-dihydro-1H-cyclopropa[b][1]benzofuran-1-yl]-3-[[4-(trifluoromethyl)phenyl]methyl]urea",['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:affects,"[{'qualifier_type_id': 'biolink:object_aspect_qualifier', 'qualifier_value': 'activity'}, {'qualifier_type_id': 'biolink:object_direction_qualifier', 'qualifier_value': 'decreased'}, {'qualifier_type_id': 'biolink:qualified_predicate', 'qualifier_value': 'biolink:causes'}]",one-hop,causes,,,,,decreased,activity,,[],"1-[(1S,1aS,6bS)-5-[(7-oxo-6,8-dihydro-5H-1,8-naphthyridin-4-yl)oxy]-1a,6b-dihydro-1H-cyclopropa[b][1]benzofuran-1-yl]-3-[[4-(trifluoromethyl)phenyl]methyl]urea causes decreased activity of BRAF",infores:bindingdb,0,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"1-[(1S,1aS,6bS)-5-[(7-oxo-6,8-dihydro-5H-1,8-naphthyridin-4-yl)oxy]-1a,6b-dihydro-1H-cyclopropa[b][1]benzofuran-1-yl]-3-[[4-(trifluoromethyl)phenyl]methyl]urea",PUBCHEM.COMPOUND:117807085,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,77,0.392,0.392,0.0,0.0,0.196,39.2,False,-0.0,False,0.392,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,77,medik:edge#27,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,biolink:gene_associated_with_condition,[],one-hop,,,,,,,,,['PMID:16439621'],DEFAULT PHRASE,infores:disgenet,1,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,N-[5-[6-ethoxy-5-[(3S)-3-methylmorpholin-4-yl]pyridin-3-yl]-6-methylpyridin-3-yl]-6-(trifluoromethyl)pyridazine-4-carboxamide,PUBCHEM.COMPOUND:117609560,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,78,0.384,0.384,0.0,0.0,0.192,38.4,False,-0.0,False,0.384,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,78,medik:creative_edge#3,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,PUBCHEM.COMPOUND:117609560,N-[5-[6-ethoxy-5-[(3S)-3-methylmorpholin-4-yl]pyridin-3-yl]-6-methylpyridin-3-yl]-6-(trifluoromethyl)pyridazine-4-carboxamide,['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:treats,[],creative,,,,,,,,,[],DEFAULT PHRASE,infores:unsecret-agent,0,
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,N-[5-[6-ethoxy-5-[(3S)-3-methylmorpholin-4-yl]pyridin-3-yl]-6-methylpyridin-3-yl]-6-(trifluoromethyl)pyridazine-4-carboxamide,PUBCHEM.COMPOUND:117609560,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,78,0.384,0.384,0.0,0.0,0.192,38.4,False,-0.0,False,0.384,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,78,medik:edge#6,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,PUBCHEM.COMPOUND:117609560,N-[5-[6-ethoxy-5-[(3S)-3-methylmorpholin-4-yl]pyridin-3-yl]-6-methylpyridin-3-yl]-6-(trifluoromethyl)pyridazine-4-carboxamide,['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:affects,"[{'qualifier_type_id': 'biolink:object_aspect_qualifier', 'qualifier_value': 'activity'}, {'qualifier_type_id': 'biolink:object_direction_qualifier', 'qualifier_value': 'decreased'}, {'qualifier_type_id': 'biolink:qualified_predicate', 'qualifier_value': 'biolink:causes'}]",one-hop,causes,,,,,decreased,activity,,[],N-[5-[6-ethoxy-5-[(3S)-3-methylmorpholin-4-yl]pyridin-3-yl]-6-methylpyridin-3-yl]-6-(trifluoromethyl)pyridazine-4-carboxamide causes decreased activity of BRAF,infores:bindingdb,0,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,N-[5-[6-ethoxy-5-[(3S)-3-methylmorpholin-4-yl]pyridin-3-yl]-6-methylpyridin-3-yl]-6-(trifluoromethyl)pyridazine-4-carboxamide,PUBCHEM.COMPOUND:117609560,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,78,0.384,0.384,0.0,0.0,0.192,38.4,False,-0.0,False,0.384,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,78,medik:edge#7,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,biolink:gene_associated_with_condition,[],one-hop,,,,,,,,,['PMID:16439621'],DEFAULT PHRASE,infores:disgenet,1,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"US9359338, Exe. 044",PUBCHEM.COMPOUND:118233884,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,79,0.376,0.376,0.0,0.0,0.188,37.6,False,-0.0,False,0.376,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,79,medik:creative_edge#92,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,PUBCHEM.COMPOUND:118233884,"US9359338, Exe. 044",['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:treats,[],creative,,,,,,,,,[],DEFAULT PHRASE,infores:unsecret-agent,0,
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"US9359338, Exe. 044",PUBCHEM.COMPOUND:118233884,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,79,0.376,0.376,0.0,0.0,0.188,37.6,False,-0.0,False,0.376,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,79,medik:edge#184,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,PUBCHEM.COMPOUND:118233884,"US9359338, Exe. 044",['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:affects,"[{'qualifier_type_id': 'biolink:object_aspect_qualifier', 'qualifier_value': 'activity'}, {'qualifier_type_id': 'biolink:object_direction_qualifier', 'qualifier_value': 'decreased'}, {'qualifier_type_id': 'biolink:qualified_predicate', 'qualifier_value': 'biolink:causes'}]",one-hop,causes,,,,,decreased,activity,,[],"US9359338, Exe. 044 causes decreased activity of BRAF",infores:bindingdb,0,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"US9359338, Exe. 044",PUBCHEM.COMPOUND:118233884,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,79,0.376,0.376,0.0,0.0,0.188,37.6,False,-0.0,False,0.376,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,79,medik:edge#185,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,biolink:gene_associated_with_condition,[],one-hop,,,,,,,,,['PMID:16439621'],DEFAULT PHRASE,infores:disgenet,1,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"N-[4-methyl-3-[[6-(4-methylpiperazin-1-yl)pyrimido[5,4-d]pyrimidin-4-yl]amino]phenyl]-3-(trifluoromethyl)benzamide",PUBCHEM.COMPOUND:68039422,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,80,0.368,0.368,0.0,0.0,0.184,36.8,False,-0.0,False,0.368,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,80,medik:creative_edge#63,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,PUBCHEM.COMPOUND:68039422,"N-[4-methyl-3-[[6-(4-methylpiperazin-1-yl)pyrimido[5,4-d]pyrimidin-4-yl]amino]phenyl]-3-(trifluoromethyl)benzamide",['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:treats,[],creative,,,,,,,,,[],DEFAULT PHRASE,infores:unsecret-agent,0,
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"N-[4-methyl-3-[[6-(4-methylpiperazin-1-yl)pyrimido[5,4-d]pyrimidin-4-yl]amino]phenyl]-3-(trifluoromethyl)benzamide",PUBCHEM.COMPOUND:68039422,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,80,0.368,0.368,0.0,0.0,0.184,36.8,False,-0.0,False,0.368,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,80,medik:edge#126,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,PUBCHEM.COMPOUND:68039422,"N-[4-methyl-3-[[6-(4-methylpiperazin-1-yl)pyrimido[5,4-d]pyrimidin-4-yl]amino]phenyl]-3-(trifluoromethyl)benzamide",['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:affects,"[{'qualifier_type_id': 'biolink:object_aspect_qualifier', 'qualifier_value': 'activity'}, {'qualifier_type_id': 'biolink:object_direction_qualifier', 'qualifier_value': 'decreased'}, {'qualifier_type_id': 'biolink:qualified_predicate', 'qualifier_value': 'biolink:causes'}]",one-hop,causes,,,,,decreased,activity,,[],"N-[4-methyl-3-[[6-(4-methylpiperazin-1-yl)pyrimido[5,4-d]pyrimidin-4-yl]amino]phenyl]-3-(trifluoromethyl)benzamide causes decreased activity of BRAF",infores:bindingdb,0,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"N-[4-methyl-3-[[6-(4-methylpiperazin-1-yl)pyrimido[5,4-d]pyrimidin-4-yl]amino]phenyl]-3-(trifluoromethyl)benzamide",PUBCHEM.COMPOUND:68039422,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,80,0.368,0.368,0.0,0.0,0.184,36.8,False,-0.0,False,0.368,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,80,medik:edge#127,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,biolink:gene_associated_with_condition,[],one-hop,,,,,,,,,['PMID:16439621'],DEFAULT PHRASE,infores:disgenet,1,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"N-[3-[[4-amino-2-(dimethylamino)pyrimido[5,4-d]pyrimidin-8-yl]amino]-4-methylphenyl]-3-(trifluoromethyl)benzamide",PUBCHEM.COMPOUND:68039483,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,81,0.36,0.36,0.0,0.0,0.18,36.0,False,-0.0,False,0.36,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,81,medik:creative_edge#64,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,PUBCHEM.COMPOUND:68039483,"N-[3-[[4-amino-2-(dimethylamino)pyrimido[5,4-d]pyrimidin-8-yl]amino]-4-methylphenyl]-3-(trifluoromethyl)benzamide",['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:treats,[],creative,,,,,,,,,[],DEFAULT PHRASE,infores:unsecret-agent,0,
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"N-[3-[[4-amino-2-(dimethylamino)pyrimido[5,4-d]pyrimidin-8-yl]amino]-4-methylphenyl]-3-(trifluoromethyl)benzamide",PUBCHEM.COMPOUND:68039483,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,81,0.36,0.36,0.0,0.0,0.18,36.0,False,-0.0,False,0.36,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,81,medik:edge#128,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,PUBCHEM.COMPOUND:68039483,"N-[3-[[4-amino-2-(dimethylamino)pyrimido[5,4-d]pyrimidin-8-yl]amino]-4-methylphenyl]-3-(trifluoromethyl)benzamide",['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:affects,"[{'qualifier_type_id': 'biolink:object_aspect_qualifier', 'qualifier_value': 'activity'}, {'qualifier_type_id': 'biolink:object_direction_qualifier', 'qualifier_value': 'decreased'}, {'qualifier_type_id': 'biolink:qualified_predicate', 'qualifier_value': 'biolink:causes'}]",one-hop,causes,,,,,decreased,activity,,[],"N-[3-[[4-amino-2-(dimethylamino)pyrimido[5,4-d]pyrimidin-8-yl]amino]-4-methylphenyl]-3-(trifluoromethyl)benzamide causes decreased activity of BRAF",infores:bindingdb,0,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"N-[3-[[4-amino-2-(dimethylamino)pyrimido[5,4-d]pyrimidin-8-yl]amino]-4-methylphenyl]-3-(trifluoromethyl)benzamide",PUBCHEM.COMPOUND:68039483,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,81,0.36,0.36,0.0,0.0,0.18,36.0,False,-0.0,False,0.36,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,81,medik:edge#129,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,biolink:gene_associated_with_condition,[],one-hop,,,,,,,,,['PMID:16439621'],DEFAULT PHRASE,infores:disgenet,1,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"1-[(1S,1aS,6bS)-5-[(7-oxo-6,8-dihydro-5H-1,8-naphthyridin-4-yl)oxy]-1a,6b-dihydro-1H-cyclopropa[b][1]benzofuran-1-yl]-3-(3-ethynylphenyl)urea",PUBCHEM.COMPOUND:117806998,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,82,0.352,0.352,0.0,0.0,0.176,35.2,False,-0.0,False,0.352,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,82,medik:creative_edge#12,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,PUBCHEM.COMPOUND:117806998,"1-[(1S,1aS,6bS)-5-[(7-oxo-6,8-dihydro-5H-1,8-naphthyridin-4-yl)oxy]-1a,6b-dihydro-1H-cyclopropa[b][1]benzofuran-1-yl]-3-(3-ethynylphenyl)urea",['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:treats,[],creative,,,,,,,,,[],DEFAULT PHRASE,infores:unsecret-agent,0,
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"1-[(1S,1aS,6bS)-5-[(7-oxo-6,8-dihydro-5H-1,8-naphthyridin-4-yl)oxy]-1a,6b-dihydro-1H-cyclopropa[b][1]benzofuran-1-yl]-3-(3-ethynylphenyl)urea",PUBCHEM.COMPOUND:117806998,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,82,0.352,0.352,0.0,0.0,0.176,35.2,False,-0.0,False,0.352,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,82,medik:edge#24,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,PUBCHEM.COMPOUND:117806998,"1-[(1S,1aS,6bS)-5-[(7-oxo-6,8-dihydro-5H-1,8-naphthyridin-4-yl)oxy]-1a,6b-dihydro-1H-cyclopropa[b][1]benzofuran-1-yl]-3-(3-ethynylphenyl)urea",['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:affects,"[{'qualifier_type_id': 'biolink:object_aspect_qualifier', 'qualifier_value': 'activity'}, {'qualifier_type_id': 'biolink:object_direction_qualifier', 'qualifier_value': 'decreased'}, {'qualifier_type_id': 'biolink:qualified_predicate', 'qualifier_value': 'biolink:causes'}]",one-hop,causes,,,,,decreased,activity,,[],"1-[(1S,1aS,6bS)-5-[(7-oxo-6,8-dihydro-5H-1,8-naphthyridin-4-yl)oxy]-1a,6b-dihydro-1H-cyclopropa[b][1]benzofuran-1-yl]-3-(3-ethynylphenyl)urea causes decreased activity of BRAF",infores:bindingdb,0,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"1-[(1S,1aS,6bS)-5-[(7-oxo-6,8-dihydro-5H-1,8-naphthyridin-4-yl)oxy]-1a,6b-dihydro-1H-cyclopropa[b][1]benzofuran-1-yl]-3-(3-ethynylphenyl)urea",PUBCHEM.COMPOUND:117806998,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,82,0.352,0.352,0.0,0.0,0.176,35.2,False,-0.0,False,0.352,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,82,medik:edge#25,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,biolink:gene_associated_with_condition,[],one-hop,,,,,,,,,['PMID:16439621'],DEFAULT PHRASE,infores:disgenet,1,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,4-amino-N-(6-methyl-1-((2-(trifluoromethyl)pyridin-4-yl)amino)isoquinolin-5-yl)quinazoline-8-carboxamide,PUBCHEM.COMPOUND:163272215,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,83,0.344,0.344,0.0,0.0,0.172,34.4,False,-0.0,False,0.344,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,83,medik:creative_edge#32,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,PUBCHEM.COMPOUND:163272215,4-amino-N-(6-methyl-1-((2-(trifluoromethyl)pyridin-4-yl)amino)isoquinolin-5-yl)quinazoline-8-carboxamide,['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:treats,[],creative,,,,,,,,,[],DEFAULT PHRASE,infores:unsecret-agent,0,
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,4-amino-N-(6-methyl-1-((2-(trifluoromethyl)pyridin-4-yl)amino)isoquinolin-5-yl)quinazoline-8-carboxamide,PUBCHEM.COMPOUND:163272215,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,83,0.344,0.344,0.0,0.0,0.172,34.4,False,-0.0,False,0.344,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,83,medik:edge#64,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,PUBCHEM.COMPOUND:163272215,4-amino-N-(6-methyl-1-((2-(trifluoromethyl)pyridin-4-yl)amino)isoquinolin-5-yl)quinazoline-8-carboxamide,['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:affects,"[{'qualifier_type_id': 'biolink:object_aspect_qualifier', 'qualifier_value': 'activity'}, {'qualifier_type_id': 'biolink:object_direction_qualifier', 'qualifier_value': 'decreased'}, {'qualifier_type_id': 'biolink:qualified_predicate', 'qualifier_value': 'biolink:causes'}]",one-hop,causes,,,,,decreased,activity,,[],4-amino-N-(6-methyl-1-((2-(trifluoromethyl)pyridin-4-yl)amino)isoquinolin-5-yl)quinazoline-8-carboxamide causes decreased activity of BRAF,infores:bindingdb,0,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,4-amino-N-(6-methyl-1-((2-(trifluoromethyl)pyridin-4-yl)amino)isoquinolin-5-yl)quinazoline-8-carboxamide,PUBCHEM.COMPOUND:163272215,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,83,0.344,0.344,0.0,0.0,0.172,34.4,False,-0.0,False,0.344,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,83,medik:edge#65,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,biolink:gene_associated_with_condition,[],one-hop,,,,,,,,,['PMID:16439621'],DEFAULT PHRASE,infores:disgenet,1,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,N-[5-[6-(difluoromethoxy)-5-morpholin-4-ylpyridin-3-yl]-6-methylpyridin-3-yl]-2-(difluoromethyl)pyridine-4-carboxamide,PUBCHEM.COMPOUND:117610026,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,84,0.336,0.336,0.0,0.0,0.168,33.6,False,-0.0,False,0.336,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,84,medik:creative_edge#87,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,PUBCHEM.COMPOUND:117610026,N-[5-[6-(difluoromethoxy)-5-morpholin-4-ylpyridin-3-yl]-6-methylpyridin-3-yl]-2-(difluoromethyl)pyridine-4-carboxamide,['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:treats,[],creative,,,,,,,,,[],DEFAULT PHRASE,infores:unsecret-agent,0,
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,N-[5-[6-(difluoromethoxy)-5-morpholin-4-ylpyridin-3-yl]-6-methylpyridin-3-yl]-2-(difluoromethyl)pyridine-4-carboxamide,PUBCHEM.COMPOUND:117610026,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,84,0.336,0.336,0.0,0.0,0.168,33.6,False,-0.0,False,0.336,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,84,medik:edge#174,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,PUBCHEM.COMPOUND:117610026,N-[5-[6-(difluoromethoxy)-5-morpholin-4-ylpyridin-3-yl]-6-methylpyridin-3-yl]-2-(difluoromethyl)pyridine-4-carboxamide,['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:affects,"[{'qualifier_type_id': 'biolink:object_aspect_qualifier', 'qualifier_value': 'activity'}, {'qualifier_type_id': 'biolink:object_direction_qualifier', 'qualifier_value': 'decreased'}, {'qualifier_type_id': 'biolink:qualified_predicate', 'qualifier_value': 'biolink:causes'}]",one-hop,causes,,,,,decreased,activity,,[],N-[5-[6-(difluoromethoxy)-5-morpholin-4-ylpyridin-3-yl]-6-methylpyridin-3-yl]-2-(difluoromethyl)pyridine-4-carboxamide causes decreased activity of BRAF,infores:bindingdb,0,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,N-[5-[6-(difluoromethoxy)-5-morpholin-4-ylpyridin-3-yl]-6-methylpyridin-3-yl]-2-(difluoromethyl)pyridine-4-carboxamide,PUBCHEM.COMPOUND:117610026,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,84,0.336,0.336,0.0,0.0,0.168,33.6,False,-0.0,False,0.336,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,84,medik:edge#175,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,biolink:gene_associated_with_condition,[],one-hop,,,,,,,,,['PMID:16439621'],DEFAULT PHRASE,infores:disgenet,1,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,4-[4-(4-Chloro-2-fluoroanilino)quinazolin-6-yl]-2-methoxyphenol,PUBCHEM.COMPOUND:71611670,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,85,0.328,0.328,0.0,0.0,0.164,32.8,False,-0.0,False,0.328,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,85,medik:creative_edge#67,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,PUBCHEM.COMPOUND:71611670,4-[4-(4-Chloro-2-fluoroanilino)quinazolin-6-yl]-2-methoxyphenol,['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:treats,[],creative,,,,,,,,,[],DEFAULT PHRASE,infores:unsecret-agent,0,
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,4-[4-(4-Chloro-2-fluoroanilino)quinazolin-6-yl]-2-methoxyphenol,PUBCHEM.COMPOUND:71611670,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,85,0.328,0.328,0.0,0.0,0.164,32.8,False,-0.0,False,0.328,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,85,medik:edge#134,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,PUBCHEM.COMPOUND:71611670,4-[4-(4-Chloro-2-fluoroanilino)quinazolin-6-yl]-2-methoxyphenol,['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:affects,"[{'qualifier_type_id': 'biolink:object_aspect_qualifier', 'qualifier_value': 'activity'}, {'qualifier_type_id': 'biolink:object_direction_qualifier', 'qualifier_value': 'decreased'}, {'qualifier_type_id': 'biolink:qualified_predicate', 'qualifier_value': 'biolink:causes'}]",one-hop,causes,,,,,decreased,activity,,[],4-[4-(4-Chloro-2-fluoroanilino)quinazolin-6-yl]-2-methoxyphenol causes decreased activity of BRAF,infores:bindingdb,0,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,4-[4-(4-Chloro-2-fluoroanilino)quinazolin-6-yl]-2-methoxyphenol,PUBCHEM.COMPOUND:71611670,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,85,0.328,0.328,0.0,0.0,0.164,32.8,False,-0.0,False,0.328,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,85,medik:edge#135,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,biolink:gene_associated_with_condition,[],one-hop,,,,,,,,,['PMID:16439621'],DEFAULT PHRASE,infores:disgenet,1,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,5-tert-butyl-2-methyl-N-[4-methyl-3-[4-(5-morpholin-4-ylpyridin-3-yl)triazol-1-yl]phenyl]furan-3-carboxamide,PUBCHEM.COMPOUND:53464408,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,86,0.32,0.32,0.0,0.0,0.16,32.0,False,-0.0,False,0.32,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,86,medik:creative_edge#117,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,PUBCHEM.COMPOUND:53464408,5-tert-butyl-2-methyl-N-[4-methyl-3-[4-(5-morpholin-4-ylpyridin-3-yl)triazol-1-yl]phenyl]furan-3-carboxamide,['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:treats,[],creative,,,,,,,,,[],DEFAULT PHRASE,infores:unsecret-agent,0,
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,5-tert-butyl-2-methyl-N-[4-methyl-3-[4-(5-morpholin-4-ylpyridin-3-yl)triazol-1-yl]phenyl]furan-3-carboxamide,PUBCHEM.COMPOUND:53464408,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,86,0.32,0.32,0.0,0.0,0.16,32.0,False,-0.0,False,0.32,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,86,medik:edge#234,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,PUBCHEM.COMPOUND:53464408,5-tert-butyl-2-methyl-N-[4-methyl-3-[4-(5-morpholin-4-ylpyridin-3-yl)triazol-1-yl]phenyl]furan-3-carboxamide,['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:affects,"[{'qualifier_type_id': 'biolink:object_aspect_qualifier', 'qualifier_value': 'activity'}, {'qualifier_type_id': 'biolink:object_direction_qualifier', 'qualifier_value': 'decreased'}, {'qualifier_type_id': 'biolink:qualified_predicate', 'qualifier_value': 'biolink:causes'}]",one-hop,causes,,,,,decreased,activity,,[],5-tert-butyl-2-methyl-N-[4-methyl-3-[4-(5-morpholin-4-ylpyridin-3-yl)triazol-1-yl]phenyl]furan-3-carboxamide causes decreased activity of BRAF,infores:bindingdb,0,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,5-tert-butyl-2-methyl-N-[4-methyl-3-[4-(5-morpholin-4-ylpyridin-3-yl)triazol-1-yl]phenyl]furan-3-carboxamide,PUBCHEM.COMPOUND:53464408,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,86,0.32,0.32,0.0,0.0,0.16,32.0,False,-0.0,False,0.32,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,86,medik:edge#235,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,biolink:gene_associated_with_condition,[],one-hop,,,,,,,,,['PMID:16439621'],DEFAULT PHRASE,infores:disgenet,1,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,N-[6-methyl-5-[6-(1-methylazetidin-3-yl)oxy-5-morpholin-4-ylpyridin-3-yl]pyridin-3-yl]-3-(trifluoromethyl)benzamide,PUBCHEM.COMPOUND:117609716,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,87,0.312,0.312,0.0,0.0,0.156,31.2,False,-0.0,False,0.312,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,87,medik:creative_edge#4,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,PUBCHEM.COMPOUND:117609716,N-[6-methyl-5-[6-(1-methylazetidin-3-yl)oxy-5-morpholin-4-ylpyridin-3-yl]pyridin-3-yl]-3-(trifluoromethyl)benzamide,['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:treats,[],creative,,,,,,,,,[],DEFAULT PHRASE,infores:unsecret-agent,0,
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,N-[6-methyl-5-[6-(1-methylazetidin-3-yl)oxy-5-morpholin-4-ylpyridin-3-yl]pyridin-3-yl]-3-(trifluoromethyl)benzamide,PUBCHEM.COMPOUND:117609716,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,87,0.312,0.312,0.0,0.0,0.156,31.2,False,-0.0,False,0.312,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,87,medik:edge#8,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,PUBCHEM.COMPOUND:117609716,N-[6-methyl-5-[6-(1-methylazetidin-3-yl)oxy-5-morpholin-4-ylpyridin-3-yl]pyridin-3-yl]-3-(trifluoromethyl)benzamide,['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:affects,"[{'qualifier_type_id': 'biolink:object_aspect_qualifier', 'qualifier_value': 'activity'}, {'qualifier_type_id': 'biolink:object_direction_qualifier', 'qualifier_value': 'decreased'}, {'qualifier_type_id': 'biolink:qualified_predicate', 'qualifier_value': 'biolink:causes'}]",one-hop,causes,,,,,decreased,activity,,[],N-[6-methyl-5-[6-(1-methylazetidin-3-yl)oxy-5-morpholin-4-ylpyridin-3-yl]pyridin-3-yl]-3-(trifluoromethyl)benzamide causes decreased activity of BRAF,infores:bindingdb,0,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,N-[6-methyl-5-[6-(1-methylazetidin-3-yl)oxy-5-morpholin-4-ylpyridin-3-yl]pyridin-3-yl]-3-(trifluoromethyl)benzamide,PUBCHEM.COMPOUND:117609716,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,87,0.312,0.312,0.0,0.0,0.156,31.2,False,-0.0,False,0.312,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,87,medik:edge#9,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,biolink:gene_associated_with_condition,[],one-hop,,,,,,,,,['PMID:16439621'],DEFAULT PHRASE,infores:disgenet,1,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,3-[4-(3-Hydroxyanilino)quinazolin-6-yl]phenol,PUBCHEM.COMPOUND:71611101,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,88,0.304,0.304,0.0,0.0,0.152,30.4,False,-0.0,False,0.304,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,88,medik:creative_edge#66,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,PUBCHEM.COMPOUND:71611101,3-[4-(3-Hydroxyanilino)quinazolin-6-yl]phenol,['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:treats,[],creative,,,,,,,,,[],DEFAULT PHRASE,infores:unsecret-agent,0,
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,3-[4-(3-Hydroxyanilino)quinazolin-6-yl]phenol,PUBCHEM.COMPOUND:71611101,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,88,0.304,0.304,0.0,0.0,0.152,30.4,False,-0.0,False,0.304,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,88,medik:edge#132,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,PUBCHEM.COMPOUND:71611101,3-[4-(3-Hydroxyanilino)quinazolin-6-yl]phenol,['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:affects,"[{'qualifier_type_id': 'biolink:object_aspect_qualifier', 'qualifier_value': 'activity'}, {'qualifier_type_id': 'biolink:object_direction_qualifier', 'qualifier_value': 'decreased'}, {'qualifier_type_id': 'biolink:qualified_predicate', 'qualifier_value': 'biolink:causes'}]",one-hop,causes,,,,,decreased,activity,,[],3-[4-(3-Hydroxyanilino)quinazolin-6-yl]phenol causes decreased activity of BRAF,infores:bindingdb,0,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,3-[4-(3-Hydroxyanilino)quinazolin-6-yl]phenol,PUBCHEM.COMPOUND:71611101,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,88,0.304,0.304,0.0,0.0,0.152,30.4,False,-0.0,False,0.304,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,88,medik:edge#133,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,biolink:gene_associated_with_condition,[],one-hop,,,,,,,,,['PMID:16439621'],DEFAULT PHRASE,infores:disgenet,1,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"5-[[1-(5-pyridin-4-yl-1H-imidazol-2-yl)-1a,6b-dihydro-1H-cyclopropa[b][1]benzofuran-5-yl]oxy]-3,4-dihydro-1H-1,8-naphthyridin-2-one",PUBCHEM.COMPOUND:71621203,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,89,0.296,0.296,0.0,0.0,0.148,29.6,False,-0.0,False,0.296,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,89,medik:creative_edge#68,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,PUBCHEM.COMPOUND:71621203,"5-[[1-(5-pyridin-4-yl-1H-imidazol-2-yl)-1a,6b-dihydro-1H-cyclopropa[b][1]benzofuran-5-yl]oxy]-3,4-dihydro-1H-1,8-naphthyridin-2-one",['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:treats,[],creative,,,,,,,,,[],DEFAULT PHRASE,infores:unsecret-agent,0,
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"5-[[1-(5-pyridin-4-yl-1H-imidazol-2-yl)-1a,6b-dihydro-1H-cyclopropa[b][1]benzofuran-5-yl]oxy]-3,4-dihydro-1H-1,8-naphthyridin-2-one",PUBCHEM.COMPOUND:71621203,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,89,0.296,0.296,0.0,0.0,0.148,29.6,False,-0.0,False,0.296,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,89,medik:edge#136,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,PUBCHEM.COMPOUND:71621203,"5-[[1-(5-pyridin-4-yl-1H-imidazol-2-yl)-1a,6b-dihydro-1H-cyclopropa[b][1]benzofuran-5-yl]oxy]-3,4-dihydro-1H-1,8-naphthyridin-2-one",['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:affects,"[{'qualifier_type_id': 'biolink:object_aspect_qualifier', 'qualifier_value': 'activity'}, {'qualifier_type_id': 'biolink:object_direction_qualifier', 'qualifier_value': 'decreased'}, {'qualifier_type_id': 'biolink:qualified_predicate', 'qualifier_value': 'biolink:causes'}]",one-hop,causes,,,,,decreased,activity,,[],"5-[[1-(5-pyridin-4-yl-1H-imidazol-2-yl)-1a,6b-dihydro-1H-cyclopropa[b][1]benzofuran-5-yl]oxy]-3,4-dihydro-1H-1,8-naphthyridin-2-one causes decreased activity of BRAF",infores:bindingdb,0,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"5-[[1-(5-pyridin-4-yl-1H-imidazol-2-yl)-1a,6b-dihydro-1H-cyclopropa[b][1]benzofuran-5-yl]oxy]-3,4-dihydro-1H-1,8-naphthyridin-2-one",PUBCHEM.COMPOUND:71621203,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,89,0.296,0.296,0.0,0.0,0.148,29.6,False,-0.0,False,0.296,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,89,medik:edge#137,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,biolink:gene_associated_with_condition,[],one-hop,,,,,,,,,['PMID:16439621'],DEFAULT PHRASE,infores:disgenet,1,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"US9359338, Exe. 205",PUBCHEM.COMPOUND:118234006,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,90,0.288,0.288,0.0,0.0,0.144,28.8,False,-0.0,False,0.288,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,90,medik:creative_edge#16,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,PUBCHEM.COMPOUND:118234006,"US9359338, Exe. 205",['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:treats,[],creative,,,,,,,,,[],DEFAULT PHRASE,infores:unsecret-agent,0,
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"US9359338, Exe. 205",PUBCHEM.COMPOUND:118234006,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,90,0.288,0.288,0.0,0.0,0.144,28.8,False,-0.0,False,0.288,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,90,medik:edge#32,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,PUBCHEM.COMPOUND:118234006,"US9359338, Exe. 205",['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:affects,"[{'qualifier_type_id': 'biolink:object_aspect_qualifier', 'qualifier_value': 'activity'}, {'qualifier_type_id': 'biolink:object_direction_qualifier', 'qualifier_value': 'decreased'}, {'qualifier_type_id': 'biolink:qualified_predicate', 'qualifier_value': 'biolink:causes'}]",one-hop,causes,,,,,decreased,activity,,[],"US9359338, Exe. 205 causes decreased activity of BRAF",infores:bindingdb,0,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"US9359338, Exe. 205",PUBCHEM.COMPOUND:118234006,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,90,0.288,0.288,0.0,0.0,0.144,28.8,False,-0.0,False,0.288,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,90,medik:edge#33,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,biolink:gene_associated_with_condition,[],one-hop,,,,,,,,,['PMID:16439621'],DEFAULT PHRASE,infores:disgenet,1,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,N-[5-(6-ethoxy-5-morpholin-4-ylpyridin-3-yl)-6-methylpyridin-3-yl]-1-ethyl-6-oxo-5-(trifluoromethyl)pyridine-3-carboxamide,PUBCHEM.COMPOUND:117609567,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,91,0.28,0.28,0.0,0.0,0.14,28.0,False,-0.0,False,0.28,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,91,medik:creative_edge#83,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,PUBCHEM.COMPOUND:117609567,N-[5-(6-ethoxy-5-morpholin-4-ylpyridin-3-yl)-6-methylpyridin-3-yl]-1-ethyl-6-oxo-5-(trifluoromethyl)pyridine-3-carboxamide,['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:treats,[],creative,,,,,,,,,[],DEFAULT PHRASE,infores:unsecret-agent,0,
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,N-[5-(6-ethoxy-5-morpholin-4-ylpyridin-3-yl)-6-methylpyridin-3-yl]-1-ethyl-6-oxo-5-(trifluoromethyl)pyridine-3-carboxamide,PUBCHEM.COMPOUND:117609567,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,91,0.28,0.28,0.0,0.0,0.14,28.0,False,-0.0,False,0.28,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,91,medik:edge#166,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,PUBCHEM.COMPOUND:117609567,N-[5-(6-ethoxy-5-morpholin-4-ylpyridin-3-yl)-6-methylpyridin-3-yl]-1-ethyl-6-oxo-5-(trifluoromethyl)pyridine-3-carboxamide,['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:affects,"[{'qualifier_type_id': 'biolink:object_aspect_qualifier', 'qualifier_value': 'activity'}, {'qualifier_type_id': 'biolink:object_direction_qualifier', 'qualifier_value': 'decreased'}, {'qualifier_type_id': 'biolink:qualified_predicate', 'qualifier_value': 'biolink:causes'}]",one-hop,causes,,,,,decreased,activity,,[],N-[5-(6-ethoxy-5-morpholin-4-ylpyridin-3-yl)-6-methylpyridin-3-yl]-1-ethyl-6-oxo-5-(trifluoromethyl)pyridine-3-carboxamide causes decreased activity of BRAF,infores:bindingdb,0,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,N-[5-(6-ethoxy-5-morpholin-4-ylpyridin-3-yl)-6-methylpyridin-3-yl]-1-ethyl-6-oxo-5-(trifluoromethyl)pyridine-3-carboxamide,PUBCHEM.COMPOUND:117609567,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,91,0.28,0.28,0.0,0.0,0.14,28.0,False,-0.0,False,0.28,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,91,medik:edge#167,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,biolink:gene_associated_with_condition,[],one-hop,,,,,,,,,['PMID:16439621'],DEFAULT PHRASE,infores:disgenet,1,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"N-[(1S,1aS,6bS)-5-[(7-oxo-6,8-dihydro-5H-1,8-naphthyridin-4-yl)oxy]-1a,6b-dihydro-1H-cyclopropa[b][1]benzofuran-1-yl]-3-(trifluoromethyl)-4-[[3-(trifluoromethyl)-6,8-dihydro-5H-[1,2,4]triazolo[4,3-a]pyrazin-7-yl]methyl]benzamide",PUBCHEM.COMPOUND:129189434,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,92,0.272,0.272,0.0,0.0,0.136,27.2,False,-0.0,False,0.272,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,92,medik:creative_edge#100,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,PUBCHEM.COMPOUND:129189434,"N-[(1S,1aS,6bS)-5-[(7-oxo-6,8-dihydro-5H-1,8-naphthyridin-4-yl)oxy]-1a,6b-dihydro-1H-cyclopropa[b][1]benzofuran-1-yl]-3-(trifluoromethyl)-4-[[3-(trifluoromethyl)-6,8-dihydro-5H-[1,2,4]triazolo[4,3-a]pyrazin-7-yl]methyl]benzamide",['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:treats,[],creative,,,,,,,,,[],DEFAULT PHRASE,infores:unsecret-agent,0,
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"N-[(1S,1aS,6bS)-5-[(7-oxo-6,8-dihydro-5H-1,8-naphthyridin-4-yl)oxy]-1a,6b-dihydro-1H-cyclopropa[b][1]benzofuran-1-yl]-3-(trifluoromethyl)-4-[[3-(trifluoromethyl)-6,8-dihydro-5H-[1,2,4]triazolo[4,3-a]pyrazin-7-yl]methyl]benzamide",PUBCHEM.COMPOUND:129189434,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,92,0.272,0.272,0.0,0.0,0.136,27.2,False,-0.0,False,0.272,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,92,medik:edge#200,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,PUBCHEM.COMPOUND:129189434,"N-[(1S,1aS,6bS)-5-[(7-oxo-6,8-dihydro-5H-1,8-naphthyridin-4-yl)oxy]-1a,6b-dihydro-1H-cyclopropa[b][1]benzofuran-1-yl]-3-(trifluoromethyl)-4-[[3-(trifluoromethyl)-6,8-dihydro-5H-[1,2,4]triazolo[4,3-a]pyrazin-7-yl]methyl]benzamide",['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:affects,"[{'qualifier_type_id': 'biolink:object_aspect_qualifier', 'qualifier_value': 'activity'}, {'qualifier_type_id': 'biolink:object_direction_qualifier', 'qualifier_value': 'decreased'}, {'qualifier_type_id': 'biolink:qualified_predicate', 'qualifier_value': 'biolink:causes'}]",one-hop,causes,,,,,decreased,activity,,[],"N-[(1S,1aS,6bS)-5-[(7-oxo-6,8-dihydro-5H-1,8-naphthyridin-4-yl)oxy]-1a,6b-dihydro-1H-cyclopropa[b][1]benzofuran-1-yl]-3-(trifluoromethyl)-4-[[3-(trifluoromethyl)-6,8-dihydro-5H-[1,2,4]triazolo[4,3-a]pyrazin-7-yl]methyl]benzamide causes decreased activity of BRAF",infores:bindingdb,0,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"N-[(1S,1aS,6bS)-5-[(7-oxo-6,8-dihydro-5H-1,8-naphthyridin-4-yl)oxy]-1a,6b-dihydro-1H-cyclopropa[b][1]benzofuran-1-yl]-3-(trifluoromethyl)-4-[[3-(trifluoromethyl)-6,8-dihydro-5H-[1,2,4]triazolo[4,3-a]pyrazin-7-yl]methyl]benzamide",PUBCHEM.COMPOUND:129189434,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,92,0.272,0.272,0.0,0.0,0.136,27.2,False,-0.0,False,0.272,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,92,medik:edge#201,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,biolink:gene_associated_with_condition,[],one-hop,,,,,,,,,['PMID:16439621'],DEFAULT PHRASE,infores:disgenet,1,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"1,3-dimethyl-N-[4-methyl-3-(1-methyl-5-morpholin-4-yl-6-oxopyridin-3-yl)phenyl]pyrazole-4-carboxamide",PUBCHEM.COMPOUND:117609744,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,93,0.264,0.264,0.0,0.0,0.132,26.4,False,-0.0,False,0.264,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,93,medik:creative_edge#6,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,PUBCHEM.COMPOUND:117609744,"1,3-dimethyl-N-[4-methyl-3-(1-methyl-5-morpholin-4-yl-6-oxopyridin-3-yl)phenyl]pyrazole-4-carboxamide",['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:treats,[],creative,,,,,,,,,[],DEFAULT PHRASE,infores:unsecret-agent,0,
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"1,3-dimethyl-N-[4-methyl-3-(1-methyl-5-morpholin-4-yl-6-oxopyridin-3-yl)phenyl]pyrazole-4-carboxamide",PUBCHEM.COMPOUND:117609744,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,93,0.264,0.264,0.0,0.0,0.132,26.4,False,-0.0,False,0.264,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,93,medik:edge#12,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,PUBCHEM.COMPOUND:117609744,"1,3-dimethyl-N-[4-methyl-3-(1-methyl-5-morpholin-4-yl-6-oxopyridin-3-yl)phenyl]pyrazole-4-carboxamide",['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:affects,"[{'qualifier_type_id': 'biolink:object_aspect_qualifier', 'qualifier_value': 'activity'}, {'qualifier_type_id': 'biolink:object_direction_qualifier', 'qualifier_value': 'decreased'}, {'qualifier_type_id': 'biolink:qualified_predicate', 'qualifier_value': 'biolink:causes'}]",one-hop,causes,,,,,decreased,activity,,[],"1,3-dimethyl-N-[4-methyl-3-(1-methyl-5-morpholin-4-yl-6-oxopyridin-3-yl)phenyl]pyrazole-4-carboxamide causes decreased activity of BRAF",infores:bindingdb,0,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"1,3-dimethyl-N-[4-methyl-3-(1-methyl-5-morpholin-4-yl-6-oxopyridin-3-yl)phenyl]pyrazole-4-carboxamide",PUBCHEM.COMPOUND:117609744,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,93,0.264,0.264,0.0,0.0,0.132,26.4,False,-0.0,False,0.264,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,93,medik:edge#13,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,biolink:gene_associated_with_condition,[],one-hop,,,,,,,,,['PMID:16439621'],DEFAULT PHRASE,infores:disgenet,1,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,3-(difluoromethyl)-N-[6-methyl-5-(1-methyl-5-morpholin-4-yl-6-oxopyridin-3-yl)pyridin-3-yl]benzamide,PUBCHEM.COMPOUND:117609734,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,94,0.256,0.256,0.0,0.0,0.128,25.6,False,-0.0,False,0.256,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,94,medik:creative_edge#85,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,PUBCHEM.COMPOUND:117609734,3-(difluoromethyl)-N-[6-methyl-5-(1-methyl-5-morpholin-4-yl-6-oxopyridin-3-yl)pyridin-3-yl]benzamide,['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:treats,[],creative,,,,,,,,,[],DEFAULT PHRASE,infores:unsecret-agent,0,
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,3-(difluoromethyl)-N-[6-methyl-5-(1-methyl-5-morpholin-4-yl-6-oxopyridin-3-yl)pyridin-3-yl]benzamide,PUBCHEM.COMPOUND:117609734,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,94,0.256,0.256,0.0,0.0,0.128,25.6,False,-0.0,False,0.256,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,94,medik:edge#170,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,PUBCHEM.COMPOUND:117609734,3-(difluoromethyl)-N-[6-methyl-5-(1-methyl-5-morpholin-4-yl-6-oxopyridin-3-yl)pyridin-3-yl]benzamide,['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:affects,"[{'qualifier_type_id': 'biolink:object_aspect_qualifier', 'qualifier_value': 'activity'}, {'qualifier_type_id': 'biolink:object_direction_qualifier', 'qualifier_value': 'decreased'}, {'qualifier_type_id': 'biolink:qualified_predicate', 'qualifier_value': 'biolink:causes'}]",one-hop,causes,,,,,decreased,activity,,[],3-(difluoromethyl)-N-[6-methyl-5-(1-methyl-5-morpholin-4-yl-6-oxopyridin-3-yl)pyridin-3-yl]benzamide causes decreased activity of BRAF,infores:bindingdb,0,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,3-(difluoromethyl)-N-[6-methyl-5-(1-methyl-5-morpholin-4-yl-6-oxopyridin-3-yl)pyridin-3-yl]benzamide,PUBCHEM.COMPOUND:117609734,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,94,0.256,0.256,0.0,0.0,0.128,25.6,False,-0.0,False,0.256,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,94,medik:edge#171,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,biolink:gene_associated_with_condition,[],one-hop,,,,,,,,,['PMID:16439621'],DEFAULT PHRASE,infores:disgenet,1,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"US9359338, Exe. 212",PUBCHEM.COMPOUND:118233816,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,95,0.248,0.248,0.0,0.0,0.124,24.8,False,-0.0,False,0.248,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,95,medik:creative_edge#91,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,PUBCHEM.COMPOUND:118233816,"US9359338, Exe. 212",['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:treats,[],creative,,,,,,,,,[],DEFAULT PHRASE,infores:unsecret-agent,0,
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"US9359338, Exe. 212",PUBCHEM.COMPOUND:118233816,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,95,0.248,0.248,0.0,0.0,0.124,24.8,False,-0.0,False,0.248,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,95,medik:edge#182,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,PUBCHEM.COMPOUND:118233816,"US9359338, Exe. 212",['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:affects,"[{'qualifier_type_id': 'biolink:object_aspect_qualifier', 'qualifier_value': 'activity'}, {'qualifier_type_id': 'biolink:object_direction_qualifier', 'qualifier_value': 'decreased'}, {'qualifier_type_id': 'biolink:qualified_predicate', 'qualifier_value': 'biolink:causes'}]",one-hop,causes,,,,,decreased,activity,,[],"US9359338, Exe. 212 causes decreased activity of BRAF",infores:bindingdb,0,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"US9359338, Exe. 212",PUBCHEM.COMPOUND:118233816,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,95,0.248,0.248,0.0,0.0,0.124,24.8,False,-0.0,False,0.248,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,95,medik:edge#183,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,biolink:gene_associated_with_condition,[],one-hop,,,,,,,,,['PMID:16439621'],DEFAULT PHRASE,infores:disgenet,1,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"US10183939, Example 18",PUBCHEM.COMPOUND:138375415,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,96,0.24,0.24,0.0,0.0,0.12,24.0,False,-0.0,False,0.24,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,96,medik:creative_edge#105,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,PUBCHEM.COMPOUND:138375415,"US10183939, Example 18",['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:treats,[],creative,,,,,,,,,[],DEFAULT PHRASE,infores:unsecret-agent,0,
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"US10183939, Example 18",PUBCHEM.COMPOUND:138375415,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,96,0.24,0.24,0.0,0.0,0.12,24.0,False,-0.0,False,0.24,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,96,medik:edge#210,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,PUBCHEM.COMPOUND:138375415,"US10183939, Example 18",['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:affects,"[{'qualifier_type_id': 'biolink:object_aspect_qualifier', 'qualifier_value': 'activity'}, {'qualifier_type_id': 'biolink:object_direction_qualifier', 'qualifier_value': 'decreased'}, {'qualifier_type_id': 'biolink:qualified_predicate', 'qualifier_value': 'biolink:causes'}]",one-hop,causes,,,,,decreased,activity,,[],"US10183939, Example 18 causes decreased activity of BRAF",infores:bindingdb,0,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"US10183939, Example 18",PUBCHEM.COMPOUND:138375415,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,96,0.24,0.24,0.0,0.0,0.12,24.0,False,-0.0,False,0.24,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,96,medik:edge#211,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,biolink:gene_associated_with_condition,[],one-hop,,,,,,,,,['PMID:16439621'],DEFAULT PHRASE,infores:disgenet,1,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"US10183939, Example 1",PUBCHEM.COMPOUND:118948488,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,97,0.232,0.232,0.0,0.0,0.116,23.2,False,-0.0,False,0.232,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,97,medik:creative_edge#96,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,PUBCHEM.COMPOUND:118948488,"US10183939, Example 1",['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:treats,[],creative,,,,,,,,,[],DEFAULT PHRASE,infores:unsecret-agent,0,
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"US10183939, Example 1",PUBCHEM.COMPOUND:118948488,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,97,0.232,0.232,0.0,0.0,0.116,23.2,False,-0.0,False,0.232,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,97,medik:edge#192,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,PUBCHEM.COMPOUND:118948488,"US10183939, Example 1",['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:affects,"[{'qualifier_type_id': 'biolink:object_aspect_qualifier', 'qualifier_value': 'activity'}, {'qualifier_type_id': 'biolink:object_direction_qualifier', 'qualifier_value': 'decreased'}, {'qualifier_type_id': 'biolink:qualified_predicate', 'qualifier_value': 'biolink:causes'}]",one-hop,causes,,,,,decreased,activity,,[],"US10183939, Example 1 causes decreased activity of BRAF",infores:bindingdb,0,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"US10183939, Example 1",PUBCHEM.COMPOUND:118948488,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,97,0.232,0.232,0.0,0.0,0.116,23.2,False,-0.0,False,0.232,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,97,medik:edge#193,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,biolink:gene_associated_with_condition,[],one-hop,,,,,,,,,['PMID:16439621'],DEFAULT PHRASE,infores:disgenet,1,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"5-(5-cyanopyridin-3-yl)-3-[3-[[ethyl(methyl)sulfamoyl]amino]-2-fluorobenzoyl]-1H-pyrrolo[2,3-b]pyridine",PUBCHEM.COMPOUND:60163850,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,98,0.224,0.224,0.0,0.0,0.112,22.4,False,-0.0,False,0.224,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,98,medik:creative_edge#123,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,PUBCHEM.COMPOUND:60163850,"5-(5-cyanopyridin-3-yl)-3-[3-[[ethyl(methyl)sulfamoyl]amino]-2-fluorobenzoyl]-1H-pyrrolo[2,3-b]pyridine",['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:treats,[],creative,,,,,,,,,[],DEFAULT PHRASE,infores:unsecret-agent,0,
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"5-(5-cyanopyridin-3-yl)-3-[3-[[ethyl(methyl)sulfamoyl]amino]-2-fluorobenzoyl]-1H-pyrrolo[2,3-b]pyridine",PUBCHEM.COMPOUND:60163850,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,98,0.224,0.224,0.0,0.0,0.112,22.4,False,-0.0,False,0.224,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,98,medik:edge#246,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,PUBCHEM.COMPOUND:60163850,"5-(5-cyanopyridin-3-yl)-3-[3-[[ethyl(methyl)sulfamoyl]amino]-2-fluorobenzoyl]-1H-pyrrolo[2,3-b]pyridine",['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:affects,"[{'qualifier_type_id': 'biolink:object_aspect_qualifier', 'qualifier_value': 'activity'}, {'qualifier_type_id': 'biolink:object_direction_qualifier', 'qualifier_value': 'decreased'}, {'qualifier_type_id': 'biolink:qualified_predicate', 'qualifier_value': 'biolink:causes'}]",one-hop,causes,,,,,decreased,activity,,[],"5-(5-cyanopyridin-3-yl)-3-[3-[[ethyl(methyl)sulfamoyl]amino]-2-fluorobenzoyl]-1H-pyrrolo[2,3-b]pyridine causes decreased activity of BRAF",infores:bindingdb,0,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"5-(5-cyanopyridin-3-yl)-3-[3-[[ethyl(methyl)sulfamoyl]amino]-2-fluorobenzoyl]-1H-pyrrolo[2,3-b]pyridine",PUBCHEM.COMPOUND:60163850,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,98,0.224,0.224,0.0,0.0,0.112,22.4,False,-0.0,False,0.224,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,98,medik:edge#247,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,biolink:gene_associated_with_condition,[],one-hop,,,,,,,,,['PMID:16439621'],DEFAULT PHRASE,infores:disgenet,1,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,5-tert-butyl-N-[4-methyl-3-[4-(5-morpholin-4-ylpyridin-3-yl)triazol-1-yl]phenyl]-4-(pyrrolidin-1-ylmethyl)furan-2-carboxamide,PUBCHEM.COMPOUND:53464348,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,99,0.216,0.216,0.0,0.0,0.108,21.6,False,-0.0,False,0.216,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,99,medik:creative_edge#115,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,PUBCHEM.COMPOUND:53464348,5-tert-butyl-N-[4-methyl-3-[4-(5-morpholin-4-ylpyridin-3-yl)triazol-1-yl]phenyl]-4-(pyrrolidin-1-ylmethyl)furan-2-carboxamide,['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:treats,[],creative,,,,,,,,,[],DEFAULT PHRASE,infores:unsecret-agent,0,
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,5-tert-butyl-N-[4-methyl-3-[4-(5-morpholin-4-ylpyridin-3-yl)triazol-1-yl]phenyl]-4-(pyrrolidin-1-ylmethyl)furan-2-carboxamide,PUBCHEM.COMPOUND:53464348,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,99,0.216,0.216,0.0,0.0,0.108,21.6,False,-0.0,False,0.216,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,99,medik:edge#230,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,PUBCHEM.COMPOUND:53464348,5-tert-butyl-N-[4-methyl-3-[4-(5-morpholin-4-ylpyridin-3-yl)triazol-1-yl]phenyl]-4-(pyrrolidin-1-ylmethyl)furan-2-carboxamide,['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:affects,"[{'qualifier_type_id': 'biolink:object_aspect_qualifier', 'qualifier_value': 'activity'}, {'qualifier_type_id': 'biolink:object_direction_qualifier', 'qualifier_value': 'decreased'}, {'qualifier_type_id': 'biolink:qualified_predicate', 'qualifier_value': 'biolink:causes'}]",one-hop,causes,,,,,decreased,activity,,[],5-tert-butyl-N-[4-methyl-3-[4-(5-morpholin-4-ylpyridin-3-yl)triazol-1-yl]phenyl]-4-(pyrrolidin-1-ylmethyl)furan-2-carboxamide causes decreased activity of BRAF,infores:bindingdb,0,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,5-tert-butyl-N-[4-methyl-3-[4-(5-morpholin-4-ylpyridin-3-yl)triazol-1-yl]phenyl]-4-(pyrrolidin-1-ylmethyl)furan-2-carboxamide,PUBCHEM.COMPOUND:53464348,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,99,0.216,0.216,0.0,0.0,0.108,21.6,False,-0.0,False,0.216,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,99,medik:edge#231,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,biolink:gene_associated_with_condition,[],one-hop,,,,,,,,,['PMID:16439621'],DEFAULT PHRASE,infores:disgenet,1,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,5-tert-butyl-N-[4-methyl-3-[4-(5-morpholin-4-ylpyridin-3-yl)triazol-1-yl]phenyl]furan-2-carboxamide,PUBCHEM.COMPOUND:53464349,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,100,0.208,0.208,0.0,0.0,0.104,20.8,False,-0.0,False,0.208,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,100,medik:creative_edge#116,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,PUBCHEM.COMPOUND:53464349,5-tert-butyl-N-[4-methyl-3-[4-(5-morpholin-4-ylpyridin-3-yl)triazol-1-yl]phenyl]furan-2-carboxamide,['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:treats,[],creative,,,,,,,,,[],DEFAULT PHRASE,infores:unsecret-agent,0,
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,5-tert-butyl-N-[4-methyl-3-[4-(5-morpholin-4-ylpyridin-3-yl)triazol-1-yl]phenyl]furan-2-carboxamide,PUBCHEM.COMPOUND:53464349,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,100,0.208,0.208,0.0,0.0,0.104,20.8,False,-0.0,False,0.208,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,100,medik:edge#232,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,PUBCHEM.COMPOUND:53464349,5-tert-butyl-N-[4-methyl-3-[4-(5-morpholin-4-ylpyridin-3-yl)triazol-1-yl]phenyl]furan-2-carboxamide,['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:affects,"[{'qualifier_type_id': 'biolink:object_aspect_qualifier', 'qualifier_value': 'activity'}, {'qualifier_type_id': 'biolink:object_direction_qualifier', 'qualifier_value': 'decreased'}, {'qualifier_type_id': 'biolink:qualified_predicate', 'qualifier_value': 'biolink:causes'}]",one-hop,causes,,,,,decreased,activity,,[],5-tert-butyl-N-[4-methyl-3-[4-(5-morpholin-4-ylpyridin-3-yl)triazol-1-yl]phenyl]furan-2-carboxamide causes decreased activity of BRAF,infores:bindingdb,0,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,5-tert-butyl-N-[4-methyl-3-[4-(5-morpholin-4-ylpyridin-3-yl)triazol-1-yl]phenyl]furan-2-carboxamide,PUBCHEM.COMPOUND:53464349,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,100,0.208,0.208,0.0,0.0,0.104,20.8,False,-0.0,False,0.208,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,100,medik:edge#233,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,biolink:gene_associated_with_condition,[],one-hop,,,,,,,,,['PMID:16439621'],DEFAULT PHRASE,infores:disgenet,1,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,3-[4-[5-(dimethylamino)pyridin-3-yl]triazol-1-yl]-4-methyl-N-[4-(trifluoromethyl)pyridin-2-yl]benzamide,PUBCHEM.COMPOUND:53465027,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,101,0.2,0.2,0.0,0.0,0.1,20.0,False,-0.0,False,0.2,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,101,medik:creative_edge#119,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,PUBCHEM.COMPOUND:53465027,3-[4-[5-(dimethylamino)pyridin-3-yl]triazol-1-yl]-4-methyl-N-[4-(trifluoromethyl)pyridin-2-yl]benzamide,['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:treats,[],creative,,,,,,,,,[],DEFAULT PHRASE,infores:unsecret-agent,0,
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,3-[4-[5-(dimethylamino)pyridin-3-yl]triazol-1-yl]-4-methyl-N-[4-(trifluoromethyl)pyridin-2-yl]benzamide,PUBCHEM.COMPOUND:53465027,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,101,0.2,0.2,0.0,0.0,0.1,20.0,False,-0.0,False,0.2,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,101,medik:edge#238,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,PUBCHEM.COMPOUND:53465027,3-[4-[5-(dimethylamino)pyridin-3-yl]triazol-1-yl]-4-methyl-N-[4-(trifluoromethyl)pyridin-2-yl]benzamide,['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:affects,"[{'qualifier_type_id': 'biolink:object_aspect_qualifier', 'qualifier_value': 'activity'}, {'qualifier_type_id': 'biolink:object_direction_qualifier', 'qualifier_value': 'decreased'}, {'qualifier_type_id': 'biolink:qualified_predicate', 'qualifier_value': 'biolink:causes'}]",one-hop,causes,,,,,decreased,activity,,[],3-[4-[5-(dimethylamino)pyridin-3-yl]triazol-1-yl]-4-methyl-N-[4-(trifluoromethyl)pyridin-2-yl]benzamide causes decreased activity of BRAF,infores:bindingdb,0,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,3-[4-[5-(dimethylamino)pyridin-3-yl]triazol-1-yl]-4-methyl-N-[4-(trifluoromethyl)pyridin-2-yl]benzamide,PUBCHEM.COMPOUND:53465027,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,101,0.2,0.2,0.0,0.0,0.1,20.0,False,-0.0,False,0.2,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,101,medik:edge#239,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,biolink:gene_associated_with_condition,[],one-hop,,,,,,,,,['PMID:16439621'],DEFAULT PHRASE,infores:disgenet,1,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,methyl N-[(2S)-1-[[4-[2-cyclopropyl-4-[3-(methanesulfonamido)phenyl]-1H-imidazol-5-yl]pyrimidin-2-yl]amino]propan-2-yl]carbamate,PUBCHEM.COMPOUND:68186594,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,102,0.192,0.192,0.0,0.0,0.096,19.2,False,-0.0,False,0.192,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,102,medik:creative_edge#65,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,PUBCHEM.COMPOUND:68186594,methyl N-[(2S)-1-[[4-[2-cyclopropyl-4-[3-(methanesulfonamido)phenyl]-1H-imidazol-5-yl]pyrimidin-2-yl]amino]propan-2-yl]carbamate,['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:treats,[],creative,,,,,,,,,[],DEFAULT PHRASE,infores:unsecret-agent,0,
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,methyl N-[(2S)-1-[[4-[2-cyclopropyl-4-[3-(methanesulfonamido)phenyl]-1H-imidazol-5-yl]pyrimidin-2-yl]amino]propan-2-yl]carbamate,PUBCHEM.COMPOUND:68186594,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,102,0.192,0.192,0.0,0.0,0.096,19.2,False,-0.0,False,0.192,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,102,medik:edge#130,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,PUBCHEM.COMPOUND:68186594,methyl N-[(2S)-1-[[4-[2-cyclopropyl-4-[3-(methanesulfonamido)phenyl]-1H-imidazol-5-yl]pyrimidin-2-yl]amino]propan-2-yl]carbamate,['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:affects,"[{'qualifier_type_id': 'biolink:object_aspect_qualifier', 'qualifier_value': 'activity'}, {'qualifier_type_id': 'biolink:object_direction_qualifier', 'qualifier_value': 'decreased'}, {'qualifier_type_id': 'biolink:qualified_predicate', 'qualifier_value': 'biolink:causes'}]",one-hop,causes,,,,,decreased,activity,,[],methyl N-[(2S)-1-[[4-[2-cyclopropyl-4-[3-(methanesulfonamido)phenyl]-1H-imidazol-5-yl]pyrimidin-2-yl]amino]propan-2-yl]carbamate causes decreased activity of BRAF,infores:bindingdb,0,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,methyl N-[(2S)-1-[[4-[2-cyclopropyl-4-[3-(methanesulfonamido)phenyl]-1H-imidazol-5-yl]pyrimidin-2-yl]amino]propan-2-yl]carbamate,PUBCHEM.COMPOUND:68186594,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,102,0.192,0.192,0.0,0.0,0.096,19.2,False,-0.0,False,0.192,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,102,medik:edge#131,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,biolink:gene_associated_with_condition,[],one-hop,,,,,,,,,['PMID:16439621'],DEFAULT PHRASE,infores:disgenet,1,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"methyl N-[(2S)-1-[[4-[3-[2,6-difluoro-3-(methanesulfonamido)phenyl]-1-propan-2-ylpyrazol-4-yl]pyrimidin-2-yl]amino]propan-2-yl]carbamate",PUBCHEM.COMPOUND:51033574,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,103,0.184,0.184,0.0,0.0,0.092,18.4,False,-0.0,False,0.184,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,103,medik:creative_edge#36,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,PUBCHEM.COMPOUND:51033574,"methyl N-[(2S)-1-[[4-[3-[2,6-difluoro-3-(methanesulfonamido)phenyl]-1-propan-2-ylpyrazol-4-yl]pyrimidin-2-yl]amino]propan-2-yl]carbamate",['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:treats,[],creative,,,,,,,,,[],DEFAULT PHRASE,infores:unsecret-agent,0,
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"methyl N-[(2S)-1-[[4-[3-[2,6-difluoro-3-(methanesulfonamido)phenyl]-1-propan-2-ylpyrazol-4-yl]pyrimidin-2-yl]amino]propan-2-yl]carbamate",PUBCHEM.COMPOUND:51033574,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,103,0.184,0.184,0.0,0.0,0.092,18.4,False,-0.0,False,0.184,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,103,medik:edge#72,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,PUBCHEM.COMPOUND:51033574,"methyl N-[(2S)-1-[[4-[3-[2,6-difluoro-3-(methanesulfonamido)phenyl]-1-propan-2-ylpyrazol-4-yl]pyrimidin-2-yl]amino]propan-2-yl]carbamate",['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:affects,"[{'qualifier_type_id': 'biolink:object_aspect_qualifier', 'qualifier_value': 'activity'}, {'qualifier_type_id': 'biolink:object_direction_qualifier', 'qualifier_value': 'decreased'}, {'qualifier_type_id': 'biolink:qualified_predicate', 'qualifier_value': 'biolink:causes'}]",one-hop,causes,,,,,decreased,activity,,[],"methyl N-[(2S)-1-[[4-[3-[2,6-difluoro-3-(methanesulfonamido)phenyl]-1-propan-2-ylpyrazol-4-yl]pyrimidin-2-yl]amino]propan-2-yl]carbamate causes decreased activity of BRAF",infores:pharos,0,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"methyl N-[(2S)-1-[[4-[3-[2,6-difluoro-3-(methanesulfonamido)phenyl]-1-propan-2-ylpyrazol-4-yl]pyrimidin-2-yl]amino]propan-2-yl]carbamate",PUBCHEM.COMPOUND:51033574,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,103,0.184,0.184,0.0,0.0,0.092,18.4,False,-0.0,False,0.184,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,103,medik:edge#73,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,biolink:gene_associated_with_condition,[],one-hop,,,,,,,,,['PMID:16439621'],DEFAULT PHRASE,infores:disgenet,1,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,methyl N-[(2S)-1-[[4-[3-[2-fluoro-3-(methanesulfonamido)phenyl]-1-propan-2-ylpyrazol-4-yl]pyrimidin-2-yl]amino]propan-2-yl]carbamate,PUBCHEM.COMPOUND:51033572,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,104,0.176,0.176,0.0,0.0,0.088,17.6,False,-0.0,False,0.176,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,104,medik:creative_edge#114,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,PUBCHEM.COMPOUND:51033572,methyl N-[(2S)-1-[[4-[3-[2-fluoro-3-(methanesulfonamido)phenyl]-1-propan-2-ylpyrazol-4-yl]pyrimidin-2-yl]amino]propan-2-yl]carbamate,['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:treats,[],creative,,,,,,,,,[],DEFAULT PHRASE,infores:unsecret-agent,0,
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,methyl N-[(2S)-1-[[4-[3-[2-fluoro-3-(methanesulfonamido)phenyl]-1-propan-2-ylpyrazol-4-yl]pyrimidin-2-yl]amino]propan-2-yl]carbamate,PUBCHEM.COMPOUND:51033572,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,104,0.176,0.176,0.0,0.0,0.088,17.6,False,-0.0,False,0.176,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,104,medik:edge#228,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,PUBCHEM.COMPOUND:51033572,methyl N-[(2S)-1-[[4-[3-[2-fluoro-3-(methanesulfonamido)phenyl]-1-propan-2-ylpyrazol-4-yl]pyrimidin-2-yl]amino]propan-2-yl]carbamate,['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:affects,"[{'qualifier_type_id': 'biolink:object_aspect_qualifier', 'qualifier_value': 'activity'}, {'qualifier_type_id': 'biolink:object_direction_qualifier', 'qualifier_value': 'decreased'}, {'qualifier_type_id': 'biolink:qualified_predicate', 'qualifier_value': 'biolink:causes'}]",one-hop,causes,,,,,decreased,activity,,[],methyl N-[(2S)-1-[[4-[3-[2-fluoro-3-(methanesulfonamido)phenyl]-1-propan-2-ylpyrazol-4-yl]pyrimidin-2-yl]amino]propan-2-yl]carbamate causes decreased activity of BRAF,infores:pharos,0,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,methyl N-[(2S)-1-[[4-[3-[2-fluoro-3-(methanesulfonamido)phenyl]-1-propan-2-ylpyrazol-4-yl]pyrimidin-2-yl]amino]propan-2-yl]carbamate,PUBCHEM.COMPOUND:51033572,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,104,0.176,0.176,0.0,0.0,0.088,17.6,False,-0.0,False,0.176,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,104,medik:edge#229,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,biolink:gene_associated_with_condition,[],one-hop,,,,,,,,,['PMID:16439621'],DEFAULT PHRASE,infores:disgenet,1,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"US8653087, III-66",PUBCHEM.COMPOUND:68035687,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,105,0.168,0.168,0.0,0.0,0.084,16.8,False,-0.0,False,0.168,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,105,medik:creative_edge#51,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,PUBCHEM.COMPOUND:68035687,"US8653087, III-66",['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:treats,[],creative,,,,,,,,,[],DEFAULT PHRASE,infores:unsecret-agent,0,
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"US8653087, III-66",PUBCHEM.COMPOUND:68035687,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,105,0.168,0.168,0.0,0.0,0.084,16.8,False,-0.0,False,0.168,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,105,medik:edge#102,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,PUBCHEM.COMPOUND:68035687,"US8653087, III-66",['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:affects,"[{'qualifier_type_id': 'biolink:object_aspect_qualifier', 'qualifier_value': 'activity'}, {'qualifier_type_id': 'biolink:object_direction_qualifier', 'qualifier_value': 'decreased'}, {'qualifier_type_id': 'biolink:qualified_predicate', 'qualifier_value': 'biolink:causes'}]",one-hop,causes,,,,,decreased,activity,,[],"US8653087, III-66 causes decreased activity of BRAF",infores:bindingdb,0,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"US8653087, III-66",PUBCHEM.COMPOUND:68035687,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,105,0.168,0.168,0.0,0.0,0.084,16.8,False,-0.0,False,0.168,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,105,medik:edge#103,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,biolink:gene_associated_with_condition,[],one-hop,,,,,,,,,['PMID:16439621'],DEFAULT PHRASE,infores:disgenet,1,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"5-[[4-amino-2-(4-methylpiperazin-1-yl)pyrimido[5,4-d]pyrimidin-8-yl]amino]-N-(5-tert-butyl-1H-pyrazol-3-yl)-2-fluorobenzamide",PUBCHEM.COMPOUND:68035580,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,106,0.16,0.16,0.0,0.0,0.08,16.0,False,-0.0,False,0.16,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,106,medik:creative_edge#48,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,PUBCHEM.COMPOUND:68035580,"5-[[4-amino-2-(4-methylpiperazin-1-yl)pyrimido[5,4-d]pyrimidin-8-yl]amino]-N-(5-tert-butyl-1H-pyrazol-3-yl)-2-fluorobenzamide",['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:treats,[],creative,,,,,,,,,[],DEFAULT PHRASE,infores:unsecret-agent,0,
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"5-[[4-amino-2-(4-methylpiperazin-1-yl)pyrimido[5,4-d]pyrimidin-8-yl]amino]-N-(5-tert-butyl-1H-pyrazol-3-yl)-2-fluorobenzamide",PUBCHEM.COMPOUND:68035580,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,106,0.16,0.16,0.0,0.0,0.08,16.0,False,-0.0,False,0.16,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,106,medik:edge#96,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,PUBCHEM.COMPOUND:68035580,"5-[[4-amino-2-(4-methylpiperazin-1-yl)pyrimido[5,4-d]pyrimidin-8-yl]amino]-N-(5-tert-butyl-1H-pyrazol-3-yl)-2-fluorobenzamide",['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:affects,"[{'qualifier_type_id': 'biolink:object_aspect_qualifier', 'qualifier_value': 'activity'}, {'qualifier_type_id': 'biolink:object_direction_qualifier', 'qualifier_value': 'decreased'}, {'qualifier_type_id': 'biolink:qualified_predicate', 'qualifier_value': 'biolink:causes'}]",one-hop,causes,,,,,decreased,activity,,[],"5-[[4-amino-2-(4-methylpiperazin-1-yl)pyrimido[5,4-d]pyrimidin-8-yl]amino]-N-(5-tert-butyl-1H-pyrazol-3-yl)-2-fluorobenzamide causes decreased activity of BRAF",infores:bindingdb,0,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"5-[[4-amino-2-(4-methylpiperazin-1-yl)pyrimido[5,4-d]pyrimidin-8-yl]amino]-N-(5-tert-butyl-1H-pyrazol-3-yl)-2-fluorobenzamide",PUBCHEM.COMPOUND:68035580,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,106,0.16,0.16,0.0,0.0,0.08,16.0,False,-0.0,False,0.16,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,106,medik:edge#97,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,biolink:gene_associated_with_condition,[],one-hop,,,,,,,,,['PMID:16439621'],DEFAULT PHRASE,infores:disgenet,1,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"4-((4-ethylpiperazin-1-yl)methyl)-N-(3-methyl-5-((7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-4-yl)oxy)-1a,6b-dihydro-1H-cyclopropa[b]benzofuran-1-yl)-3-(trifluoromethyl)benzamide",PUBCHEM.COMPOUND:117807404,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,107,0.152,0.152,0.0,0.0,0.076,15.2,False,-0.0,False,0.152,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,107,medik:creative_edge#15,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,PUBCHEM.COMPOUND:117807404,"4-((4-ethylpiperazin-1-yl)methyl)-N-(3-methyl-5-((7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-4-yl)oxy)-1a,6b-dihydro-1H-cyclopropa[b]benzofuran-1-yl)-3-(trifluoromethyl)benzamide",['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:treats,[],creative,,,,,,,,,[],DEFAULT PHRASE,infores:unsecret-agent,0,
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"4-((4-ethylpiperazin-1-yl)methyl)-N-(3-methyl-5-((7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-4-yl)oxy)-1a,6b-dihydro-1H-cyclopropa[b]benzofuran-1-yl)-3-(trifluoromethyl)benzamide",PUBCHEM.COMPOUND:117807404,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,107,0.152,0.152,0.0,0.0,0.076,15.2,False,-0.0,False,0.152,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,107,medik:edge#30,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,PUBCHEM.COMPOUND:117807404,"4-((4-ethylpiperazin-1-yl)methyl)-N-(3-methyl-5-((7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-4-yl)oxy)-1a,6b-dihydro-1H-cyclopropa[b]benzofuran-1-yl)-3-(trifluoromethyl)benzamide",['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:affects,"[{'qualifier_type_id': 'biolink:object_aspect_qualifier', 'qualifier_value': 'activity'}, {'qualifier_type_id': 'biolink:object_direction_qualifier', 'qualifier_value': 'decreased'}, {'qualifier_type_id': 'biolink:qualified_predicate', 'qualifier_value': 'biolink:causes'}]",one-hop,causes,,,,,decreased,activity,,[],"4-((4-ethylpiperazin-1-yl)methyl)-N-(3-methyl-5-((7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-4-yl)oxy)-1a,6b-dihydro-1H-cyclopropa[b]benzofuran-1-yl)-3-(trifluoromethyl)benzamide causes decreased activity of BRAF",infores:bindingdb,0,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"4-((4-ethylpiperazin-1-yl)methyl)-N-(3-methyl-5-((7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-4-yl)oxy)-1a,6b-dihydro-1H-cyclopropa[b]benzofuran-1-yl)-3-(trifluoromethyl)benzamide",PUBCHEM.COMPOUND:117807404,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,107,0.152,0.152,0.0,0.0,0.076,15.2,False,-0.0,False,0.152,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,107,medik:edge#31,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,biolink:gene_associated_with_condition,[],one-hop,,,,,,,,,['PMID:16439621'],DEFAULT PHRASE,infores:disgenet,1,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"5-[[3-(Cyclopropylmethylsulfonylamino)-2-fluorophenyl]methyl]-3,4-difluoro-2-(2-fluoro-4-iodoanilino)benzamide",PUBCHEM.COMPOUND:156808839,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,108,0.144,0.144,0.0,0.0,0.072,14.4,False,-0.0,False,0.144,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,108,medik:creative_edge#111,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,PUBCHEM.COMPOUND:156808839,"5-[[3-(Cyclopropylmethylsulfonylamino)-2-fluorophenyl]methyl]-3,4-difluoro-2-(2-fluoro-4-iodoanilino)benzamide",['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:treats,[],creative,,,,,,,,,[],DEFAULT PHRASE,infores:unsecret-agent,0,
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"5-[[3-(Cyclopropylmethylsulfonylamino)-2-fluorophenyl]methyl]-3,4-difluoro-2-(2-fluoro-4-iodoanilino)benzamide",PUBCHEM.COMPOUND:156808839,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,108,0.144,0.144,0.0,0.0,0.072,14.4,False,-0.0,False,0.144,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,108,medik:edge#222,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,PUBCHEM.COMPOUND:156808839,"5-[[3-(Cyclopropylmethylsulfonylamino)-2-fluorophenyl]methyl]-3,4-difluoro-2-(2-fluoro-4-iodoanilino)benzamide",['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:affects,"[{'qualifier_type_id': 'biolink:object_aspect_qualifier', 'qualifier_value': 'activity'}, {'qualifier_type_id': 'biolink:object_direction_qualifier', 'qualifier_value': 'decreased'}, {'qualifier_type_id': 'biolink:qualified_predicate', 'qualifier_value': 'biolink:causes'}]",one-hop,causes,,,,,decreased,activity,,[],"5-[[3-(Cyclopropylmethylsulfonylamino)-2-fluorophenyl]methyl]-3,4-difluoro-2-(2-fluoro-4-iodoanilino)benzamide causes decreased activity of BRAF",infores:bindingdb,0,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"5-[[3-(Cyclopropylmethylsulfonylamino)-2-fluorophenyl]methyl]-3,4-difluoro-2-(2-fluoro-4-iodoanilino)benzamide",PUBCHEM.COMPOUND:156808839,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,108,0.144,0.144,0.0,0.0,0.072,14.4,False,-0.0,False,0.144,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,108,medik:edge#223,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,biolink:gene_associated_with_condition,[],one-hop,,,,,,,,,['PMID:16439621'],DEFAULT PHRASE,infores:disgenet,1,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"1-cyclopropyl-N-[4-methyl-3-[[6-(4-methylpiperazin-1-yl)pyrimido[5,4-d]pyrimidin-4-yl]amino]phenyl]methanesulfonamide",PUBCHEM.COMPOUND:68039308,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,109,0.136,0.136,0.0,0.0,0.068,13.6,False,-0.0,False,0.136,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,109,medik:creative_edge#62,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,PUBCHEM.COMPOUND:68039308,"1-cyclopropyl-N-[4-methyl-3-[[6-(4-methylpiperazin-1-yl)pyrimido[5,4-d]pyrimidin-4-yl]amino]phenyl]methanesulfonamide",['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:treats,[],creative,,,,,,,,,[],DEFAULT PHRASE,infores:unsecret-agent,0,
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"1-cyclopropyl-N-[4-methyl-3-[[6-(4-methylpiperazin-1-yl)pyrimido[5,4-d]pyrimidin-4-yl]amino]phenyl]methanesulfonamide",PUBCHEM.COMPOUND:68039308,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,109,0.136,0.136,0.0,0.0,0.068,13.6,False,-0.0,False,0.136,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,109,medik:edge#124,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,PUBCHEM.COMPOUND:68039308,"1-cyclopropyl-N-[4-methyl-3-[[6-(4-methylpiperazin-1-yl)pyrimido[5,4-d]pyrimidin-4-yl]amino]phenyl]methanesulfonamide",['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:affects,"[{'qualifier_type_id': 'biolink:object_aspect_qualifier', 'qualifier_value': 'activity'}, {'qualifier_type_id': 'biolink:object_direction_qualifier', 'qualifier_value': 'decreased'}, {'qualifier_type_id': 'biolink:qualified_predicate', 'qualifier_value': 'biolink:causes'}]",one-hop,causes,,,,,decreased,activity,,[],"1-cyclopropyl-N-[4-methyl-3-[[6-(4-methylpiperazin-1-yl)pyrimido[5,4-d]pyrimidin-4-yl]amino]phenyl]methanesulfonamide causes decreased activity of BRAF",infores:bindingdb,0,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"1-cyclopropyl-N-[4-methyl-3-[[6-(4-methylpiperazin-1-yl)pyrimido[5,4-d]pyrimidin-4-yl]amino]phenyl]methanesulfonamide",PUBCHEM.COMPOUND:68039308,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,109,0.136,0.136,0.0,0.0,0.068,13.6,False,-0.0,False,0.136,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,109,medik:edge#125,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,biolink:gene_associated_with_condition,[],one-hop,,,,,,,,,['PMID:16439621'],DEFAULT PHRASE,infores:disgenet,1,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"US8653087, III-93",PUBCHEM.COMPOUND:68035728,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,110,0.128,0.128,0.0,0.0,0.064,12.8,False,-0.0,False,0.128,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,110,medik:creative_edge#52,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,PUBCHEM.COMPOUND:68035728,"US8653087, III-93",['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:treats,[],creative,,,,,,,,,[],DEFAULT PHRASE,infores:unsecret-agent,0,
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"US8653087, III-93",PUBCHEM.COMPOUND:68035728,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,110,0.128,0.128,0.0,0.0,0.064,12.8,False,-0.0,False,0.128,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,110,medik:edge#104,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,PUBCHEM.COMPOUND:68035728,"US8653087, III-93",['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:affects,"[{'qualifier_type_id': 'biolink:object_aspect_qualifier', 'qualifier_value': 'activity'}, {'qualifier_type_id': 'biolink:object_direction_qualifier', 'qualifier_value': 'decreased'}, {'qualifier_type_id': 'biolink:qualified_predicate', 'qualifier_value': 'biolink:causes'}]",one-hop,causes,,,,,decreased,activity,,[],"US8653087, III-93 causes decreased activity of BRAF",infores:bindingdb,0,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"US8653087, III-93",PUBCHEM.COMPOUND:68035728,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,110,0.128,0.128,0.0,0.0,0.064,12.8,False,-0.0,False,0.128,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,110,medik:edge#105,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,biolink:gene_associated_with_condition,[],one-hop,,,,,,,,,['PMID:16439621'],DEFAULT PHRASE,infores:disgenet,1,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"1-[(1aS,6bS)-5-[(7-oxo-6,8-dihydro-5H-1,8-naphthyridin-4-yl)oxy]-1a,6b-dihydro-1H-cyclopropa[b][1]benzofuran-1-yl]-3-[[4-fluoro-2-(trifluoromethyl)phenyl]methyl]urea",PUBCHEM.COMPOUND:129191986,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,111,0.12,0.12,0.0,0.0,0.06,12.0,False,-0.0,False,0.12,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,111,medik:creative_edge#20,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,PUBCHEM.COMPOUND:129191986,"1-[(1aS,6bS)-5-[(7-oxo-6,8-dihydro-5H-1,8-naphthyridin-4-yl)oxy]-1a,6b-dihydro-1H-cyclopropa[b][1]benzofuran-1-yl]-3-[[4-fluoro-2-(trifluoromethyl)phenyl]methyl]urea",['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:treats,[],creative,,,,,,,,,[],DEFAULT PHRASE,infores:unsecret-agent,0,
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"1-[(1aS,6bS)-5-[(7-oxo-6,8-dihydro-5H-1,8-naphthyridin-4-yl)oxy]-1a,6b-dihydro-1H-cyclopropa[b][1]benzofuran-1-yl]-3-[[4-fluoro-2-(trifluoromethyl)phenyl]methyl]urea",PUBCHEM.COMPOUND:129191986,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,111,0.12,0.12,0.0,0.0,0.06,12.0,False,-0.0,False,0.12,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,111,medik:edge#40,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,PUBCHEM.COMPOUND:129191986,"1-[(1aS,6bS)-5-[(7-oxo-6,8-dihydro-5H-1,8-naphthyridin-4-yl)oxy]-1a,6b-dihydro-1H-cyclopropa[b][1]benzofuran-1-yl]-3-[[4-fluoro-2-(trifluoromethyl)phenyl]methyl]urea",['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:affects,"[{'qualifier_type_id': 'biolink:object_aspect_qualifier', 'qualifier_value': 'activity'}, {'qualifier_type_id': 'biolink:object_direction_qualifier', 'qualifier_value': 'decreased'}, {'qualifier_type_id': 'biolink:qualified_predicate', 'qualifier_value': 'biolink:causes'}]",one-hop,causes,,,,,decreased,activity,,[],"1-[(1aS,6bS)-5-[(7-oxo-6,8-dihydro-5H-1,8-naphthyridin-4-yl)oxy]-1a,6b-dihydro-1H-cyclopropa[b][1]benzofuran-1-yl]-3-[[4-fluoro-2-(trifluoromethyl)phenyl]methyl]urea causes decreased activity of BRAF",infores:bindingdb,0,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"1-[(1aS,6bS)-5-[(7-oxo-6,8-dihydro-5H-1,8-naphthyridin-4-yl)oxy]-1a,6b-dihydro-1H-cyclopropa[b][1]benzofuran-1-yl]-3-[[4-fluoro-2-(trifluoromethyl)phenyl]methyl]urea",PUBCHEM.COMPOUND:129191986,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,111,0.12,0.12,0.0,0.0,0.06,12.0,False,-0.0,False,0.12,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,111,medik:edge#41,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,biolink:gene_associated_with_condition,[],one-hop,,,,,,,,,['PMID:16439621'],DEFAULT PHRASE,infores:disgenet,1,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"3-[[4-amino-2-(4-methylpiperazin-1-yl)pyrimido[5,4-d]pyrimidin-8-yl]amino]-N-[3-bromo-5-(trifluoromethyl)phenyl]-4-methylbenzamide",PUBCHEM.COMPOUND:46181492,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,112,0.112,0.112,0.0,0.0,0.056,11.2,False,-0.0,False,0.112,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,112,medik:creative_edge#33,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,PUBCHEM.COMPOUND:46181492,"3-[[4-amino-2-(4-methylpiperazin-1-yl)pyrimido[5,4-d]pyrimidin-8-yl]amino]-N-[3-bromo-5-(trifluoromethyl)phenyl]-4-methylbenzamide",['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:treats,[],creative,,,,,,,,,[],DEFAULT PHRASE,infores:unsecret-agent,0,
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"3-[[4-amino-2-(4-methylpiperazin-1-yl)pyrimido[5,4-d]pyrimidin-8-yl]amino]-N-[3-bromo-5-(trifluoromethyl)phenyl]-4-methylbenzamide",PUBCHEM.COMPOUND:46181492,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,112,0.112,0.112,0.0,0.0,0.056,11.2,False,-0.0,False,0.112,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,112,medik:edge#66,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,PUBCHEM.COMPOUND:46181492,"3-[[4-amino-2-(4-methylpiperazin-1-yl)pyrimido[5,4-d]pyrimidin-8-yl]amino]-N-[3-bromo-5-(trifluoromethyl)phenyl]-4-methylbenzamide",['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:affects,"[{'qualifier_type_id': 'biolink:object_aspect_qualifier', 'qualifier_value': 'activity'}, {'qualifier_type_id': 'biolink:object_direction_qualifier', 'qualifier_value': 'decreased'}, {'qualifier_type_id': 'biolink:qualified_predicate', 'qualifier_value': 'biolink:causes'}]",one-hop,causes,,,,,decreased,activity,,[],"3-[[4-amino-2-(4-methylpiperazin-1-yl)pyrimido[5,4-d]pyrimidin-8-yl]amino]-N-[3-bromo-5-(trifluoromethyl)phenyl]-4-methylbenzamide causes decreased activity of BRAF",infores:bindingdb,0,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"3-[[4-amino-2-(4-methylpiperazin-1-yl)pyrimido[5,4-d]pyrimidin-8-yl]amino]-N-[3-bromo-5-(trifluoromethyl)phenyl]-4-methylbenzamide",PUBCHEM.COMPOUND:46181492,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,112,0.112,0.112,0.0,0.0,0.056,11.2,False,-0.0,False,0.112,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,112,medik:edge#67,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,biolink:gene_associated_with_condition,[],one-hop,,,,,,,,,['PMID:16439621'],DEFAULT PHRASE,infores:disgenet,1,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"1-[(1S,1aS,6bS)-5-[(7-oxo-6,8-dihydro-5H-1,8-naphthyridin-4-yl)oxy]-1a,6b-dihydro-1H-cyclopropa[b][1]benzofuran-1-yl]-3-(2-chloro-4-methoxyphenyl)urea",PUBCHEM.COMPOUND:124149005,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,113,0.104,0.104,0.0,0.0,0.052,10.4,False,-0.0,False,0.104,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,113,medik:creative_edge#18,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,PUBCHEM.COMPOUND:124149005,"1-[(1S,1aS,6bS)-5-[(7-oxo-6,8-dihydro-5H-1,8-naphthyridin-4-yl)oxy]-1a,6b-dihydro-1H-cyclopropa[b][1]benzofuran-1-yl]-3-(2-chloro-4-methoxyphenyl)urea",['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:treats,[],creative,,,,,,,,,[],DEFAULT PHRASE,infores:unsecret-agent,0,
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"1-[(1S,1aS,6bS)-5-[(7-oxo-6,8-dihydro-5H-1,8-naphthyridin-4-yl)oxy]-1a,6b-dihydro-1H-cyclopropa[b][1]benzofuran-1-yl]-3-(2-chloro-4-methoxyphenyl)urea",PUBCHEM.COMPOUND:124149005,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,113,0.104,0.104,0.0,0.0,0.052,10.4,False,-0.0,False,0.104,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,113,medik:edge#36,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,PUBCHEM.COMPOUND:124149005,"1-[(1S,1aS,6bS)-5-[(7-oxo-6,8-dihydro-5H-1,8-naphthyridin-4-yl)oxy]-1a,6b-dihydro-1H-cyclopropa[b][1]benzofuran-1-yl]-3-(2-chloro-4-methoxyphenyl)urea",['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:affects,"[{'qualifier_type_id': 'biolink:object_aspect_qualifier', 'qualifier_value': 'activity'}, {'qualifier_type_id': 'biolink:object_direction_qualifier', 'qualifier_value': 'decreased'}, {'qualifier_type_id': 'biolink:qualified_predicate', 'qualifier_value': 'biolink:causes'}]",one-hop,causes,,,,,decreased,activity,,[],"1-[(1S,1aS,6bS)-5-[(7-oxo-6,8-dihydro-5H-1,8-naphthyridin-4-yl)oxy]-1a,6b-dihydro-1H-cyclopropa[b][1]benzofuran-1-yl]-3-(2-chloro-4-methoxyphenyl)urea causes decreased activity of BRAF",infores:bindingdb,0,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"1-[(1S,1aS,6bS)-5-[(7-oxo-6,8-dihydro-5H-1,8-naphthyridin-4-yl)oxy]-1a,6b-dihydro-1H-cyclopropa[b][1]benzofuran-1-yl]-3-(2-chloro-4-methoxyphenyl)urea",PUBCHEM.COMPOUND:124149005,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,113,0.104,0.104,0.0,0.0,0.052,10.4,False,-0.0,False,0.104,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,113,medik:edge#37,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,biolink:gene_associated_with_condition,[],one-hop,,,,,,,,,['PMID:16439621'],DEFAULT PHRASE,infores:disgenet,1,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"2-(1,1-difluoropropyl)-N-[5-(6-ethoxy-5-morpholin-4-ylpyridazin-3-yl)-6-methylpyridin-3-yl]pyridine-4-carboxamide",PUBCHEM.COMPOUND:90456930,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,114,0.096,0.096,0.0,0.0,0.048,9.6,False,-0.0,False,0.096,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,114,medik:creative_edge#76,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,PUBCHEM.COMPOUND:90456930,"2-(1,1-difluoropropyl)-N-[5-(6-ethoxy-5-morpholin-4-ylpyridazin-3-yl)-6-methylpyridin-3-yl]pyridine-4-carboxamide",['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:treats,[],creative,,,,,,,,,[],DEFAULT PHRASE,infores:unsecret-agent,0,
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"2-(1,1-difluoropropyl)-N-[5-(6-ethoxy-5-morpholin-4-ylpyridazin-3-yl)-6-methylpyridin-3-yl]pyridine-4-carboxamide",PUBCHEM.COMPOUND:90456930,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,114,0.096,0.096,0.0,0.0,0.048,9.6,False,-0.0,False,0.096,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,114,medik:edge#152,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,PUBCHEM.COMPOUND:90456930,"2-(1,1-difluoropropyl)-N-[5-(6-ethoxy-5-morpholin-4-ylpyridazin-3-yl)-6-methylpyridin-3-yl]pyridine-4-carboxamide",['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:affects,"[{'qualifier_type_id': 'biolink:object_aspect_qualifier', 'qualifier_value': 'activity'}, {'qualifier_type_id': 'biolink:object_direction_qualifier', 'qualifier_value': 'decreased'}, {'qualifier_type_id': 'biolink:qualified_predicate', 'qualifier_value': 'biolink:causes'}]",one-hop,causes,,,,,decreased,activity,,[],"2-(1,1-difluoropropyl)-N-[5-(6-ethoxy-5-morpholin-4-ylpyridazin-3-yl)-6-methylpyridin-3-yl]pyridine-4-carboxamide causes decreased activity of BRAF",infores:bindingdb,0,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"2-(1,1-difluoropropyl)-N-[5-(6-ethoxy-5-morpholin-4-ylpyridazin-3-yl)-6-methylpyridin-3-yl]pyridine-4-carboxamide",PUBCHEM.COMPOUND:90456930,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,114,0.096,0.096,0.0,0.0,0.048,9.6,False,-0.0,False,0.096,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,114,medik:edge#153,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,biolink:gene_associated_with_condition,[],one-hop,,,,,,,,,['PMID:16439621'],DEFAULT PHRASE,infores:disgenet,1,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"N-[1-(4-acetylanilino)-6-methylisoquinolin-5-yl]-4-aminothieno[3,2-d]pyrimidine-7-carboxamide",PUBCHEM.COMPOUND:71622312,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,115,0.088,0.088,0.0,0.0,0.044,8.8,False,-0.0,False,0.088,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,115,medik:creative_edge#69,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,PUBCHEM.COMPOUND:71622312,"N-[1-(4-acetylanilino)-6-methylisoquinolin-5-yl]-4-aminothieno[3,2-d]pyrimidine-7-carboxamide",['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:treats,[],creative,,,,,,,,,[],DEFAULT PHRASE,infores:unsecret-agent,0,
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"N-[1-(4-acetylanilino)-6-methylisoquinolin-5-yl]-4-aminothieno[3,2-d]pyrimidine-7-carboxamide",PUBCHEM.COMPOUND:71622312,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,115,0.088,0.088,0.0,0.0,0.044,8.8,False,-0.0,False,0.088,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,115,medik:edge#138,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,PUBCHEM.COMPOUND:71622312,"N-[1-(4-acetylanilino)-6-methylisoquinolin-5-yl]-4-aminothieno[3,2-d]pyrimidine-7-carboxamide",['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:affects,"[{'qualifier_type_id': 'biolink:object_aspect_qualifier', 'qualifier_value': 'activity'}, {'qualifier_type_id': 'biolink:object_direction_qualifier', 'qualifier_value': 'decreased'}, {'qualifier_type_id': 'biolink:qualified_predicate', 'qualifier_value': 'biolink:causes'}]",one-hop,causes,,,,,decreased,activity,,[],"N-[1-(4-acetylanilino)-6-methylisoquinolin-5-yl]-4-aminothieno[3,2-d]pyrimidine-7-carboxamide causes decreased activity of BRAF",infores:bindingdb,0,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"N-[1-(4-acetylanilino)-6-methylisoquinolin-5-yl]-4-aminothieno[3,2-d]pyrimidine-7-carboxamide",PUBCHEM.COMPOUND:71622312,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,115,0.088,0.088,0.0,0.0,0.044,8.8,False,-0.0,False,0.088,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,115,medik:edge#139,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,biolink:gene_associated_with_condition,[],one-hop,,,,,,,,,['PMID:16439621'],DEFAULT PHRASE,infores:disgenet,1,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,2-(2-cyanopropan-2-yl)-N-[5-[2-[(1-hydroxy-2-methylpropan-2-yl)amino]-6-morpholin-4-ylpyrimidin-4-yl]-6-methylpyridin-3-yl]pyridine-4-carboxamide,PUBCHEM.COMPOUND:117610023,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,116,0.08,0.08,0.0,0.0,0.04,8.0,False,-0.0,False,0.08,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,116,medik:creative_edge#86,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,PUBCHEM.COMPOUND:117610023,2-(2-cyanopropan-2-yl)-N-[5-[2-[(1-hydroxy-2-methylpropan-2-yl)amino]-6-morpholin-4-ylpyrimidin-4-yl]-6-methylpyridin-3-yl]pyridine-4-carboxamide,['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:treats,[],creative,,,,,,,,,[],DEFAULT PHRASE,infores:unsecret-agent,0,
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,2-(2-cyanopropan-2-yl)-N-[5-[2-[(1-hydroxy-2-methylpropan-2-yl)amino]-6-morpholin-4-ylpyrimidin-4-yl]-6-methylpyridin-3-yl]pyridine-4-carboxamide,PUBCHEM.COMPOUND:117610023,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,116,0.08,0.08,0.0,0.0,0.04,8.0,False,-0.0,False,0.08,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,116,medik:edge#172,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,PUBCHEM.COMPOUND:117610023,2-(2-cyanopropan-2-yl)-N-[5-[2-[(1-hydroxy-2-methylpropan-2-yl)amino]-6-morpholin-4-ylpyrimidin-4-yl]-6-methylpyridin-3-yl]pyridine-4-carboxamide,['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:affects,"[{'qualifier_type_id': 'biolink:object_aspect_qualifier', 'qualifier_value': 'activity'}, {'qualifier_type_id': 'biolink:object_direction_qualifier', 'qualifier_value': 'decreased'}, {'qualifier_type_id': 'biolink:qualified_predicate', 'qualifier_value': 'biolink:causes'}]",one-hop,causes,,,,,decreased,activity,,[],2-(2-cyanopropan-2-yl)-N-[5-[2-[(1-hydroxy-2-methylpropan-2-yl)amino]-6-morpholin-4-ylpyrimidin-4-yl]-6-methylpyridin-3-yl]pyridine-4-carboxamide causes decreased activity of BRAF,infores:bindingdb,0,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,2-(2-cyanopropan-2-yl)-N-[5-[2-[(1-hydroxy-2-methylpropan-2-yl)amino]-6-morpholin-4-ylpyrimidin-4-yl]-6-methylpyridin-3-yl]pyridine-4-carboxamide,PUBCHEM.COMPOUND:117610023,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,116,0.08,0.08,0.0,0.0,0.04,8.0,False,-0.0,False,0.08,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,116,medik:edge#173,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,biolink:gene_associated_with_condition,[],one-hop,,,,,,,,,['PMID:16439621'],DEFAULT PHRASE,infores:disgenet,1,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,N-[6-methyl-5-(1-methyl-5-morpholin-4-yl-6-oxopyridin-3-yl)pyridin-3-yl]-3-propan-2-yloxybenzamide,PUBCHEM.COMPOUND:117609755,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,117,0.072,0.072,0.0,0.0,0.036,7.2,False,-0.0,False,0.072,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,117,medik:creative_edge#7,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,PUBCHEM.COMPOUND:117609755,N-[6-methyl-5-(1-methyl-5-morpholin-4-yl-6-oxopyridin-3-yl)pyridin-3-yl]-3-propan-2-yloxybenzamide,['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:treats,[],creative,,,,,,,,,[],DEFAULT PHRASE,infores:unsecret-agent,0,
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,N-[6-methyl-5-(1-methyl-5-morpholin-4-yl-6-oxopyridin-3-yl)pyridin-3-yl]-3-propan-2-yloxybenzamide,PUBCHEM.COMPOUND:117609755,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,117,0.072,0.072,0.0,0.0,0.036,7.2,False,-0.0,False,0.072,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,117,medik:edge#14,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,PUBCHEM.COMPOUND:117609755,N-[6-methyl-5-(1-methyl-5-morpholin-4-yl-6-oxopyridin-3-yl)pyridin-3-yl]-3-propan-2-yloxybenzamide,['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:affects,"[{'qualifier_type_id': 'biolink:object_aspect_qualifier', 'qualifier_value': 'activity'}, {'qualifier_type_id': 'biolink:object_direction_qualifier', 'qualifier_value': 'decreased'}, {'qualifier_type_id': 'biolink:qualified_predicate', 'qualifier_value': 'biolink:causes'}]",one-hop,causes,,,,,decreased,activity,,[],N-[6-methyl-5-(1-methyl-5-morpholin-4-yl-6-oxopyridin-3-yl)pyridin-3-yl]-3-propan-2-yloxybenzamide causes decreased activity of BRAF,infores:bindingdb,0,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,N-[6-methyl-5-(1-methyl-5-morpholin-4-yl-6-oxopyridin-3-yl)pyridin-3-yl]-3-propan-2-yloxybenzamide,PUBCHEM.COMPOUND:117609755,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,117,0.072,0.072,0.0,0.0,0.036,7.2,False,-0.0,False,0.072,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,117,medik:edge#15,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,biolink:gene_associated_with_condition,[],one-hop,,,,,,,,,['PMID:16439621'],DEFAULT PHRASE,infores:disgenet,1,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"N-(3-(3-(9H-purin-6-yl)pyridin-2-ylamino)-2,4-difluorophenyl)-4-(trifluoromethoxy)benzenesulfonamide",PUBCHEM.COMPOUND:57344994,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,118,0.064,0.064,0.0,0.0,0.032,6.4,False,-0.0,False,0.064,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,118,medik:creative_edge#39,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,PUBCHEM.COMPOUND:57344994,"N-(3-(3-(9H-purin-6-yl)pyridin-2-ylamino)-2,4-difluorophenyl)-4-(trifluoromethoxy)benzenesulfonamide",['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:treats,[],creative,,,,,,,,,[],DEFAULT PHRASE,infores:unsecret-agent,0,
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"N-(3-(3-(9H-purin-6-yl)pyridin-2-ylamino)-2,4-difluorophenyl)-4-(trifluoromethoxy)benzenesulfonamide",PUBCHEM.COMPOUND:57344994,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,118,0.064,0.064,0.0,0.0,0.032,6.4,False,-0.0,False,0.064,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,118,medik:edge#78,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,PUBCHEM.COMPOUND:57344994,"N-(3-(3-(9H-purin-6-yl)pyridin-2-ylamino)-2,4-difluorophenyl)-4-(trifluoromethoxy)benzenesulfonamide",['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:affects,"[{'qualifier_type_id': 'biolink:object_aspect_qualifier', 'qualifier_value': 'activity'}, {'qualifier_type_id': 'biolink:object_direction_qualifier', 'qualifier_value': 'decreased'}, {'qualifier_type_id': 'biolink:qualified_predicate', 'qualifier_value': 'biolink:causes'}]",one-hop,causes,,,,,decreased,activity,,[],"N-(3-(3-(9H-purin-6-yl)pyridin-2-ylamino)-2,4-difluorophenyl)-4-(trifluoromethoxy)benzenesulfonamide causes decreased activity of BRAF",infores:bindingdb,0,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"N-(3-(3-(9H-purin-6-yl)pyridin-2-ylamino)-2,4-difluorophenyl)-4-(trifluoromethoxy)benzenesulfonamide",PUBCHEM.COMPOUND:57344994,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,118,0.064,0.064,0.0,0.0,0.032,6.4,False,-0.0,False,0.064,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,118,medik:edge#79,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,biolink:gene_associated_with_condition,[],one-hop,,,,,,,,,['PMID:16439621'],DEFAULT PHRASE,infores:disgenet,1,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"1-[(1S,1aS,6bS)-5-[(7-oxo-6,8-dihydro-5H-1,8-naphthyridin-4-yl)oxy]-1a,6b-dihydro-1H-cyclopropa[b][1]benzofuran-1-yl]-3-[(3-fluorophenyl)methyl]urea",PUBCHEM.COMPOUND:124149058,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,119,0.056,0.056,0.0,0.0,0.028,5.6,False,-0.0,False,0.056,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,119,medik:creative_edge#98,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,PUBCHEM.COMPOUND:124149058,"1-[(1S,1aS,6bS)-5-[(7-oxo-6,8-dihydro-5H-1,8-naphthyridin-4-yl)oxy]-1a,6b-dihydro-1H-cyclopropa[b][1]benzofuran-1-yl]-3-[(3-fluorophenyl)methyl]urea",['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:treats,[],creative,,,,,,,,,[],DEFAULT PHRASE,infores:unsecret-agent,0,
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"1-[(1S,1aS,6bS)-5-[(7-oxo-6,8-dihydro-5H-1,8-naphthyridin-4-yl)oxy]-1a,6b-dihydro-1H-cyclopropa[b][1]benzofuran-1-yl]-3-[(3-fluorophenyl)methyl]urea",PUBCHEM.COMPOUND:124149058,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,119,0.056,0.056,0.0,0.0,0.028,5.6,False,-0.0,False,0.056,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,119,medik:edge#196,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,PUBCHEM.COMPOUND:124149058,"1-[(1S,1aS,6bS)-5-[(7-oxo-6,8-dihydro-5H-1,8-naphthyridin-4-yl)oxy]-1a,6b-dihydro-1H-cyclopropa[b][1]benzofuran-1-yl]-3-[(3-fluorophenyl)methyl]urea",['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:affects,"[{'qualifier_type_id': 'biolink:object_aspect_qualifier', 'qualifier_value': 'activity'}, {'qualifier_type_id': 'biolink:object_direction_qualifier', 'qualifier_value': 'decreased'}, {'qualifier_type_id': 'biolink:qualified_predicate', 'qualifier_value': 'biolink:causes'}]",one-hop,causes,,,,,decreased,activity,,[],"1-[(1S,1aS,6bS)-5-[(7-oxo-6,8-dihydro-5H-1,8-naphthyridin-4-yl)oxy]-1a,6b-dihydro-1H-cyclopropa[b][1]benzofuran-1-yl]-3-[(3-fluorophenyl)methyl]urea causes decreased activity of BRAF",infores:bindingdb,0,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"1-[(1S,1aS,6bS)-5-[(7-oxo-6,8-dihydro-5H-1,8-naphthyridin-4-yl)oxy]-1a,6b-dihydro-1H-cyclopropa[b][1]benzofuran-1-yl]-3-[(3-fluorophenyl)methyl]urea",PUBCHEM.COMPOUND:124149058,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,119,0.056,0.056,0.0,0.0,0.028,5.6,False,-0.0,False,0.056,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,119,medik:edge#197,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,biolink:gene_associated_with_condition,[],one-hop,,,,,,,,,['PMID:16439621'],DEFAULT PHRASE,infores:disgenet,1,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"US8653087, III-472",PUBCHEM.COMPOUND:68036272,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,120,0.048,0.048,0.0,0.0,0.024,4.8,False,-0.0,False,0.048,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,120,medik:creative_edge#59,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,PUBCHEM.COMPOUND:68036272,"US8653087, III-472",['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:treats,[],creative,,,,,,,,,[],DEFAULT PHRASE,infores:unsecret-agent,0,
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"US8653087, III-472",PUBCHEM.COMPOUND:68036272,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,120,0.048,0.048,0.0,0.0,0.024,4.8,False,-0.0,False,0.048,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,120,medik:edge#118,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,PUBCHEM.COMPOUND:68036272,"US8653087, III-472",['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:affects,"[{'qualifier_type_id': 'biolink:object_aspect_qualifier', 'qualifier_value': 'activity'}, {'qualifier_type_id': 'biolink:object_direction_qualifier', 'qualifier_value': 'decreased'}, {'qualifier_type_id': 'biolink:qualified_predicate', 'qualifier_value': 'biolink:causes'}]",one-hop,causes,,,,,decreased,activity,,[],"US8653087, III-472 causes decreased activity of BRAF",infores:bindingdb,0,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"US8653087, III-472",PUBCHEM.COMPOUND:68036272,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,120,0.048,0.048,0.0,0.0,0.024,4.8,False,-0.0,False,0.048,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,120,medik:edge#119,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,biolink:gene_associated_with_condition,[],one-hop,,,,,,,,,['PMID:16439621'],DEFAULT PHRASE,infores:disgenet,1,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,4-amino-N-(1-((4-methoxyphenyl)amino)-6-methylisoquinolin-5-yl)quinazoline-8-carboxamide,PUBCHEM.COMPOUND:163272126,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,121,0.04,0.04,0.0,0.0,0.02,4.0,False,-0.0,False,0.04,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,121,medik:creative_edge#113,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,PUBCHEM.COMPOUND:163272126,4-amino-N-(1-((4-methoxyphenyl)amino)-6-methylisoquinolin-5-yl)quinazoline-8-carboxamide,['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:treats,[],creative,,,,,,,,,[],DEFAULT PHRASE,infores:unsecret-agent,0,
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,4-amino-N-(1-((4-methoxyphenyl)amino)-6-methylisoquinolin-5-yl)quinazoline-8-carboxamide,PUBCHEM.COMPOUND:163272126,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,121,0.04,0.04,0.0,0.0,0.02,4.0,False,-0.0,False,0.04,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,121,medik:edge#226,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,PUBCHEM.COMPOUND:163272126,4-amino-N-(1-((4-methoxyphenyl)amino)-6-methylisoquinolin-5-yl)quinazoline-8-carboxamide,['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:affects,"[{'qualifier_type_id': 'biolink:object_aspect_qualifier', 'qualifier_value': 'activity'}, {'qualifier_type_id': 'biolink:object_direction_qualifier', 'qualifier_value': 'decreased'}, {'qualifier_type_id': 'biolink:qualified_predicate', 'qualifier_value': 'biolink:causes'}]",one-hop,causes,,,,,decreased,activity,,[],4-amino-N-(1-((4-methoxyphenyl)amino)-6-methylisoquinolin-5-yl)quinazoline-8-carboxamide causes decreased activity of BRAF,infores:bindingdb,0,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,4-amino-N-(1-((4-methoxyphenyl)amino)-6-methylisoquinolin-5-yl)quinazoline-8-carboxamide,PUBCHEM.COMPOUND:163272126,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,121,0.04,0.04,0.0,0.0,0.02,4.0,False,-0.0,False,0.04,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,121,medik:edge#227,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,biolink:gene_associated_with_condition,[],one-hop,,,,,,,,,['PMID:16439621'],DEFAULT PHRASE,infores:disgenet,1,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"US8653087, III-489",PUBCHEM.COMPOUND:68036289,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,122,0.032,0.032,0.0,0.0,0.016,3.2,False,-0.0,False,0.032,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,122,medik:creative_edge#61,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,PUBCHEM.COMPOUND:68036289,"US8653087, III-489",['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:treats,[],creative,,,,,,,,,[],DEFAULT PHRASE,infores:unsecret-agent,0,
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"US8653087, III-489",PUBCHEM.COMPOUND:68036289,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,122,0.032,0.032,0.0,0.0,0.016,3.2,False,-0.0,False,0.032,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,122,medik:edge#122,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,PUBCHEM.COMPOUND:68036289,"US8653087, III-489",['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:affects,"[{'qualifier_type_id': 'biolink:object_aspect_qualifier', 'qualifier_value': 'activity'}, {'qualifier_type_id': 'biolink:object_direction_qualifier', 'qualifier_value': 'decreased'}, {'qualifier_type_id': 'biolink:qualified_predicate', 'qualifier_value': 'biolink:causes'}]",one-hop,causes,,,,,decreased,activity,,[],"US8653087, III-489 causes decreased activity of BRAF",infores:bindingdb,0,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"US8653087, III-489",PUBCHEM.COMPOUND:68036289,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,122,0.032,0.032,0.0,0.0,0.016,3.2,False,-0.0,False,0.032,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,122,medik:edge#123,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,biolink:gene_associated_with_condition,[],one-hop,,,,,,,,,['PMID:16439621'],DEFAULT PHRASE,infores:disgenet,1,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"US8653087, III-483",PUBCHEM.COMPOUND:68036283,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,123,0.024,0.024,0.0,0.0,0.012,2.4,False,-0.0,False,0.024,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,123,medik:creative_edge#60,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,PUBCHEM.COMPOUND:68036283,"US8653087, III-483",['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:treats,[],creative,,,,,,,,,[],DEFAULT PHRASE,infores:unsecret-agent,0,
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"US8653087, III-483",PUBCHEM.COMPOUND:68036283,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,123,0.024,0.024,0.0,0.0,0.012,2.4,False,-0.0,False,0.024,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,123,medik:edge#120,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,PUBCHEM.COMPOUND:68036283,"US8653087, III-483",['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:affects,"[{'qualifier_type_id': 'biolink:object_aspect_qualifier', 'qualifier_value': 'activity'}, {'qualifier_type_id': 'biolink:object_direction_qualifier', 'qualifier_value': 'decreased'}, {'qualifier_type_id': 'biolink:qualified_predicate', 'qualifier_value': 'biolink:causes'}]",one-hop,causes,,,,,decreased,activity,,[],"US8653087, III-483 causes decreased activity of BRAF",infores:bindingdb,0,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"US8653087, III-483",PUBCHEM.COMPOUND:68036283,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,123,0.024,0.024,0.0,0.0,0.012,2.4,False,-0.0,False,0.024,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,123,medik:edge#121,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,biolink:gene_associated_with_condition,[],one-hop,,,,,,,,,['PMID:16439621'],DEFAULT PHRASE,infores:disgenet,1,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"3,4-Difluoro-2-(2-fluoro-4-iodoanilino)-5-[[2-fluoro-3-[(1-methylcyclopropyl)sulfonylamino]phenyl]methyl]benzamide",PUBCHEM.COMPOUND:156808697,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,124,0.016,0.016,0.0,0.0,0.008,1.6,False,-0.0,False,0.016,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,124,medik:creative_edge#27,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,PUBCHEM.COMPOUND:156808697,"3,4-Difluoro-2-(2-fluoro-4-iodoanilino)-5-[[2-fluoro-3-[(1-methylcyclopropyl)sulfonylamino]phenyl]methyl]benzamide",['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:treats,[],creative,,,,,,,,,[],DEFAULT PHRASE,infores:unsecret-agent,0,
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"3,4-Difluoro-2-(2-fluoro-4-iodoanilino)-5-[[2-fluoro-3-[(1-methylcyclopropyl)sulfonylamino]phenyl]methyl]benzamide",PUBCHEM.COMPOUND:156808697,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,124,0.016,0.016,0.0,0.0,0.008,1.6,False,-0.0,False,0.016,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,124,medik:edge#54,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,PUBCHEM.COMPOUND:156808697,"3,4-Difluoro-2-(2-fluoro-4-iodoanilino)-5-[[2-fluoro-3-[(1-methylcyclopropyl)sulfonylamino]phenyl]methyl]benzamide",['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:affects,"[{'qualifier_type_id': 'biolink:object_aspect_qualifier', 'qualifier_value': 'activity'}, {'qualifier_type_id': 'biolink:object_direction_qualifier', 'qualifier_value': 'decreased'}, {'qualifier_type_id': 'biolink:qualified_predicate', 'qualifier_value': 'biolink:causes'}]",one-hop,causes,,,,,decreased,activity,,[],"3,4-Difluoro-2-(2-fluoro-4-iodoanilino)-5-[[2-fluoro-3-[(1-methylcyclopropyl)sulfonylamino]phenyl]methyl]benzamide causes decreased activity of BRAF",infores:bindingdb,0,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"3,4-Difluoro-2-(2-fluoro-4-iodoanilino)-5-[[2-fluoro-3-[(1-methylcyclopropyl)sulfonylamino]phenyl]methyl]benzamide",PUBCHEM.COMPOUND:156808697,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,124,0.016,0.016,0.0,0.0,0.008,1.6,False,-0.0,False,0.016,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,124,medik:edge#55,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,biolink:gene_associated_with_condition,[],one-hop,,,,,,,,,['PMID:16439621'],DEFAULT PHRASE,infores:disgenet,1,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"3,4-Difluoro-2-(2-fluoro-4-iodoanilino)-5-[[2-fluoro-3-(2-methylpropylsulfonylamino)phenyl]methyl]benzamide",PUBCHEM.COMPOUND:156808840,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,125,0.008,0.008,0.0,0.0,0.004,0.8,False,-0.0,False,0.008,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,125,medik:creative_edge#112,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,PUBCHEM.COMPOUND:156808840,"3,4-Difluoro-2-(2-fluoro-4-iodoanilino)-5-[[2-fluoro-3-(2-methylpropylsulfonylamino)phenyl]methyl]benzamide",['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:treats,[],creative,,,,,,,,,[],DEFAULT PHRASE,infores:unsecret-agent,0,
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"3,4-Difluoro-2-(2-fluoro-4-iodoanilino)-5-[[2-fluoro-3-(2-methylpropylsulfonylamino)phenyl]methyl]benzamide",PUBCHEM.COMPOUND:156808840,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,125,0.008,0.008,0.0,0.0,0.004,0.8,False,-0.0,False,0.008,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,125,medik:edge#224,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,PUBCHEM.COMPOUND:156808840,"3,4-Difluoro-2-(2-fluoro-4-iodoanilino)-5-[[2-fluoro-3-(2-methylpropylsulfonylamino)phenyl]methyl]benzamide",['biolink:SmallMolecule'],biolink:SmallMolecule,biolink:affects,"[{'qualifier_type_id': 'biolink:object_aspect_qualifier', 'qualifier_value': 'activity'}, {'qualifier_type_id': 'biolink:object_direction_qualifier', 'qualifier_value': 'decreased'}, {'qualifier_type_id': 'biolink:qualified_predicate', 'qualifier_value': 'biolink:causes'}]",one-hop,causes,,,,,decreased,activity,,[],"3,4-Difluoro-2-(2-fluoro-4-iodoanilino)-5-[[2-fluoro-3-(2-methylpropylsulfonylamino)phenyl]methyl]benzamide causes decreased activity of BRAF",infores:bindingdb,0,infores:unsecret-agent
5e451c60-f11c-4cd5-92bd-2e5f3957fe45,infores:unsecret-agent,"3,4-Difluoro-2-(2-fluoro-4-iodoanilino)-5-[[2-fluoro-3-(2-methylpropylsulfonylamino)phenyl]methyl]benzamide",PUBCHEM.COMPOUND:156808840,biolink:SmallMolecule,Hypoplasia of the corpus callosum,HP:0002079,biolink:Disease,125,0.008,0.008,0.0,0.0,0.004,0.8,False,-0.0,False,0.008,False,-0.0,False,-0.0,False,-0.0,['infores:unsecret-agent'],1,125,medik:edge#225,HP:0002079,Hypoplasia of the corpus callosum,['biolink:Disease'],biolink:Disease,NCBIGene:673,BRAF,['biolink:Gene'],biolink:Gene,biolink:gene_associated_with_condition,[],one-hop,,,,,,,,,['PMID:16439621'],DEFAULT PHRASE,infores:disgenet,1,infores:unsecret-agent
